

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 February 2004 (26.02.2004)

PCT

(10) International Publication Number
WO 2004/016224 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number:
PCT/US2003/025891
- (22) International Filing Date: 19 August 2003 (19.08.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/404,484 19 August 2002 (19.08.2002) US
- (71) Applicant (for all designated States except US): **PHARMACIA CORPORATION** [US/US]; Corporate Patent Department, P.O. Box 1027, St. Louis, MO 63006 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **WEINSTEIN, Edward, J.** [US/US]; 15449 Highcroft Drive, Chesterfield, MO 63017 (US).
- (74) Agents: **BAUER, S. Christopher et al.**; Pharmacia Corporation, Corporate Patent Department, P.O. Box 1027, St. Louis, MO 63006 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: ANTISENSE MODULATION OF VEGF CO-REGULATED CHEMOKINE-1 EXPRESSION

(57) Abstract: Antisense compounds, compositions, and methods are provided for modulating the expression of VEGF Co-regulated chemokine-1 (VCC-1). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding VCC-1. Methods of using these compounds for modulation of VCC-1 expression and for treatment of diseases associated with expression of VCC-1 are provided.

WO 2004/016224 A2

ANTISENSE MODULATION OF VEGF CO-REGULATED
CHEMOKINE-1 EXPRESSION

5 The present application claims priority under Title 35, United States Code,
§119 to United States Provisional application Serial No. 60/404,484, filed
August 19, 2002, which is incorporated by reference in its entirety as if
written herein.

FIELD OF THE INVENTION

10

[001] The present invention provides compositions and methods for
modulating the expression of VEGF Co-regulated chemokine-1 (VCC-1). In
particular, this invention relates to antisense compounds, particularly
oligonucleotides, specifically hybridizable with nucleic acids encoding
15 VEGF Co-regulated chemokine-1. Such oligonucleotides have been shown
to modulate the expression of VEGF Co-regulated chemokine-1.

BACKGROUND OF THE INVENTION

20 [002] Angiogenesis is the growth of new capillary blood vessels from pre-
existing vessels and capillaries and is crucial in a large number of processes, such
as wound repair, embryonic development, and the growth of solid tumors. In
neovascularization, endothelial cells will undergo migration, elongation,
proliferation, and orientation leading to lumen formation, re-establishment of a
25 basement membrane and eventual anastomosis with other vessels (Patan, S., 2000 *J.*
Neurooncol. 50(1-2): 1-15).

[003] Cytokines are small proteins that bind to cell surface receptors in order
to modulate activity of a variety of cells. VCC-1 appears to be a CXC chemokine,
which is a sub-family of the cytokines, named due to their conserved Cys-Xaa-Cys
30 sequence near the N-terminus of the protein. Family members also contain two
additional conserved cysteine residues and are roughly 70 – 130 amino acids in
size. They are secreted proteins with a leader sequence of 20 – 25 amino acids,
which is cleaved off before release. A characteristic three-dimensional folding of

the chemokines is stabilized by the disulfide bonds that form between the conserved cysteine 1 and cysteine 2 and between cysteine 3 and cysteine 4 (reviewed in Baggiolini, M., 2001 *J. Int. Med.* **250**: 91-104).

[004] Among the known CXC chemokines are interleukin-8 (IL-8), γ -
5 interferon-inducible protein 10 (IP-10), platelet factor 4 (PF4), monokine induced by γ -interferon (MIG), epithelial neutrophil activating protein-78 (ENA-78), the growth related oncogene peptides (GRO) GRO- α , GRO- β and GRO- γ , and others. These proteins mediate a diverse number of activities including activation of neutrophils, induction of chemotaxis, induction of angiogenesis and tumorigenesis,
10 as well as inhibition of angiogenesis and tumorigenesis (Belperio, J.A., *et al.*, 2000 *J. Leuk. Bio.* **68**: 1-8).

[005] All of the biological effects of chemokines are exerted through their interaction with a cell surface receptor. There are six CXC chemokine receptors (CXCRs) identified to date (reviewed by Horuk *et al.*, 2001 *Cytokine Growth*
15 *Factor Rev.* **12**: 313-335). The CXCRs are members of the superfamily of serpentine proteins that signal through heterotrimeric G-proteins. These proteins have been shown to possess the ability to bind multiple chemokines with high affinity.

[006] The regulation of angiogenesis is controlled at least in part by
20 angiostatic and angiogenic cytokines. IL-8 has been shown to mediate endothelial cell chemotactic and proliferative activity *in vitro* (Strieter R.M., *et al.*, 1992, *Am. J. Pathol.* **141**: 1279-1284 and Koch, A.E., *et al.*, 1992 *Science* **258**:1798-1801). In contrast, IP-10, MIG, and PF4 have been found to have angiostatic properties both *in vitro* and *in vivo* (Maione, T.E., *et al.*, 1990, *Science* **247**: 77-79; Strieter, R.M.,
25 *et al.*, 1995, *Biochem. Biophys. Res. Commun.* **210**(1): 51-57; and Arenberg, DA, *et al.*, 1997 *Methods Enzymol* **283**: 190-220).

[007] Since tumor growth is dependent upon angiogenesis, it follows that CXC chemokines play a role in growth and metastasis of tumors. The clearest example of angiogenic chemokines modulating tumorigenesis and growth was
30 shown by over-expression of GRO α , β and γ in human melanocytes, which lead to an anchorage-independent growth phenotype *in vitro* and the ability to form tumors *in vivo* in nude mice (Luan, J., *et al.*, 1997, *J. Leukoc. Bio.* **62**: 588-597 and Owen,

J.D., *et al.*, 1997 *Int. J. Cancer* **73**: 94-103). Furthermore, both IL-8 and ENA-78 expression in non-small cell lung carcinoma (NSCLC) has been correlated with tumor angiogenesis (Yatsunami, J., *et al.*, 1997, *Cancer Lett.* **120**: 101-108, and Arenberg, DA, *et al.*, 1998 *J. Clin. Invest.* **102**: 465-472).

- 5 [008] Other CXC chemokines appear to either inhibit tumor cell growth or induce necrosis of tumor cells. Nude mice with Burkitt's tumor subcutaneously implanted were inoculated daily with recombinant MIG. This consistently caused tumor necrosis with vascular damage (Sgadari, C., *et al.*, 1997 *Blood* **89**(8): 2635-). The same was seen in Burkitt's tumor bearing nude mice treated with IP-10
- 10 (Sgadari, C., *et al.*, 1996 *Proc. Natl. Acad. Sci. U.S.A.* **93**:13791-13796). SCID mice bearing NSCLC tumors and treated with MIG also show growth inhibition, decreased numbers of metastasis, and a decrease in tumor-derived vessel density (Addison, C.L., *et al.*, 2000 *Hum. Gene Ther.* **11**: 247-261).
- [009] Antisense technology is emerging as an effective means for
- 15 reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of VCC-1 expression.

SUMMARY OF THE INVENTION

- 20 [0010] The present invention is directed to antisense compounds, particularly oligonucleotides, which are targeted to a nucleic acid encoding VCC-1, and which modulate the expression of VCC-1. Pharmaceutical and other compositions comprising the antisense compounds of the invention are
- 25 also provided. Further provided are methods of modulating the expression of VCC-1 in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with
- 30 expression of VCC-1 by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the cDNA sequence and the VCC-1 protein sequence encoded therefrom.

5

DETAILED DESCRIPTION OF THE INVENTION

[0011] The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding VCC-1, ultimately modulating the amount of VCC-1 produced. This is accomplished by providing antisense compounds, which specifically hybridize with one or more nucleic acids encoding VCC-1. As used herein, the terms "target nucleic acid" and "nucleic acid encoding VCC-1" encompass DNA encoding VCC-1, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds, which specifically hybridize to it, is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of VCC-1. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation, of gene expression and mRNA is a preferred target.

[0012] It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins

with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding VCC-1. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding VCC-1, regardless of the sequence(s) of such codons.

[0013] It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e. 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either

direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

[0014] The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

[0015] Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be

effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

[0016] Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

[0017] In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases, which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

[0018] Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

[0019] The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans. In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

[0020] VCC-1 antisense oligonucleotides that have activity in the cardiovascular, angiogenic, and endothelial assays described herein, and/or whose gene product has been found to be localized to the cardiovascular system, is likely to have therapeutic uses in a variety of cardiovascular, endothelial, and angiogenic disorders, including systemic disorders that affect vessels, such as diabetes mellitus. Its therapeutic utility could include diseases of the arteries, capillaries, veins, and/or lymphatics. Examples of treatments hereunder include treating muscle wasting disease, treating osteoporosis, aiding in implant fixation to stimulate the growth of cells around the implant and therefore facilitate its attachment to its intended site,

increasing IGF stability in tissues or in serum, if applicable, and increasing binding to the IGF receptor (since IGF has been shown in vitro to enhance human marrow erythroid and granulocytic progenitor cell growth).

5 [0021] VCC-1 antisense oligonucleotides can be used to inhibit the production of excess connective tissue during wound healing or pulmonary fibrosis if VCC-1 promotes such production. This would include treatment of acute myocardial infarction and heart failure.

[0022] Moreover, the present invention provides the treatment of cardiac hypertrophy, regardless of the underlying cause, by administering a therapeutically effective dose of VCC-1 antisense oligonucleotides.

10 [0023] The treatment for cardiac hypertrophy can be performed at any of its various stages, which may result from a variety of diverse pathologic conditions, including myocardial infarction, hypertension, hypertrophic cardiomyopathy, and valvular regurgitation. The treatment extends to all stages of the progression of cardiac hypertrophy, with or without structural damage of the heart muscle, regardless of the underlying cardiac disorder.

[0024] VCC-1 antisense oligonucleotides would be useful for treatment of disorders where it is desired to limit or prevent angiogenesis. Examples of such disorders include vascular tumors such as hemangioma, tumor angiogenesis, neovascularization in the retina, choroid, or cornea, associated with diabetic retinopathy or premature infant retinopathy or macular degeneration and proliferative vitreoretinopathy, rheumatoid arthritis, Crohn's disease, atherosclerosis, ovarian hyperstimulation, psoriasis, endometriosis associated with neovascularization, restenosis subsequent to balloon angioplasty, scar tissue overproduction, for example, that seen in a keloid that forms after surgery, fibrosis after myocardial infarction, or fibrotic lesions associated with pulmonary fibrosis.

25 [0025] Specific types of diseases are described below, where VCC-1 antisense oligonucleotides may serve as useful for vascular- related drug targeting or as therapeutic targets for the treatment or prevention of the disorders.

30 [0026] Atherosclerosis is a disease characterized by accumulation of plaques of intimal thickening in arteries, due to accumulation of lipids, proliferation of smooth muscle cells, and formation of fibrous tissue within the arterial wall. The disease can affect large, medium, and small arteries in any organ. Changes in endothelial

and vascular smooth muscle cell function are known to play an important role in modulating the accumulation and regression of these plaques.

[0027] Hypertension is characterized by raised vascular pressure in the systemic arterial, pulmonary arterial, or portal venous systems. Elevated pressure may result from or result in impaired endothelial function and/or vascular disease.

[0028] Inflammatory vasculitides include giant cell arteritis, Takayasu's arteritis, polyarteritis nodosa (including the microangiopathic form), Kawasaki's disease, microscopic polyarthritis, Wegener's granulomatosis, and a variety 101 of infectious-related vascular disorders (including Henoch-Schonlein Prupura).
10 Altered endothelial cell function has been shown to be important in these diseases. Reynaud's disease and Reynaud's phenomenon are characterized by intermittent abnormal impairment of the circulation through the extremities on exposure to cold. Altered endothelial cell function has been shown to be important in this disease.

[0029] Aneurysms are saccular or fusiform dilatations of the arterial or venous tree that are associated with altered endothelial cell and/or vascular smooth muscle cells.

[0030] Arterial restenosis (restenosis of the arterial wall) may occur following angioplasty as a result of alteration in the function and proliferation of endothelial and vascular smooth muscle cells.

20 [0031] Thrombophlebitis and lymphangitis are inflammatory disorders of veins and lymphatics, respectively, that may result from, and/or in, altered endothelial cell function. Similarly, lymphedema is a condition involving impaired lymphatic vessels resulting from endothelial cell function.

[0032] The family of benign and malignant vascular tumors is characterized by abnormal proliferation and growth of cellular elements of the vascular system. For example, lymphangiomas are benign tumors of the lymphatic system that are congenital, often cystic, malformations of the lymphatics that usually occur in newborns.

[0033] Cystic tumors tend to grow into the adjacent tissue. Cystic tumors usually occur in the cervical and axillary region. They can also occur in the soft tissue of the extremities. The main symptoms are dilated, sometimes reticular, structured lymphatics and lymphocysts surrounded by connective tissue.

[0034] Lymphangiomas are assumed to be caused by improperly connected embryonic lymphatics or their deficiency. The result is impaired local lymph drainage.

[0035] Another use for VCC-1 antisense antagonists is in the prevention of
5 tumor angiogenesis, which involves vascularization of a tumor to enable it to
growth and/or metastasize. This process is dependent on the growth of new blood
vessels. Examples of neoplasms and related conditions that involve tumor
angiogenesis include breast carcinomas, lung carcinomas, gastric carcinomas,
esophageal carcinomas, colorectal carcinomas, liver carcinomas, ovarian
10 carcinomas, thecomas, arrhenoblastomas, cervical carcinomas, endometrial
carcinoma, endometrial hyperplasia, endometriosis, fibrosarcomas,
choriocarcinoma, head and neck cancer, nasopharyngeal carcinoma, laryngeal
carcinomas, hepatoblastoma, Kaposi's sarcoma, melanoma, skin carcinomas,
hemangioma, cavernous hemangioma, hemangioblastoma, pancreas carcinomas,
15 retinoblastoma, astrocytoma, glioblastoma, Schwannoma, oligodendroglioma,
medulloblastoma, neuroblastomas, rhabdomyosarcoma, osteogenic sarcoma,
leiomyosarcomas, urinary tract carcinomas, thyroid carcinomas, Wilm's tumor,
renal cell carcinoma, prostate carcinoma, abnormal vascular proliferation associated
with phakomatoses, edema (such as that associated with brain tumors), and Meigs'
20 syndrome.

[0036] Healing of trauma such as wound healing and tissue repair is also a
targeted use for VCC-1 antisense oligonucleotides. Formation and regression of
new blood vessels is essential for tissue healing and repair. This category includes
bone, cartilage, tendon, ligament, and/or nerve tissue growth or regeneration, as
25 well as wound healing and tissue repair and replacement, and in the treatment of
burns, incisions, and ulcers.

[0037] VCC-1 antisense oligonucleotides that induce cartilage and/or bone
growth in circumstances where bone is not normally formed have application in the
healing of bone fractures and cartilage damage or defects in humans and other
30 animals. Such a preparation employing VCC-1 antisense oligonucleotides may have
prophylactic use in closed as well as open fracture reduction and also in the
improved fixation of artificial joints. De novo bone formation induced by an
osteogenic agent contributes to the repair of congenital, trauma induced, or

oncologic, resection-induced craniofacial defects, and also is useful in cosmetic plastic surgery.

5 [0038] It is expected that VCC-1 antisense oligonucleotides may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, or endothelium), muscle (smooth, skeletal, or cardiac), and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate.

10 [0039] VCC-1 antisense oligonucleotides may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage. Also, VCC-1 antisense oligonucleotides may be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells, or for inhibiting the
15 growth of tissues described above.

[0040] VCC-1 antisense oligonucleotides may also be used in the treatment of periodontal diseases and in other tooth-repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells, or induce differentiation of progenitors of bone-forming cells VCC-1
20 antisense oligonucleotides may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes, since blood vessels play an important role in the regulation of bone turnover and growth.

25 [0041] Another category of tissue regeneration activity that may be attributable to VCC-1 antisense oligonucleotides is tendon/ligament formation. A protein that induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed has application in the healing of tendon or ligament tears, deformities, and other tendon or ligament defects in humans and
30 other animals. Such a preparation may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of

VCC-1 antisense oligonucleotides contributes to the repair of congenital, trauma-induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions herein may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions herein may also be useful in the treatment of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

[0042] VCC-1 antisense oligonucleotides may also be administered prophylactically to patients with cardiac hypertrophy, to prevent the progression of the condition, and avoid sudden death, including death of asymptomatic patients. Such preventative therapy is particularly warranted in the case of patients diagnosed with massive left ventricular cardiac hypertrophy (a maximal wall thickness of 35 mm. or more in adults, or a comparable value in children), or in instances when the hemodynamic burden on the heart is particularly strong.

[0043] VCC-1 antisense oligonucleotides may also be useful in the management of atrial fibrillation, which develops in a substantial portion of patients diagnosed with hypertrophic cardiomyopathy. Further indications include angina, myocardial infarctions such as acute myocardial infarctions, and heart failure such as congestive heart failure. Additional non-neoplastic conditions include psoriasis, diabetic and other proliferative retinopathies including retinopathy of prematurity, retrolental fibroplasia, neovascular glaucoma, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, chronic inflammation, lung inflammation, nephrotic syndrome, preeclampsia, ascites, pericardial effusion (such as that associated with pericarditis), and pleural effusion.

[0044] In view of the above, VCC-1 antisense oligonucleotides, which are shown to alter or impact endothelial cell function, proliferation, and/or form, are likely to play an important role in the etiology and pathogenesis of many or all of the disorders noted above, and as such can serve as

therapeutic targets to augment or inhibit these processes or for vascular-related drug targeting in these disorders.

Combination Therapies

- 5 [0045] The effectiveness of VCC-1 antisense oligonucleotides in preventing or treating the disorder in question may be improved by administering the active agent serially or in combination with another agent that is effective for those purposes, either in the same composition or as separate compositions. For example, for treatment of cardiac hypertrophy, VCC-1 antisense therapy can be combined with
- 10 the administration of inhibitors of known cardiac myocyte hypertrophy factors, e.g., inhibitors of cc-adrenergic agonists such as phenylephrine; endothelin-1 inhibitors such as BOSENTAN™ and MOXONODIN™; inhibitors to CT- I (US Pat. No. 5,679,545); inhibitors to LIF; ACE inhibitors; des- aspartate-angiotensin I inhibitors (U.S. Pat. No. 5,773,415), and angiotensin II inhibitors.
- 15 [0046] For treatment of cardiac hypertrophy associated with hypertension, VCC-1 antisense oligonucleotides can be administered in combination with P-adrenergic receptor blocking agents, e.g., propranolol, timolol, tertalolol, carteolol, nadolol, betaxolol, penbutolol, acetobutolol, atenolol, metoprolol, or carvedilol; ACE inhibitors, e.g., quinapril, captopril, enalapril, ramipril, benazepril, fosinopril,
- 20 or lisinopril; diuretics, e.g., chlorothiazide, hydrochlorothiazide, hydroflumethiazide, methylchlorothiazide, benzthiazide, dichlorphenamide, acetazolamide, or indapamide; and/or calcium channel blockers, e.g., diltiazem, nifedipine, verapamil, or nocardipine. Pharmaceutical compositions comprising the therapeutic agents identified herein by their generic names are commercially
- 25 available, and are to be administered following the manufacturers' instructions for dosage, administration, adverse effects, contraindications, etc. 119 See, e.z., *Physicians' Desk Reference* (Medical Economics Data Production Co.: Montvale, N.J., 1997), 51 st Edition. Preferred candidates for combination therapy in the treatment of hypertrophic cardiomyopathy are P-adrenergic-blocking drugs (e.g.,
- 30 propranolol, timolol, tertalolol, carteolol, nadolol, betaxolol, penbutolol, acetobutolol, atenolol, metoprolol, or carvedilol), verapamil, difedipine, or diltiazem. Treatment of hypertrophy associated with high blood pressure may require the use of antihypertensive drug therapy, using calcium channel blockers,

e.g., diltiazem, nifedipine, verapamil, or nicardipine; P-adrenergic blocking agents; diuretics, e.g., chlorothiazide, hydrochlorothiazide, hydroflumethiazide, methylchlorothiazide, benzthiazide, dichlorphenamide, acetazolamide, or indapamide; and/or ACE-inhibitors, e. g., quinapril, captopril, enalapril, ramipril, benazepril, fosinopril, or lisinopril.

[0047] For other indications, VCC-1 antisense oligonucleotides may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as EGF, PDGF, TGF- or TGF-, IGF, FGF, and CTGF.

10 [0048] In addition, VCC-1 antisense oligonucleotides used to treat cancer may be combined with cytotoxic, chemotherapeutic, or growth-inhibitory agents as identified above. Also, for cancer treatment, VCC-1 antisense oligonucleotides are suitably administered serially or in combination with radiological treatments, whether involving irradiation or administration of radioactive substances.

15 [0049] The effective amounts of the therapeutic agents administered in combination with VCC-1 antisense oligonucleotides thereof will be at the physician's, or veterinarian's discretion. Dosage administration and adjustment is done to achieve maximal management of the conditions to be treated. For example, for treating hypertension, these amounts ideally take into account use of diuretics or digitalis, and conditions such as hyper- or hypotension, renal impairment, etc. The
20 dose will additionally depend on such factors as the type of the therapeutic agent to be used and the specific patient being treated. Typically, the amount employed will be the same dose as that used, if the given therapeutic agent is administered without VCC-1 antisense oligonucleotides.

25 [0050] For treatment of breast carcinoma, VCC-1 antisense oligonucleotides can be administered in combination with, but not limited to, Trastuzumab (Herceptin) with chemotherapy, paclitaxel, docetaxel, epirubicin, mitoxantrone, topotecan, capecitabine, vinorelbine, thiotepa, vincristine, vinblastine, carboplatin or cisplatin, plicamycin, anastrozole, letrozole, exemestane, toremifene, or
30 progestins.

[0051] For treatment of acute lymphocytic leukemia, VCC-1 antisense oligonucleotides can be administered in combination with, but not limited to,

doxorubicin, cytarabine, cyclophosphamide, etoposide, teniposide, allopurinol, or autologous bone marrow transplantation.

[0052] For treatment of acute myelocytic and myelomonocytic leukemia, VCC-1, antisense oligonucleotides can be administered in combination with, but not

5 limited to, gemtuzumab ozogamicin (Mylotarg), mitoxantrone, idarubicin, etoposide, mercaptopurine, thioguanine, azacitidine, amsacrine, methotrexate, doxorubicin, tretinoin, allopurinol, leukapheresis, prednisone, or arsenic trioxide for acute promyelocytic leukemia.

[0053] For treatment of chronic myelocytic leukemia, VCC-1 antisense
10 oligonucleotides can be administered in combination with, but not limited to, busulfan, mercaptopurine, thioguanine, cytarabine, plicamycin, melphalan, autologous bone marrow transplantation, or allopurinol.

[0054] For treatment of chronic lymphocytic leukemia, VCC-1 antisense oligonucleotides can be administered in combination with, but not limited to,
15 vincristine, cyclophosphamide, doxorubicin, cladribine (2-chlorodeoxyadenosine; CdA), allogeneic bone marrow transplant, androgens, or allopurinol.

[0055] For treatment of multiple myeloma, VCC-1 antisense oligonucleotides can be administered in combination with, but not limited to, etoposide, cytarabine, alpha interferon, dexamethasone, or autologous bone marrow transplantation.

20 [0056] For treatment of carcinoma of the lung (small cell and non-small cell), VCC-1 antisense oligonucleotides can be administered in combination with, but not limited to, cyclophosphamide, doxorubicin, vincristine, etoposide, mitomycin, ifosfamide, paclitaxel, irinotecan, or radiation therapy.

[0057] For treatment of carcinoma of the colon and rectum, VCC-1 antisense
25 oligonucleotides can be administered in combination with, but not limited to, capecitabine, methotrexate, mitomycin, carmustine, cisplatin, irinotecan, or floxuridine.

[0058] For treatment of carcinoma of the kidney, VCC-1 antisense oligonucleotides can be administered in combination with, but not limited to, alpha
30 interferon, progestins, infusional FUDR, or fluorouracil.

[0059] For treatment of carcinoma of the prostate, VCC-1 antisense oligonucleotides can be administered in combination with, but not limited to,

ketoconazole, doxorubicin, aminoglutethimide, progestins, cyclophosphamide, cisplatin, vinblastine, etoposide, suramin, PC-SPES, or estramustine phosphate.

[0060] For treatment of melanoma, VCC-1 antisense oligonucleotides can be administered in combination with, but not limited to, carmustine, lomustine,

5 melphalan, thiotepa, cisplatin, paclitaxel, tamoxifen, or vincristine.

[0061] For treatment of carcinoma of the ovary, VCC-1 antisense oligonucleotides can be administered in combination with, but not limited to, docetaxel, doxorubicin, topotecan, cyclophosphamide, doxorubicin, etoposide, or liposomal doxorubicin.

10 [0062] While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases
15 (i.e. from about 8 to about 30 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12 to about 25 nucleobases. As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes
20 of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the
25 phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as
30 forming the internucleoside backbone of the oligonucleotide. The normal I linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

[0063] Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or

non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as

5 sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

[0064] Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, 10 phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and 15 boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

[0065] Representative United States patents that teach the preparation of 20 the above phosphorus-containing linkages include, but are not limited to, U.S. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 25 5,625,050, each of which is herein incorporated by reference.

[0066] Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain 30 heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and

thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

5 [0067] Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 10 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein incorporated by reference.

[0068] In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are 15 replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is 20 replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. 5,539,082; 5,714,331; 25 and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, 1991, 254, 1497-1500.

[0069] Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides 30 with heteroatom backbones, and in particular -CH₂-NH-O-CH₂-, -CH₂-N(CH₃)-O-CH₂- [known as a methylene (methylimino) or MMI backbone], -CH₂-O-N(CH₃)-CH₂-, -CH₂N(CH₃)-N(CH₃)-CH₂- and -O-N(CH₃)-CH₂-CH₂- [wherein the native phosphodiester backbone is represented as -O-P-

O-CH₂-] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

- 5 **[0070]** Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀
- 10 alkenyl and alkynyl. Particularly preferred are O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON[(CH₂)_nCH₃]₂ where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C₁ to C₁₀, (lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl
- 15 or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving
- 20 the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O- (2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes
- 25 2'-dimethylaminoethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as described in examples herein below, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, also described in examples herein below.
- 30 **[0071]** Other preferred modifications include 2'-methoxy (2'-O CH₃) , 2'-aminopropoxy (2'-O CH₂ CH₂ CH₂NH₂) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in

2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, each of which is herein incorporated by reference in its entirety.

[0072] Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B. ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These

include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds, *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

[0073] Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,750,692, and 5,681,941, each of which is herein incorporated by reference.

[0074] Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates, which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, 1991, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, 1990, 259, 327-330; Svinarchuk et al., *Biochimie*, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 365'-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et

al., *Tetrahedron Lett.*, 1995, 36, 365¹-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923-937).

5 **[0075]** Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718;
10 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667;
15 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, each of which is herein incorporated by reference.

[0076] It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned
20 modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds, which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more
25 chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake,
30 and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease, which cleaves the RNA strand of RNA:DNA

duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

[0077] Chimeric antisense compounds of the invention may be formed

as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, each of which is herein incorporated by reference in its entirety.

[0078] The antisense compounds used in accordance with this invention may be conveniently, and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

[0079] The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules. The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United

States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S.

5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158;

5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556;

5 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619;

5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528;

5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which

is herein incorporated by reference.

[0080] The antisense compounds of the invention encompass any

10 pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is

capable of providing (directly or indirectly) the biologically active

metabolite or residue thereof. Accordingly, for example, the disclosure is

also drawn to prodrugs and pharmaceutically acceptable salts of the

15 compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

[0081] The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other

20 chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published December 9, 1993 or in WO 94/26764 to Imbach et al.

25 **[0082]** The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

[0083] Pharmaceutically acceptable base addition salts are formed with 30 metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N, N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine,

dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 119). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the
5 desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to
10 their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates,
15 salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or
20 phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-
25 phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic
30 acid, benzenesulfonic acid, 4-methylbenzenesulfoic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid.

Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

[0084] For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

[0085] The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, and prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder, which can be treated by modulating the expression of VCC-1, is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

[0086] The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding VCC-1, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense

oligonucleotides of the invention with a nucleic acid encoding VCC-1 can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such
5 detection means for detecting the level of VCC-1 in a sample may also be prepared.

[0087] The present invention also includes pharmaceutical compositions and formulations, which include the antisense compounds of the invention.

The pharmaceutical compositions of the present invention may be
10 administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal,
15 epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral
20 administration.

[0088] Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the
25 like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

[0089] Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents,
30 emulsifiers, dispersing aids or binders may be desirable.

[0090] Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions, which may also contain buffers, diluents and other suitable additives such as, but

not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

[0091] Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing
5 formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

[0092] The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared
10 according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided
15 solid carriers or both, and then, if necessary, shaping the product.

[0093] The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as
20 suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances, which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

[0094] In one embodiment of the present invention the pharmaceutical
25 compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally
30 known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

Emulsions

[0095] The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug, which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

[0096] Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well

dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

[0097] Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

[0098] Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, non-swelling clays such as

bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

[0099] A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives, and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

[00100] Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed phase droplets and by increasing the viscosity of the external phase.

[00101] Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

- [00102] The application of emulsion formulations via dermatological, oral, and parenteral routes and methods for their manufacture has been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.
- [00103] In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile, which is a single optically isotropic, and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 1852-5). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric

packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 271).

[00104] The phenomenological approach utilizing phase diagrams has
5 been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.),
10 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

[00105] Surfactants used in the preparation of microemulsions include,
15 but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprates (MCA750), decaglycerol monooleate (MO750), decaglycerol
20 sequioleate (S0750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among
25 surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene
30 glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and triglycerides, polyoxyethylated glyceryl fatty acid

esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

[00106] Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based
5 microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., *Pharmaceutical Research*, 1994, 11, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis,
10 possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., *Pharmaceutical Research*, 1994, 11, 1385; Ho et al., *J. Pharm. Sci.*, 1996, 85, 138-143). Often
15 microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and
20 pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina,
25 buccal cavity and other areas of administration.

[00107] Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and
30 nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in*

Therapeutic Drug Carrier Systems, 1991, p. 92). Each of these classes has been discussed above.

Liposomes

- 5 [00108] There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery.
- 10 As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.
- [00109] Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic
- 15 liposomes possess the advantage of being able to fuse to the cell wall. Noncationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages in vivo.
- [00110] In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under
- 20 the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome, which is highly deformable and able to pass through such fine pores.
- [00111] Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes
- 25 can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, P. 245). Important considerations in the preparation of liposome
- 30 formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.
- [00112] Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is

structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

5 [00113] Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug,
10 increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

[00114] Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds
15 including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

[00115] Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes, which interact with the negatively charged
20 DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, 1987, 147, 980 - 985)

25 [00116] Liposomes, which are pH-sensitive or negatively charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding
30 the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled Release*, 1992, 19, 269-274).

- [00117] One major type of liposomal composition includes phospholipids other than naturally derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC).
- 5 Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of
- 10 phospholipid and/or phosphatidylcholine and/or cholesterol.
- [00118] Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an
- 15 emulsion) was ineffective (Weiner et al., *Journal of Drug Targeting*, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al.,
- 20 *Antiviral Research*, 1992, 18, 259-265).
- [00119] Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl
- 25 dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin
- 30 (Hu et al. *S.T.P. Pharma. Sci.*, 1994, 4, 6, 466).
- [00120] Liposomes also include "sterically stabilized" liposomes, a term, which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced

circulation lifetimes relative to liposomes lacking such, specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_{M1} , or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., *FEBS Letters*, 1987, 223, 42; Wu et al., *Cancer Research*, 1993, 53, 3765).

[00121] Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, 1987, 507, 64) reported the ability of monosialoganglioside G_{M1} , galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (*Proc. Natl. Acad. Sci. U.S.A.*, 1988, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

[00122] Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (*Bull. Chem. Soc. Jpn.*, 1980, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G that contains a PEG moiety. Illum et al. (*FEBS Lett.*, 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klivanov et al. (*FEBS Lett.*, 1990, 268, 235) described experiments

demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, 1990, 1029, 91) extended such observations to other PEG derivatized

5 phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized

10 with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin et al.) and in WO

15 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Patent Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

20 **[00123]** A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA.

25 U.S. Patent No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

[00124] Transfersomes are yet another type of liposomes, and are highly

30 deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets, which are so highly deformable that they are easily able to penetrate through pores that are smaller than the droplet. Transfersomes are adaptable to the

environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

[00125] Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285)

[00126] If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

[00127] If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic.

Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most

important members of the anionic surfactant class are the alkyl sulfates and the soaps.

[00128] If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic.

- 5 Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

- [00129] If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric
10 surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

[00130] The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285). Penetration Enhancers

- 15 [00131] In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been
20 discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

- [00132] Penetration enhancers may be classified as belonging to one of
25 five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating nonsurfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

- 30 [00133] Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the

result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

[00134] Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and diglycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

[00135] Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds. McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate

(STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*, 1990, 79, 579-583).

[00136] Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, 1993, 618, 315-339). Chelating agents of the invention include but are not limited to disodium. ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9, and N-amino acyl derivatives of beta-diketones (enamines)(Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Buur et al., *J. Control Rel.*, 1990, 14, 43-51).

[00137] Non-chelating non-surfactants: As used herein, nonchelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33). This class of penetration enhancers includes, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin, and

phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, 1987, 39, 621-626).

[00138] Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

10 [00139] Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

Carriers

15 [00140] Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'isothiocyano-stilbene-2,2'-disulfonic acid (Miyao et al., *Antisense Res. Dev.*, 1995, 5, 115-121; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*, 1996, 6, 177-183).

Excipients

[00141] In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with
5 the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl
10 methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium
15 benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

[00142] Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration, which does not deleteriously react with nucleic acids, can also be used to formulate the compositions of
20 the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

[00143] Formulations for topical administration of nucleic acids may
25 include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration, which do not
30 deleteriously react with nucleic acids, can be used.

[00144] Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin,

lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Other Components

- 5 [00145] The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or
10 anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological
15 activities of the components of the compositions of the present invention.' The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not
20 deleteriously interact with the nucleic acid(s) of the formulation.
- [00146] Aqueous suspensions may contain substances, which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol, and/or dextran. The suspension may also contain stabilizers.
- 25 [00147] Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include, but are not limited to, anticancer drugs such as daunorubicin, dactinomycin,
30 doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-fluorouracil (5-FU), floxuridine (5-FUdR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and

diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 1206-1228). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including
5 but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). other non-antisense chemotherapeutic agents are also within the scope of this
10 invention. Two or more combined compounds may be used together or sequentially.

[00148] In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional
15 antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

[00149] The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the
20 art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill
25 can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC₅₀s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 µg to 100 g per kg of body weight, and may be given
30 once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be

desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 µg to 100 g per kg of body weight, once or more daily, to once every 20 years.

- 5 [00150] While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

10 EXAMPLES

Example 1

Nucleoside Phosphoramidites for Oligonucleotide Synthesis Deoxy and 2'-alkoxy amidites

- 15 [00151] 2'-Deoxy and 2'-methoxy beta-cyanoethyl-diisopropyl phosphoramidites are available from commercial sources (e.g. ChemGenes, Needham MA or Glen Research, Inc. Sterling VA). Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides
20 synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides is utilized, except the wait step after pulse delivery of tetrazole and base is increased to 360 seconds.

- [00152] Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides are synthesized according to published methods [Sanghvi, et.
25 al., *Nucleic Acids Research*, 1993, 21, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA).

2'-Fluoro amidites

2'-Fluorodeoxyadenosine amidites

- 30 [00153] 2'-fluoro oligonucleotides are synthesized as described previously [Kawasaki, et. al., *J. Med. Chem.*, 1993, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine is

synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S_N2-displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine is selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups is accomplished using standard methodologies and standard methods are used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

10 **2'-Fluorodeoxyguanosine**

[00154] The synthesis of 2'-deoxy-2'-fluoroguanosine is accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyrylarabinofuranosylguanosine. Deprotection of the TPDS group is followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation is followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies are used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

20 **2'-Fluorouridine**

[00155] Synthesis of 2'-deoxy-2'-fluorouridine is accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil is treated with 70% hydrogen fluoride-pyridine. Standard procedures are used to obtain the 5'-DMT and 5'-DMT-3'-phosphoramidites.

25 **2'-Fluorodeoxycytidine**

[00156] 2'-deoxy-2'-fluorocytidine is synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures are used to obtain the 5'-DMT and 5'-DMT-3'-phosphoramidites.

2'-O-(2-Methoxyethyl) modified amidites

[00157] 2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]

- 5 [00158] 5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) are added to DMF (300 mL). The mixture is heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1
10 hour, the slightly darkened solution is concentrated under reduced pressure. The resulting syrup is poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether is decanted and the residue is dissolved in a minimum amount of methanol (ca. 400 mL). The solution is poured into fresh ether (2.5 L) to yield a stiff gum. The ether is decanted and the gum is
15 dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that is crushed to a light tan powder. The material is used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid.

2'-O-Methoxyethyl-5-methyluridine

- 20 [00159] 2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) are added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel is opened and the solution evaporated to dryness and triturated with MeOH (200 mL).
25 The residue is suspended in hot acetone (1 L). The insoluble salts are filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) is dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) is packed in CH₂Cl₂ /acetone /MeOH (20:5:3) containing 0.5% Et₃NH. The residue is dissolved in CH₂Cl₂ (250 mL) and adsorbed
30 onto silica (150 g) prior to loading onto the column. The product is eluted with the packing solvent to give the title product. Additional material can be obtained by reworking impure fractions.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

[00160] 2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) is co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) is added and the mixture stirred at room temperature for one hour. A
5 second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) is added and the reaction stirred for an additional one hour. Methanol (170 mL) is then added to stop the reaction. The solvent is evaporated and triturated with CH₃CN (200 mL). The residue is dissolved in CHCl₃ (1.5 L) and extracted with 2x500 mL of saturated NaHCO₃ and 2x500 mL of saturated NaCl. The
10 organic phase is dried over Na₂SO₄, filtered, and evaporated. The residue is purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/hexane/acetone (5:5:1) containing 0-5% Et₃NH. The pure fractions are evaporated to give the title product.

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

[00161] 2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) are combined and stirred at room temperature for 24 hours. The reaction is monitored by TLC by first quenching the TLC sample with the addition of
20 MeOH. Upon completion of the reaction, as judged by TLC, MeOH (50 mL) is added and the mixture evaporated at 35°C. The residue is dissolved in CHCl₃ (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers are back extracted with 200 mL of CHCl₃. The combined organics are dried with
25 sodium sulfate and evaporated to a residue. The residue is purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane(4:1). Pure product fractions are evaporated to yield the title compounds.

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine

[00162] A first solution is prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) is added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to -5°C and

stirred for 0.5 h using an overhead stirrer. POCl_3 is added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution is added dropwise, over a 45 minute period, to the latter solution. The resulting
5 reaction mixture is stored overnight in a cold room. Salts are filtered from the reaction mixture and the solution is evaporated. The residue is dissolved in EtOAc (1 L) and the insoluble solids are removed by filtration. The filtrate is washed with 1x300 mL of NaHCO_3 and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue is triturated
10 with EtOAc to give the title compound.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

[00163] A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH_4OH (30 mL) is stirred at room temperature for 2 hours.
15 The dioxane solution is evaporated and the residue azeotroped with MeOH (2x200 mL). The residue is dissolved in MeOH (300 mL) and transferred to a 2-liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH_3 gas is added and the vessel heated to 100°C for 2 hours (TLC showed complete conversion). The vessel contents are evaporated to dryness and the
20 residue is dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics are dried over sodium sulfate and the solvent is evaporated to give the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

[00164] 2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) is dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) is added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent is evaporated and the residue azeotroped with MeOH (200 mL). The residue is dissolved in
30 CHCl_3 (700 mL) and extracted with saturated NaHCO_3 (2x300 mL) and saturated NaCl (2x300 mL), dried over MgSO_4 and evaporated to give a residue. The residue is chromatographed on a 1.5 kg silica column using

EtOAc/hexane (1:1) containing 0-5% Et₃NH as the eluting solvent. The pure product fractions are evaporated to give the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite

- 5 [00165] N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) is dissolved in CH₂Cl₂ (1 L) Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra(isopropyl)phosphite (40.5 mL, 0.123 M) are added with stirring, under a nitrogen atmosphere. The resulting mixture is stirred for 20 hours at room temperature (TLC showed
10 the reaction to be 95% complete). The reaction mixture is extracted with saturated NaHCO₃ (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes are back-extracted with CH₂Cl₂ (300 mL), and the extracts are combined, dried over MgSO₄ and concentrated. The residue obtained is chromatographed on a 1.5 kg silica column using EtOAc/hexane (3:1) as the
15 eluting solvent. The pure fractions were combined to give the title compound.

2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites

- 20 [00166] 2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl
25 moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

5'-O-tert-Butyldiphenylsilyl -O² -2'-anhydro-5-methyluridine

- [00167] O² -2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.4'6 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol)
30 are dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) is added in one portion. The reaction is stirred for 16 h at ambient temperature. TLC

(Rf 0.22, ethyl acetate) indicated a complete reaction. The solution is concentrated under reduced pressure to a thick oil. This is partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer is dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil is dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution is cooled to -10°C. The resulting crystalline product is collected by filtration, washed with ethyl ether (3x200 mL), and dried (40°C, 1mm Hg, 24 h) to a white solid

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine
[00168] In a 2 L stainless steel, unstirred pressure reactor is added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) is added cautiously at first until the evolution of hydrogen gas subsides. 5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine (149 g, 0.3'1 mol) and sodium bicarbonate (0.074 g, 0.003 eq) are added with manual stirring. The reactor is sealed and heated in an oil bath until an internal temperature of 160°C is reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel is cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction is stopped, concentrated under reduced pressure (10 to 1mm, Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue is purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions are combined, stripped and dried to product as a white crisp foam, contaminated starting material, and pure reusable starting material.

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine
[00169] 5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) is mixed with triphenylphosphine (11.63g,

44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol). It is then dried over P₂O₅ under high vacuum for two days at 40°C. The reaction mixture is flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) is added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 5 44.36mmol) is added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition is complete, the reaction is stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent is evaporated in vacuum. Residue 10 obtained is placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine as white foam.

5'-O-tert-butylidiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

15 [00170] 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) is dissolved in dry CH₂Cl₂ (4.5mL) and methylhydrazine (300mL, 4.64mmol) is added dropwise at -10°C to 0°C. After 1 h the mixture is filtered, the filtrate is washed with ice cold CH₂Cl₂ and the combined organic phase is washed with water, brine and dried over 20 anhydrous Na₂SO₄. The solution is concentrated to get 2'-O(aminooxyethyl)thymidine, which is then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) is added and the resulting mixture is stirred for 1 h. Solvent is removed under vacuum; residue chromatographed to get 5'-O-tert-butylidiphenylsilyl-2'-O-[(2- 25 formadoximinooxy) ethyl]-5-methyluridine as white foam.

5'-O-tert-Butylidiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine

[00171] 5'-O-tert-butylidiphenylsilyl-2'-O-[(2- formadoximinooxy)ethyl]- 5-methyluridine (1.77g, 3.12mmol) is dissolved in a solution of 1M 30 pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6.13mmol) is added to this solution at 10°C under inert atmosphere. The reaction mixture is stirred for 10 minutes at 10°C. After that the reaction vessel is removed from the ice bath and stirred at

room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO₃ solution (5%, 10mL) is added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase is dried over anhydrous Na₂SO₄, evaporated to dryness. Residue is dissolved in a solution of 1M PPTS in MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) is added and the reaction mixture is stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) is added, and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture is removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO₃ (25mL) solution is added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer is dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue obtained is purified by flash column chromatography and eluted with 5% MeOH in CH₂Cl₂ to get 5'-O-tertbutyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine as a white foam.

2'-O-(dimethylaminoxyethyl)-5-methyluridine

[00172] Triethylamine trihydrofluoride (3.91mL, 24.0mmol) is dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF is then added to 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction is monitored by TLC (5% MeOH in CH₂Cl₂). Solvent is removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH₂Cl₂ to get 2'-O-(dimethylaminoxyethyl)-5-methyluridine.

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine

[00173] 2'-O-(dimethylaminoxyethyl)-5-methyluridine (750mg, 2.17mmol) is dried over P₂O₅ under high vacuum overnight at 40°C. It is then co-evaporated with anhydrous pyridine (20mL). The residue obtained is dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2.60mmol) is added to the mixture and the reaction mixture is stirred at room temperature until all of the starting material disappeared.

Pyridine is removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH₂Cl₂ (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine.

5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-

5 **[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

[00174] 5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine (1.08g, 1.67mmol) is co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) is added and dried over P20, under high vacuum overnight at 40°C. Then the reaction mixture
10 is dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl-N,N,N¹,N¹-tetraisopropylphosphoramidite (2.12mL, 6.08mmol) is added. The reaction mixture is stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction is monitored by TLC (hexane:ethyl acetate 1:1). The solvent is evaporated, then the residue is dissolved in ethyl acetate
15 (70mL) and washed with 5% aqueous NaHCO₃ (40mL). Ethyl acetate layer is dried over anhydrous Na₂SO₄ and concentrated. Residue obtained is chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam.

20 **2'-(Aminooxyethoxy) nucleoside amidites**

[00175] 2'-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

25 **N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

[00176] The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of
30 diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2ethylacetyl)guanosine by

treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites

[00177] 2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

[00178] 2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O²-, 2' - anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed, placed in an oil bath, and heated to 155°C for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3x200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent. As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy) ethyl]-5-methyl uridine

- [00179] To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]1-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and extracted with CH₂Cl₂ (2x200 mL). The combined CH₂Cl₂ layers are washed with saturated NaHCO₃ solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate.
- 10 Evaporation of the solvent followed by silica gel chromatography using MeOH: CH₂Cl₂:Et₃N (20:1, v/v, with 1% triethylamine) gives the title compound.

5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite

- 15 [00180] Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxyN,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH₂Cl₂ (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the
- 20 solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

Example 2

25 **Oligonucleotide synthesis**

- [00181] Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.
- 30 [00182] Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle is replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation

wait step is increased to 68 sec and is followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (18 h), the oligonucleotides are purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

[00183] Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

[00184] 3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

[00185] Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

[00186] Alkylphosphonothioate oligonucleotides are prepared as described in WO 94/17093 and WO 94/02499 herein incorporated by reference.

[00187] 3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

[00188] Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

[00189] Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

Example 3

Oligonucleoside Synthesis

[00190] Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked

oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825; 5,386,023; 5,489,677; 5,602,240; and 5,610,289, all of which are herein

5 incorporated by reference.

[00191] Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

[00192] Ethylene oxide linked oligonucleosides are prepared as described
10 in U.S. Patent 5,223,618, herein incorporated by reference.

Example 4

PNA Synthesis

[00193] Peptide nucleic acids (PNAs) are prepared in accordance with
15 any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, 1996, 4, 523. They may also be prepared in accordance with U.S. Patents 5,539,082; 5,700,922; and 5,719,262, herein incorporated by
20 reference.

Example 5

Synthesis of Chimeric Oligonucleotides

[00194] Chimeric oligonucleotides, oligonucleosides or mixed
oligonucleotides/oligonucleosides of the invention can be of several
25 different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or
30 gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric Phosphorothioate
Oligonucleotides

[00195] Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect all bases and sample is again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides

[00196] [2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides are prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of phosphorothioate oligonucleotides are prepared as per the procedure above for 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

[2'-O-(2-Methoxyethyl)Phosphodiester]--[2'-deoxy Phosphorothioate]--[2'-O-(2-Methoxyethyl)] Phosphodiester] Chimeric Oligonucleotides

[00197] [2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-

(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4-dihydro-2H-benzothiole-3-one 1,1 dioxides (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

[00198] Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by reference.

10 **Example 6**

Oligonucleotide Isolation

[00199] After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol.

15 Synthesized oligonucleotides are analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full-length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis are periodically checked by ³¹P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides are purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* 1991, 266, 18162-18171.

Example 7

25 **Oligonucleotide Synthesis - 96 Well Plate Format**

[00200] Oligonucleotides are synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages are afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages are generated by sulfurization utilizing 3,4-dihydro-2H-benzothiole-3-one 1,1 dioxides (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites can be purchased from commercial

vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected betacyanoethyldiisopropyl phosphoramidites.

- 5 **[00201]** Oligonucleotides are cleaved from support and deprotected with concentrated NH_4OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product is then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

10

Example 8

Oligonucleotide Analysis - 96 Well Plate Format

- [00202]** The concentration of oligonucleotide in each well is assessed by dilution of samples and UV absorption spectroscopy. The full-length
15 integrity of the individual products is evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition is confirmed by mass analysis of the compounds utilizing electrospray-mass
20 spectroscopy. All assay test plates are diluted from the master plate using single and multi-channel robotic pipettors. Plates are judged to be acceptable if at least 85% of the compounds on the plate are at least 85% full length.

25 **Example 9**

Cell culture and oligonucleotide treatment

- [00203]** The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely
30 determined using, for example, PCR or Northern blot analysis. The following 6 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art,

for example Northern blot analysis, Ribonuclease protection assays, or RT-PCR.

T-24 cells:

[00204] The human transitional cell bladder carcinoma cell line T-24 is
5 obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells are routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100
10 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells are routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells are seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

[00205] For Northern blotting or other analysis, cells may be seeded onto
15 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

[00206] The human lung carcinoma cell line A549 can be obtained from
the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells
20 are routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells are routinely passaged by trypsinization and
25 dilution when they reached 90% confluence.

NHDF cells:

[00207] Human neonatal dermal fibroblast (NHDF) can be obtained from
the Clonetics Corporation (Walkersville MD). NHDFs are routinely
maintained in Fibroblast Growth Medium (Clonetics Corporation,
30 Walkersville MD) supplemented as recommended by the supplier. Cells are maintained for up to 10 passages as recommended by the supplier.

HEK cells:

[00208] Human embryonic keratinocytes (HEK) can be obtained from the Clonetics Corporation (Walkersville MD). HEKs are routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville MD) formulated as recommended by the supplier. Cells are routinely maintained for up to 10 passages as recommended by the supplier.

MCF-7 cells:

[00209] The human breast carcinoma cell line MCF-7 is obtained from the American Type Culture Collection (Manassas, VA). MCF-7 cells are routinely cultured in DMEM low glucose (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells are routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells are seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

[00210] For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

LA4 cells:

[00211] The mouse lung epithelial cell line LA4 is obtained from the American Type Culture Collection (Manassas, VA). LA4 cells are routinely cultured in F12K medium (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 15% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells are routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells are seeded into 96-well plates (Falcon-Primaria #3872) at a density of 3000-6000 cells/ well for use in RT-PCR analysis.

[00212] For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

Treatment with antisense compounds:

[00213] When cells reached 80% confluence, they are treated with oligonucleotide. For cells grown in 96-well plates, wells are washed once with 200 μ L OPTI-MEMTM-1 reduced-serum medium (Gibco BRL) and

then treated with 130 μ L of OPTI-MEM™-1 containing 3.75 μ g/mL LIPOFECTIN™ (Gibco BRL) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium is replaced with fresh medium. Cells are harvested 16-24 hours after oligonucleotide treatment.

[00214] The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations.

Example 10

Analysis of oligonucleotide inhibition of VCC-1 expression

[00215] Antisense modulation of VCC-1 expression can be assayed in a variety of ways known in the art. For example, VCC-1 mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions. Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both

(multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed as multiplexable. Other methods of PCR are also known in the art.

5 [00216] Protein levels of VCC-1 can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to VCC-1 can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley Sons, Inc., 1997.

20 [00217] Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

30

Example 11**Poly(A)+ mRNA isolation**

- [00218] Poly(A)+ mRNA is isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation
- 5 are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium is removed from the cells and each well is washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40,
- 10 20 mM vanadyl-ribonucleoside complex) is added to each well, the plate is gently agitated and then incubated at room temperature for five minutes. 55 μ L of lysate is transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates are incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1
- 15 mM EDTA, 0.3 M NaCl). After the final wash, the plate is blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C is added to each well, the plate is incubated on a 90°C hot plate for 5 minutes, and the eluate is then transferred to a fresh 96-well plate.
- 20 [00219] Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Example 12**Total RNA Isolation**

- 25 [00220] Total mRNA is isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium is removed from the cells and each well is washed with 200 μ L cold PBS. 100 μ L Buffer RLT is added to each well and the plate vigorously
- 30 agitated for 20 seconds. 100 μ L of 70% ethanol is then added to each well and the contents mixed by pipetting three times up and down. The samples are then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum

source. Vacuum is applied for 15 seconds. 1 mL of Buffer RW1 is added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE is then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash is then repeated and the vacuum is applied for an additional 10 minutes. The plate is then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate is then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA is then eluted by pipetting 60µL water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step is repeated with an additional 60µL water.

[00221] The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

Example 13

Real-time Quantitative PCR Analysis of VCC-1 mRNA Levels

[00222] Quantitation of VCC-1 mRNA levels is determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE, FAM™, or VIC, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon

Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target
5 sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each
10 cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is
15 used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

[00223] PCR reagents can be obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions are carried out by adding 25 µL PCR cocktail (1x TAQMAN™ buffer A, 5.5 mM MgCl₂, 300 µM each of dATP, dCTP and dGTP, 600 µM of dUTP, 100 nM each of forward primer, reverse
20 primer, and probe, 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLD™, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25 µL poly(A) mRNA solution. The RT reaction is carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at
25 95°C to activate the AMPLITAQ GOLD™, 40 cycles of a two-step PCR protocol are carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

[00224] Probes and primers to human VCC-1 were designed to hybridize to a human VCC-1 sequence, using published sequence, information
30 (GenBank accession number XM_058945, incorporated herein as Figure 1. For human VCC-1 the PCR primers were:
forward primer: CGACAGTTGCGATGAAAGTTCT SEQ ID NO:1100

reverse primer: AGAGACCATGGACATCAGCATTAG SEQ ID NO:1101
 and the PCR probe is: FAMTM- TCTCTTCCCTCCTCCTGTTGCTGCC SEQ
 ID NO:1102 -TAMRA where FAMTM (PE-Applied Biosystems, Foster
 City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied
 5 Biosystems, Foster City, CA) is the quencher dye. For human cyclophilin
 the PCR primers were:
 forward primer: CCCACCGTGTTCCTTCGACAT SEQ ID NO:1103
 reverse primer: TTTCTGCTGTCTTTGGGACCTT SEQ ID NO 1104 and
 the PCR probe is: 5' JOE- CGCGTCTCCTTTGAGCTGTTTGCA SEQ ID
 10 NO:1105 - TAMRA 3' where JOE (PE-Applied Biosystems, Foster City,
 CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems,
 Foster City, CA) is the quencher dye.

Example 14

15 Antisense inhibition of human VCC-1 expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

[00225] In accordance with the present invention, a series of
 oligonucleotides are designed to target different regions of the human VCC-
 20 1 RNA, using published sequences (XM_058945, incorporated herein as
 Figure 1. The oligonucleotides are shown in Table 1. "Position" indicates
 the first (5'-most) nucleotide number on the particular target sequence to
 which the oligonucleotide binds. The indicated parameters for each oligo
 were predicted using RNAstructure 3.7 by David H. Mathews, Michael
 25 Zuker, and Douglas H. Turner. The parameters are described either as free
 energy (The energy that is released when a reaction occurs. The more
 negative the number, the more likely the reaction will occur. All free
 energy units are in kcal/mol.) or melting temperature (The temperature at
 which two anneal strands of polynucleic acid separate. The higher the
 30 temperature, greater the affinity between the 2 strands.) When designing an
 antisense oligonucleotide that will bind with high affinity, it is desirable to
 consider the structure of the target RNA strand and the antisense oligomer.

Specifically, for an oligomer to bind tightly (in the table described as 'duplex formation'), it should be complementary to a stretch of target RNA that has little self-structure (in the table the free energy of which is described as 'target structure'). Also, the oligomer should have little self-structure, either intramolecular (in the table the free energy of which is described as 'intramolecular oligo') or bimolecular (in the table the free energy of which is described as 'intermolecular oligo'). Breaking up any self-structure amounts to a binding penalty. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'deoxy nucleotides, which is flanked on both sides (5' and 3' directions) by four-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. Cytidine residues in the 2'-MOE wings are 5-methylcytidines. All cytidine residues are 5-methylcytidines.

TABLE 1

position	oligo	total binding	duplex formation	T _m of Duplex	target structure	Intra-molecular oligo	Inter-molecular oligo
414	CTGTGGTGCCTTTGGTGTCT SEQ ID NO:1	-26.2	-28.3	82.5	-2.1	0	-5.7
419	GCTTTCTGTGGTGCCTTTGG SEQ ID NO:2	-25.8	-27.9	80.7	-2.1	0	-5.7
415	TCTGTGGTGCCTTTGGTGTCT SEQ ID NO:3	-25.7	-27.8	82.4	-2.1	0	-5
410	GGTGCCTTTGGTGTCTTGT SEQ ID NO:4	-25.5	-27.6	81.5	-2.1	0	-4.9
411	TGGTGCCTTTGGTGTCTTGT SEQ ID NO:5	-25.4	-27.5	80.8	-2.1	0	-5.7
412	GTGGTGCCTTTGGTGTCTTG SEQ ID NO:6	-25.4	-27.5	80.8	-2.1	0	-5.7
413	TGTGGTGCCTTTGGTGTCTT SEQ ID NO:7	-25.4	-27.5	80.8	-2.1	0	-5.7
416	TTCTGTGGTGCCTTTGGTGT SEQ ID NO:8	-25.4	-27.5	80.8	-2.1	0	-5.7
418	CTTTCTGTGGTGCCTTTGGT SEQ ID NO:9	-25.2	-27.3	79.8	-2.1	0	-5.7
424	GTTTGGCTTTCTGTGGTGCC SEQ ID NO:10	-24.8	-28.2	82.4	-2.1	-1.2	-5.2
956	GTGAGGTCTTGGTGGGGAT SEQ ID NO:11	-24.7	-27.4	80.4	-2.7	0	-2.4
409	GTGCCTTTGGTGTCTTGT SEQ ID NO:12	-24.4	-26.5	79.1	-2.1	0	-3.4
420	GGCTTTCTGTGGTGCCTTTG SEQ ID NO:13	-24.4	-27.9	80.7	-2.1	-1.3	-5.7
417	TTTCTGTGGTGCCTTTGGTG SEQ ID NO:14	-24.3	-26.4	77.5	-2.1	0	-5.7

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex	struc- ture	molecular oligo	molecular oligo
425	TGTTTGGCTTTCTGTGGTGC SEQ ID NO:15	-24.1	-26.2	78.4	-2.1	0	-3.7
421	TGGCTTTCTGTGGTGCCTTT SEQ ID NO:16	-23.8	-27.9	80.7	-2.1	-2	-6
422	TTGGCTTTCTGTGGTGCCTT SEQ ID NO:17	-23.8	-27.9	80.7	-2.1	-2	-6
423	TTTGGCTTTCTGTGGTGCCT SEQ ID NO:18	-23.8	-27.9	80.7	-2.1	-2	-6
407	GCCTTTGGTGTCTTGTMTTC SEQ ID NO:19	-23.7	-25.8	77.8	-2.1	0	-3.2
957	AGTGAGGGTCTTGGTGGGGA SEQ ID NO:20	-23.4	-27.4	80.8	-4	0	-2.4
408	TGCCTTTGGTGTCTTGTMTT SEQ ID NO:21	-23.3	-25.4	75.7	-2.1	0	-3.4
955	TGAGGGTCTTGGTGGGATA SEQ ID NO:22	-23.2	-25.9	76	-2.7	0	-2.4
952	GGGTCTTGGTGGGATAAGT SEQ ID NO:23	-23.1	-25.8	75.8	-2.7	0	-3.2
171	GGCAGCAACAGGAGGGA SEQ ID NO:24	-22.6	-27	75.9	-4.4	0	-5.3
566	GAGTGTCTGGTAGGTGTGCT SEQ ID NO:25	-22.5	-26.7	81.5	-4.2	0	-3.6
954	GAGGGTCTTGGTGGGATAA SEQ ID NO:26	-22.5	-25.2	73.6	-2.7	0	-2.4
426	TTGTTTGGCTTTCTGTGGTG SEQ ID NO:27	-22.4	-24.5	74	-2.1	0	-3.7
565	AGTGTCTGGTAGGTGTGCTC SEQ ID NO:28	-22.3	-26.5	82.1	-4.2	0	-3.6
403	TTGGTGTCTTGTMTTCTTCA SEQ ID NO:29	-22.2	-23.1	72	-0.7	0	-1.9
404	TTTGGTGTCTTGTMTTCTTC SEQ ID NO:30	-22.1	-22.5	71.2	0	0	-1.5
613	GAATGATTTAGGGGTGGGTA SEQ ID NO:31	-22.1	-22.5	67	0	0	-2.1
172	TGGCAGCAACAGGAGGGG SEQ ID NO:32	-22	-26.4	74.4	-4.4	0	-5.3
614	GGAATGATTTAGGGGTGGGT SEQ ID NO:33	-22	-24	70.2	-2	0	-2.3
889	GGGTCATCTGGTTGTGAATT SEQ ID NO:34	-21.9	-23.7	71	-1.8	0	-3.3
953	AGGGTCTTGGTGGGATAAG SEQ ID NO:35	-21.9	-24.6	72.5	-2.7	0	-2.4
1	CGTTCCCATTTGAGGCGAG SEQ ID NO:36	-21.8	-27.6	74.4	-4.5	-1.2	-6.4
890	TGGGTCATCTGGTTGTGAAT SEQ ID NO:37	-21.8	-23.6	70.4	-1.8	0	-3.3
891	ATGGGTCATCTGGTTGTGAA SEQ ID NO:38	-21.8	-23.6	70.4	-1.8	0	-3.3
892	AATGGGTCATCTGGTTGTGA SEQ ID NO:39	-21.8	-23.6	70.4	-1.8	0	-3.3
567	AGAGTGTCTGGTAGGTGTGC SEQ ID NO:40	-21.6	-25.8	79.6	-4.2	0	-2.6
951	GGTCTTGGTGGGATAAGTA SEQ ID NO:41	-21.6	-24.3	72.4	-2.7	0	-3.2
715	CTGGGTAAGGGGAGGGCACA SEQ ID NO:42	-21.5	-27.5	77	-6	0	-4
958	GAGTGAGGGTCTTGGTGGGG SEQ ID NO:43	-21.4	-27.4	80.8	-6	0	-2.2
405	CTTTGGTGTCTTGTMTTCTT SEQ ID NO:44	-21.3	-23	71.5	-1.7	0	-1.3
174	AGTGGCAGCAACAGGAGGAG SEQ ID NO:45	-21	-25.2	72.9	-4.2	0	-2.4
562	GTCTGGTAGGTGTGCTCACT SEQ ID NO:46	-20.9	-27.1	81.9	-4.2	-2	-4.2

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex	struc- ture	molecular oligo	molecular oligo
173	GTGGCAGCAACAGGAGGAGG SEQ ID NO:47	-20.8	-26.4	75.3	-5.6	0	-6.1
161	GGAGGAGGGAAGAGATTAGA SEQ ID NO:48	-20.7	-21.5	64.7	-0.6	0	-1.5
170	GCAGCAACAGGAGGAGGGAA SEQ ID NO:49	-20.7	-25.1	71	-4.4	0	-4.7
175	TAGTGGCAGCAACAGGAGGA SEQ ID NO:50	-20.7	-24.9	72	-4.2	0	-2.4
888	GGTCATCTGGTTGTGAATTG SEQ ID NO:51	-20.7	-22.5	68.1	-1.8	-0	-3.1
714	TGGGTAAGGGGAGGGCACAG SEQ ID NO:52	-20.6	-26.6	75.4	-6	0	-4
897	GGTAAAATGGGTCATCTGGT SEQ ID NO:53	-20.6	-22.4	66.3	-1.8	0	-2.9
898	GGGTAATAATGGGTCATCTGG SEQ ID NO:54	-20.6	-22.4	65.7	-1.8	0	-2.9
227	GGCCTCTGGCGACCCCTGGA SEQ ID NO:55	-20.5	-34.5	87.6	-11.5	-2.5	-8.4
564	GTGTCGTTGGTAGGTGTGCTCA SEQ ID NO:56	-20.5	-27.2	82.9	-6.7	0	-0.6
893	AAATGGGTCATCTGGTTGTG SEQ ID NO:57	-20.5	-22.3	66.7	-1.8	0	-2.9
950	GTCTTGGTGGGGATAAGTAT SEQ ID NO:58	-20.4	-23.1	69.6	-2.7	0	-3.2
946	TGGTGGGGATAAGTATGTGT SEQ ID NO:59	-20.2	-22.9	68.7	-2.7	0	-1.8
162	AGGAGGAGGGAAGAGATTAG SEQ ID NO:60	-20.1	-20.9	63.6	-0.6	0	-1.5
226	GCCTCTGGCGACCCCTGGAT SEQ ID NO:61	-20.1	-33.3	85.2	-11.5	-1.7	-7.8
612	AATGATTTAGGGGTGGGTAC SEQ ID NO:62	-20.1	-22.1	66.2	-2	0	-4
948	CTTGGTGGGGATAAGTATGT SEQ ID NO:63	-20	-22.7	67.8	-2.7	0	-2.1
228	TGGCCTCTGGCGACCCCTGG SEQ ID NO:64	-19.9	-33.9	86.2	-11.5	-2.5	-8.1
229	GTGGCCTCTGGCGACCCCTG SEQ ID NO:65	-19.9	-33.9	87.2	-11.5	-2.5	-8.3
402	TGGTGTCTTGTCTTCTTCAC SEQ ID NO:66	-19.9	-23.2	72.3	-3.3	0	-3.6
427	CTTGTCTTGGCTTTCTGTGGT SEQ ID NO:67	-19.9	-25.4	76.3	-5.5	0	-3.7
560	CTGGTAGGTGTGCTCACTGT SEQ ID NO:68	-19.9	-26.7	79.6	-4.8	-2	-4.2
945	GGTGGGGATAAGTATGTGTA SEQ ID NO:69	-19.9	-22.6	68.2	-2.7	0	-1.8
135	ATCGCAACTGTGCGGTGCAGC SEQ ID NO:70	-19.8	-27.2	75.3	-5.8	-1.6	-6.8
406	CCTTTGGTGTCTTGTCTTCT SEQ ID NO:71	-19.8	-24.9	75.1	-5.1	0	-2
606	TTAGGGGTGGGTACAGTGGG SEQ ID NO:72	-19.8	-26.4	77.4	-5.9	-0.4	-5.2
894	AAAATGGGTCATCTGGTTGT SEQ ID NO:73	-19.8	-21.6	64.5	-1.8	0	-2.9
2	GCGTTCCCATTTGAGGGCGA SEQ ID NO:74	-19.7	-29.4	78.2	-8.2	-1.4	-7.1
401	GGTGTCTTGTCTTCTTCACA SEQ ID NO:75	-19.7	-23.9	73.7	-3	-1.1	-4.7
561	TCTGGTAGGTGTGCTCACTG SEQ ID NO:76	-19.7	-25.9	77.7	-4.2	-2	-4.2
225	CCTCTGGCGACCCCTGGATT SEQ ID NO:77	-19.6	-31.6	81.5	-11.5	-0.1	-4.5
137	TCATCGCAACTGTGCGGTGCA SEQ ID NO:78	-19.5	-26.5	73.5	-5.8	-1.1	-7

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex	struc- ture	molecular oligo	molecular oligo
605	TAGGGGTGGGTACAGTGGGA SEQ ID NO:79	-19.5	-26.9	78.5	-7.4	0.2	-5.2
896	GTAAAATGGGTCATCTGGTT SEQ ID NO:80	-19.5	-21.3	64.1	-1.8	0	-2.9
1048	GTATGCTTTTTTTTTTTTGT SEQ ID NO:81	-19.5	-19.9	63.1	0	0	-3.6
1049	GGTATGCTTTTTTTTTTTTG SEQ ID NO:82	-19.5	-19.9	62.5	0	0	-2.9
1050	TGGTATGCTTTTTTTTTTTT SEQ ID NO:83	-19.5	-19.9	62.5	0	0	-3.6
1051	TTGGTATGCTTTTTTTTTTT SEQ ID NO:84	-19.5	-19.9	62.5	0	0	-3.6
132	GCAACTGTCGGTGCAGCTGT SEQ ID NO:85	-19.4	-28.1	79.1	-7.3	-1.3	-9.7
899	AGGGTAAAATGGGTCATCTG SEQ ID NO:86	-19.4	-21.2	63.4	-1.8	0	-2.9
140	CTTTCATCGCAACTGTCCGGT SEQ ID NO:87	-19.3	-25.1	71	-5.8	0	-4.7
158	GGAGGGAAGAGATTAGAACT SEQ ID NO:88	-19.3	-20.1	60.9	-0.6	0	-2.3
965	GGAGACAGAGTGAGGGTCTT SEQ ID NO:89	-19.3	-24.7	74.4	-3.9	-1.4	-5.5
138	TTCATCGCAACTGTGCGTGC SEQ ID NO:90	-19.2	-25.9	72.8	-5.8	-0.8	-7
176	TTAGTGGCAGCAACAGGAGG SEQ ID NO:91	-19.2	-24.4	71	-5.2	0	-2.4
949	TCTTGCTGGGGATAAGTATG SEQ ID NO:92	-19.2	-21.9	66.1	-2.7	0	-2.7
963	AGACAGAGTGAGGGTCTTGG SEQ ID NO:93	-19.2	-24.1	72.7	-3.9	-0.9	-5.1
400	GTGTCTTGTTTCTTCACAT SEQ ID NO:94	-19.1	-22.7	70.8	-3	-0.3	-3.9
611	ATGATTTAGGGGTGGGTACA SEQ ID NO:95	-19.1	-23.5	69.8	-3.7	-0.4	-5.2
615	TGGAATGATTTAGGGGTGGG SEQ ID NO:96	-19.1	-22.8	66.8	-3.7	0	-2.3
900	TAGGGTAAAATGGGTCATCT SEQ ID NO:97	-19.1	-20.9	62.9	-1.8	0	-2.9
947	TTGGTGGGGATAAGTATGTG SEQ ID NO:98	-19.1	-21.8	65.7	-2.7	0	-1.8
962	GACAGAGTGAGGGTCTTGGT SEQ ID NO:99	-19	-25.3	76.1	-5.8	-0.1	-4.4
169	CAGCAACAGGAGGAGGGAAG SEQ ID NO:100	-18.9	-23.3	67.1	-4.4	0	-4.1
160	GAGGAGGGAAGAGATTAGAA SEQ ID NO:101	-18.8	-19.6	60	-0.6	0	-1.5
168	AGCAACAGGAGGAGGGAAGA SEQ ID NO:102	-18.8	-23.2	67.2	-4.4	0	-4.1
887	GTCATCTGGTTGTGAATTGG SEQ ID NO:103	-18.8	-22.5	68.1	-3.7	0	-3.1
1065	CCGTGTCTGGTTCATTGGTA SEQ ID NO:104	-18.8	-26.3	76	-7.5	0	-2.9
64	TCCCTGGGGATGACTCAGGT SEQ ID NO:105	-18.7	-28.7	80.3	-6.9	-3.1	-9.3
136	CATCGCAACTGTCCGTGCAG SEQ ID NO:106	-18.7	-26.1	72.2	-5.8	-1.6	-8.4
607	TTTAGGGGTGGGTACAGTGG SEQ ID NO:107	-18.7	-25.3	75.1	-5.9	-0.4	-5.2
1061	GTCTGGTTCATTGGTATGCT SEQ ID NO:108	-18.7	-25	75.5	-5.8	-0.1	-3.6
568	AAGAGTGTCTGGTAGGTGTG SEQ ID NO:109	-18.5	-23.3	71.8	-4.8	0	-2.9
685	GACGAGAGAAGAAGACACTA SEQ ID NO:110	-18.5	-18.9	57.3	0	0	-3.5

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation Duplex	Tm of struc- ture	molecular oligo	molecular oligo	
966	TGGAGACAGACTGAGGGTCT SEQ ID NO:111	-18.5	-24.6	73.8	-4.8	-1.2	-5.9
1052	ATTGGTATGCTTTTTTTTTT SEQ ID NO:112	-18.5	-19.8	62.1	-1.2	0	-3.6
1064	CGTGTCTGGTTCATTGGTAT SEQ ID NO:113	-18.5	-24.3	72.2	-5.8	0	-2.7
159	AGGAGGGAAGAGATTAGAAC SEQ ID NO:114	-18.4	-19.2	59.2	-0.6	0	-1.4
686	TGACGAGAGAAGAAGACACT SEQ ID NO:115	-18.4	-19.2	57.8	-0.6	0	-3.5
1047	TATGCTTTTTTTTGTGTC SEQ ID NO:116	-18.4	-19.1	61.3	-0.4	0	-3.6
141	ACTTTCATCGCAACTGTCGG SEQ ID NO:117	-18.3	-24.1	68.4	-5.8	0	-4.7
683	CGAGAGAAGAAGACACTAGA SEQ ID NO:118	-18.3	-18.7	56.9	0	0	-4.5
895	TAAATGGGTCATCTGGTTG SEQ ID NO:119	-18.3	-20.1	60.9	-1.8	0	-2.9
3	AGCGTTCCCATTTGAGGGCG SEQ ID NO:120	-18.2	-28.8	77.2	-9	-1.5	-9.2
157	GAGGGAAGAGATTAGAACTT SEQ ID NO:121	-18.2	-19	58.7	-0.6	0	-2.6
563	TGTCTGGTAGGTGTGCTCAC SEQ ID NO:122	-18.2	-26.2	79.5	-6.7	-1.2	-3.3
901	ATAGGGTAAATGGGTCATC SEQ ID NO:123	-18.2	-20	61	-1.8	0	-2.9
155	GGGAAGAGATTAGAACTTTC SEQ ID NO:124	-18.1	-18.9	58.9	-0.6	0	-3.2
964	GAGACAGAGTGAGGGTCTTG SEQ ID NO:125	-18.1	-23.5	71.3	-3.9	-1.4	-5.5
716	CCTGGGTAAGGGGAGGGCAC SEQ ID NO:126	-18	-28.8	79.5	-10	-0.6	-5.2
934	GTATGTGTAGAATCTGGATT SEQ ID NO:127	-18	-20.1	62.6	-2.1	0	-6.7
233	CCCTGTGGCCTCTGGCGACC SEQ ID NO:128	-17.9	-33.9	87.2	-16	1.9	-7.2
684	ACGAGAGAAGAAGACACTAG SEQ ID NO:129	-17.9	-18.3	56.2	0	0	-4
935	AGTATGTGTAGAATCTGGAT SEQ ID NO:130	-17.9	-20	62.5	-2.1	0	-4.5
65	ATCCCTGGGGATGACTCAGG SEQ ID NO:131	-17.8	-27.5	76.7	-6.9	-2.8	-11.1
224	CTCTGGCGACCCCTGGATTC SEQ ID NO:132	-17.8	-30	80	-11.5	-0.4	-5.2
271	GCCTTCCTGGAGCCATCTCC SEQ ID NO:133	-17.8	-32.1	87.2	-11.9	-2.4	-6.8
399	TGTCTTGTCTTCTTCACATT SEQ ID NO:134	-17.8	-21.6	67.5	-3.8	0	-2.7
485	GCAGAGCAAAGCTTCTTAGC SEQ ID NO:135	-17.8	-23.9	70.4	-4.8	-1.2	-7.7
713	GGGTAAGGGGAGGGCACAGG SEQ ID NO:136	-17.8	-27.8	78.2	-10	0	-4
905	GTGAATAGGGTAAATGGGT SEQ ID NO:137	-17.8	-19.6	59.2	-1.8	0	-1.2
1062	TGTCTGGTTCATTGGTATGC SEQ ID NO:138	-17.8	-24.1	73.1	-5.8	-0.1	-2.6
151	AGAGATTAGAACTTTCATCG SEQ ID NO:139	-17.7	-18.5	57.7	-0.6	0	-4.2
156	AGGGAAGAGATTAGAACTTT SEQ ID NO:140	-17.7	-18.5	57.7	-0.6	0	-3.2
232	CCTGTGGCCTCTGGCGACCC SEQ ID NO:141	-17.7	-33.9	87.2	-16.2	1.9	-6.5
903	GAATAGGGTAAATGGGTCA SEQ ID NO:142	-17.7	-19.5	58.9	-1.8	0	-2.1

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex structure	molecular oligo	molecular oligo	
959	AGAGTGAGGGTCTTGGTGGG SEQ ID NO:143	-17.7	-26.2	78.3	-8.5	0	-2.5
1063	GTGTCTGGTTCATTGGTATG SEQ ID NO:144	-17.7	-23.5	72.1	-5.8	0	-2.7
139	TTTCATCGCAACTGTCCGGTG SEQ ID NO:145	-17.6	-24.2	69	-5.8	-0.6	-6.7
223	TCTGGCGACCCCTGGATTCA SEQ ID NO:146	-17.6	-29.8	79.1	-11.5	-0.4	-5.2
428	GCTTGTGTTGGCTTCTGTGG SEQ ID NO:147	-17.6	-26	77.3	-8.4	0	-3.7
486	GGCAGAGCAAAGCTTCTTAG SEQ ID NO:148	-17.6	-23.3	68.7	-4.8	-0.7	-7.7
1060	TCTGGTTCATTGGTATGCTT SEQ ID NO:149	-17.6	-23.9	72.2	-5.8	-0.1	-3.6
487	AGGCAGAGCAAAGCTTCTTA SEQ ID NO:150	-17.5	-23.3	68.7	-4.8	-0.9	-7.7
608	ATTTAGGGGTGGGTACAGTG SEQ ID NO:151	-17.5	-24.1	72.2	-5.9	-0.4	-5.2
680	GAGAAGAAGACACTAGAGAG SEQ ID NO:152	-17.5	-17.9	56.4	0	0	-4.5
681	AGAGAAGAAGACACTAGAGA SEQ ID NO:153	-17.5	-17.9	56.4	0	0	-4.5
682	GAGAGAAGAAGACACTAGAG SEQ ID NO:154	-17.5	-17.9	56.4	0	0	-4.5
981	GAACAAGTAGGCCAATGGAG SEQ ID NO:155	-17.5	-21.8	63.2	-3.8	0	-7.7
982	TGAACAAGTAGGCCAATGGA SEQ ID NO:156	-17.5	-21.8	62.9	-3.8	0	-7.7
1053	CATTGGTATGCTTTTTTTT SEQ ID NO:157	-17.5	-20.4	63	-2.9	0	-3.6
163	CAGGAGGAGGGAAGAGATTA SEQ ID NO:158	-17.4	-21.6	64.6	-4.2	0	-1.5
220	GGCGACCCCTGGATTCAGGC SEQ ID NO:159	-17.3	-31.5	82.7	-11.5	-2.7	-11
862	CCCATTGGAAGGAAACAATT SEQ ID NO:160	-17.3	-19.5	57	-2.2	0	-3.4
1059	CTGGTTCATTGGTATGCTTT SEQ ID NO:161	-17.3	-23.6	70.8	-5.8	-0.1	-3.6
131	CAACTGTCGGTGCAGCTGTA SEQ ID NO:162	-17.2	-26	74.1	-7.3	-1.3	-9.9
936	AAGTATGTGTAGAATCTGGA SEQ ID NO:163	-17.2	-19.3	60.3	-2.1	0	-4
961	ACAGAGTGAGGGTCTTGGTG SEQ ID NO:164	-17.2	-24.7	74.5	-7.5	0	-2.8
230	TGTGGCCTCTGGCGACCCCT SEQ ID NO:165	-17.1	-33.9	87.2	-16.8	1.9	-7.6
902	AATAGGGTAAAATGGGTCAT SEQ ID NO:166	-17.1	-18.9	57.6	-1.8	0	-2.9
972	GGCCAATGGAGACAGAGTGA SEQ ID NO:167	-17.1	-24.7	70.4	-6.7	-0.8	-8.5
219	GCGACCCCTGGATTCAGGCT SEQ ID NO:168	-17	-31.2	82.1	-11.5	-2.7	-9.6
222	CTGGCGACCCCTGGATTCAG SEQ ID NO:169	-17	-29.4	77.8	-11.5	-0.7	-6.6
554	GGTGTGCTCACTGTCTTCTT SEQ ID NO:170	-17	-26.5	80.4	-7.5	-2	-4.2
904	TGAATAGGGTAAAATGGGTC SEQ ID NO:171	-17	-18.8	57.6	-1.8	0	-1.7
1058	TGGTTCATTGGTATGCTTTT SEQ ID NO:172	-17	-22.8	69.1	-5.8	0.5	-3.6
150	GAGATTAGAACTTTCATCGC SEQ ID NO:173	-16.9	-20.3	61.6	-3.4	0	-4.2
154	GGAAGAGATTAGAACTTTCA SEQ ID NO:174	-16.9	-18.4	57.6	-0.6	-0.4	-4.6

position	oligo	duplex			target	Intra-	Inter-
		total	form-	Tm of	struc-	molecular	molecular
		binding	ation	Duplex	ture	oligo	oligo
164	ACAGGAGGAGGGAAGAGATT SEQ ID NO:175	-16.9	-22.1	65.7	-5.2	0	-1.3
555	AGGTGTGCTCACTGTCTTCT SEQ ID NO:176	-16.9	-26.4	80.3	-7.5	-2	-4.2
619	GCACTGGAATGATTTAGGGG SEQ ID NO:177	-16.9	-22.8	66.5	-5.9	0	-3.4
967	ATGGAGACAGAGTGAGGGTC SEQ ID NO:178	-16.9	-23.7	71.6	-5.9	-0.8	-5.2
983	ATGAACAAGTAGGCCAATGG SEQ ID NO:179	-16.9	-21.2	61.6	-3.8	0	-7.7
1066	ACCGTGTCTGGTTCATTGGT SEQ ID NO:180	-16.9	-26.8	77.3	-9	-0.7	-4.7
610	TGATTTAGGGGTGGGTACAG SEQ ID NO:181	-16.6	-23.5	70.1	-6.2	-0.4	-5.2
679	AGAAGAAGACACTAGAGAGA SEQ ID NO:182	-16.6	-17.9	56.4	-1.2	0	-4.5
906	AGTGAATAGGGTAAAATGGG SEQ ID NO:183	-16.6	-18.4	56.5	-1.8	0	-1.2
1057	GGTTCATTGGTATGCTTTT SEQ ID NO:184	-16.6	-22.9	69.7	-5.8	-0.1	-3.6
142	AACTTTCATCGCAACTGTGCG SEQ ID NO:185	-16.4	-22.2	63.8	-5.8	0	-4.1
153	GAAGAGATTAGAACTTTCAT SEQ ID NO:186	-16.4	-17.2	55	-0.6	0	-4.6
177	ATTAGTGGCAGCAACAGGAG SEQ ID NO:187	-16.4	-23.2	68.4	-6.8	0	-2.4
687	CTGACGAGAGAAGAAGACAC SEQ ID NO:188	-16.4	-19.2	57.8	-2.8	0	-3.5
973	AGGCCAATGGAGACAGAGTG SEQ ID NO:189	-16.4	-24.1	69.4	-6.7	-0.8	-9.2
149	AGATTAGAACTTTCATCGCA SEQ ID NO:190	-16.3	-20.4	61.5	-4.1	0	-4.2
231	CTGTGGCCTCTGGCGACCCC SEQ ID NO:191	-16.3	-33.9	87.2	-17.6	1.9	-7.3
237	CGGTCCCTGTGGCCTCTGGC SEQ ID NO:192	-16.3	-33.9	90.1	-16	-1.5	-7.2
559	TGGTAGGTGTGCTCACTGTC SEQ ID NO:193	-16.3	-26.2	79.5	-7.9	-2	-4.2
616	CTGGAATGATTTAGGGGTGG SEQ ID NO:194	-16.3	-22.5	66.2	-6.2	0	-2.3
618	CACTGGAATGATTTAGGGGT SEQ ID NO:195	-16.3	-22.2	65.5	-5.9	0	-2.3
932	ATGTGTAGAATCTGGATTCA SEQ ID NO:196	-16.3	-20.3	62.8	-2.1	-1.7	-11
937	TAAGTATGTGTAGAATCTGG SEQ ID NO:197	-16.3	-18.4	58.4	-2.1	0	-4
984	GATGAACAAGTAGGCCAATG SEQ ID NO:198	-16.3	-20.6	60.4	-3.8	0	-7.7
985	AGATGAACAAGTAGGCCAAT SEQ ID NO:199	-16.3	-20.6	60.7	-3.8	0	-7.7
1054	TCATTGGTATGCTTTTTTTT SEQ ID NO:200	-16.3	-20.7	64.2	-3.9	-0.1	-3.6
99	AATATAATGGAAGGTTCCCT SEQ ID NO:201	-16.2	-20.9	61.3	-3.7	-0.8	-7.1
143	GAACTTTCATCGCAACTGTC SEQ ID NO:202	-16.2	-22	64.8	-5.8	0	-3.6
152	AAGAGATTAGAACTTTCATC SEQ ID NO:203	-16.2	-17	55	-0.6	0	-4.6
217	GACCCCTGGATTTCAGGCTGC SEQ ID NO:204	-16.2	-30.4	82.4	-11.5	-2.7	-9.6
429	TGCTTGTGTTGGCTTTCTGTG SEQ ID NO:205	-16.2	-24.8	74.3	-7.7	-0.7	-3.7
430	ATGCTTGTGTTGGCTTTCTGT SEQ ID NO:206	-16.2	-24.8	74.4	-7.7	-0.7	-3.7

position	oligo	total binding	duplex form- ation	Tm of Duplex	target struc- ture	Intra- molecular oligo	Inter- molecular oligo
718	AGCCTGGGTAAGGGGAGGGC SEQ ID NO:207	-16.2	-29.7	82.6	-12.1	-1.3	-6.7
933	TATGTGTAGAATCTGGATTC SEQ ID NO:208	-16.2	-19.3	60.9	-2.1	-0.6	-9.7
971	GCCAAATGGAGACAGAGTGAG SEQ ID NO:209	-16.2	-23.5	68.1	-6.7	-0.3	-6.3
270	CCTTCCTGGAGCCATCTCCT SEQ ID NO:210	-16.1	-31.2	84.7	-11.9	-3.2	-7.4
398	GTCTTGTTTTCTTCACATTG SEQ ID NO:211	-16.1	-21.6	67.5	-5.5	0	-2.7
558	GGTAGGTGTGCTCACTGTCT SEQ ID NO:212	-16.1	-27.1	81.9	-9.7	-1.2	-3.4
886	TCATCTGGTTGTGAATTGGC SEQ ID NO:213	-16.1	-23.1	69.1	-7	0	-3.1
974	TAGGCCAATGGAGACAGAGT SEQ ID NO:214	-16.1	-23.8	69	-6.7	-0.8	-9.2
480	GCAAAGCTTCTTAGCTGACA SEQ ID NO:215	-16	-23.2	68	-4.8	-2.4	-8.1
569	GAAGAGTGTCTGGTAGGTGT SEQ ID NO:216	-16	-23.9	73.5	-7.9	0	-2.9
604	AGGGGTGGGTACAGTGGGAG SEQ ID NO:217	-16	-27.2	79.4	-10.5	-0.4	-5.2
100	GAATATAATGGAAGGTTCCT SEQ ID NO:218	-15.9	-20.6	60.7	-3.7	-0.8	-7.1
609	GATTTAGGGGTGGGTACAGT SEQ ID NO:219	-15.9	-24.7	73.9	-8.1	-0.4	-5.2
130	AACTGTCGGTGCAGCTGTAA SEQ ID NO:220	-15.8	-24.6	70.6	-7.3	-1.3	-9.9
144	AGAACTTTCATCGCAACTGT SEQ ID NO:221	-15.8	-21.6	63.6	-5.8	0	-4.2
481	AGCAAAGCTTCTTAGCTGAC SEQ ID NO:222	-15.8	-22.5	67.1	-4.8	-1.9	-8.8
863	CCCCATTTGAAGGAAACAAT SEQ ID NO:223	-15.8	-21.4	60.1	-5.6	0	-3.4
103	GAAGAATATAATGGAAGGTT SEQ ID NO:224	-15.7	-16.1	51.7	0	0	-2.5
218	CGACCCCTGGATTTCAGGCTG SEQ ID NO:225	-15.7	-29.4	77.8	-11.5	-2.2	-9.1
221	TGGCGACCCCTGGATTTCAGG SEQ ID NO:226	-15.7	-29.7	78.4	-11.5	-2.5	-11
939	GATAAGTATGTGTAGAATCT SEQ ID NO:227	-15.7	-17.8	57.1	-2.1	0	-3.6
944	GTGGGGATAAGTATGTGTAG SEQ ID NO:228	-15.7	-21.4	65.7	-5.7	0	-1.8
993	TGAGTGAAAGATGAACAAGT SEQ ID NO:229	-15.7	-16.9	53.4	-1.1	0	-2.9
1002	TTTGTCGAATGAGTGAAAGA SEQ ID NO:230	-15.7	-18.1	55.9	-2.4	0	-5
63	CCCTGGGGATGACTCAGGTC SEQ ID NO:231	-15.6	-28.7	80.3	-10	-3.1	-9
104	TGAAGAATATAATGGAAGGT SEQ ID NO:232	-15.6	-16	51.4	0	0	-2.7
133	CGCAACTGTCGGTGCAGCTG SEQ ID NO:233	-15.6	-27.7	75.4	-10.5	-1.6	-8.3
1001	TTGTCGAATGAGTGAAAGAT SEQ ID NO:234	-15.6	-18	55.6	-2.4	0	-5
717	GCCTGGGTAAGGGGAGGGCA SEQ ID NO:235	-15.5	-30.4	83.3	-13.4	-1.4	-7
990	GTGAAAGATGAACAAGTAGG SEQ ID NO:236	-15.5	-17.2	54.1	-1.7	0	-2.9
1000	TGTCGAATGAGTGAAAGATG SEQ ID NO:237	-15.5	-17.9	55.3	-2.4	0	-5
178	CATTAGTGGCAGCAACAGGA SEQ ID NO:238	-15.4	-23.9	69.3	-8.5	0	-1.6

position	oligo	total binding	duplex form- ation	Tm of Duplex	target struc- ture	Intra- molecular oligo	Inter- molecular oligo
236	GGTCCCTGTGGCCTCTGGCG SEQ ID NO:239	-15.4	-33.9	90.1	-16	-2.5	-7.7
475	GCTTCTTAGCTGACATTGTT SEQ ID NO:240	-15.4	-23.5	70.9	-6.8	-1.2	-7.2
980	AACAAGTAGGCCAATGGAGA SEQ ID NO:241	-15.4	-21.8	63.2	-5.9	0	-7.7
992	GAGTGAAGATGAACAAGTA SEQ ID NO:242	-15.4	-16.6	52.9	-1.1	0	-2.9
94	AATGGAAGGTTCCCTGCTGG SEQ ID NO:243	-15.3	-26.1	72.6	-9.9	-0.8	-7.1
488	AAGGCAGAGCAAAGCTTCTT SEQ ID NO:244	-15.3	-22.9	67	-6.6	-0.9	-7.7
1055	TTCATTGGTATGCTTTT SEQ ID NO:245	-15.3	-20.7	64.2	-4.9	-0.1	-3.6
90	GAAGGTTCCCTGCTGGAGGC SEQ ID NO:246	-15.2	-29.2	81.2	-13.1	-0.8	-7.8
98	ATATAATGGAAGGTTCCCTG SEQ ID NO:247	-15.2	-21.6	63.2	-5.5	-0.8	-7.1
484	CAGAGCAAAGCTTCTTAGCT SEQ ID NO:248	-15.2	-23	68.1	-5.6	-2.2	-8.5
603	GGGGTGGGTACAGTGGGAGA SEQ ID NO:249	-15.1	-27.8	80.5	-12	-0.4	-5.2
938	ATAAGTATGTGTAGAATCTG SEQ ID NO:250	-15.1	-17.2	55.7	-2.1	0	-4
1003	ATTTGTGCAATGAGTGAAAG SEQ ID NO:251	-15.1	-17.5	54.7	-2.4	0	-4.5
474	CTTCTTAGCTGACATTGTTT SEQ ID NO:252	-15	-21.8	66.8	-6.8	0	-5.3
678	GAAGAAGACACTAGAGAGAG SEQ ID NO:253	-15	-17.9	56.4	-2.9	0	-4.5
975	GTAGGCCAATGGAGACAGAG SEQ ID NO:254	-15	-23.8	69	-7.8	-0.8	-9.2
28	GTGGTCTATGCTTTTAGTCCC SEQ ID NO:255	-14.9	-26.8	79.2	-11.9	0	-4
66	GATCCCTGGGGATGACTCAG SEQ ID NO:256	-14.9	-26.9	75.5	-10	-1.4	-11.9
482	GAGCAAAGCTTCTTAGCTGA SEQ ID NO:257	-14.9	-22.9	67.8	-5.6	-2.4	-8.8
847	CAATTTGATCTGTGACATT SEQ ID NO:258	-14.9	-19	58.8	-4.1	0	-4.9
134	TCGCAACTGTCGGTGCAGCT SEQ ID NO:259	-14.8	-28.1	77.2	-11.7	-1.6	-8.4
620	AGCACTGGAATGATTTAGGG SEQ ID NO:260	-14.8	-21.6	64.1	-6.8	0	-4.1
858	TTTGAAGGAAACAATTTGA SEQ ID NO:261	-14.8	-15.6	50.5	-0.6	0	-4.4
991	AGTGAAAGATGAACAAGTAG SEQ ID NO:262	-14.8	-16	51.8	-1.1	0	-2.9
1046	ATGCTTTTTTTTTTTGTCC SEQ ID NO:263	-14.8	-21.4	65.9	-6.6	0	-3.6
1069	AAGACCGTGTCTGGTTCATT SEQ ID NO:264	-14.8	-24.3	70.5	-8.1	-1.3	-8.3
1077	TCTTTAATAAGACCGTGTCT SEQ ID NO:265	-14.8	-20.8	62.2	-4.8	-1.1	-8
483	AGAGCAAAGCTTCTTAGCTG SEQ ID NO:266	-14.7	-22.3	66.7	-5.2	-2.4	-8.8
885	CATCTGGTTGTGAATTGGCA SEQ ID NO:267	-14.7	-23.4	68.7	-8.7	0	-4
91	GGAAGGTTCCCTGCTGGAGG SEQ ID NO:268	-14.6	-28.6	79.4	-13.1	-0.8	-6.8
102	AAGAATATAATGGAAGGTTT SEQ ID NO:269	-14.6	-15.9	51.7	-1.2	0	-3.3
165	AACAGGAGGAGGGAAGAGAT SEQ ID NO:270	-14.6	-21.3	63.2	-6.7	0	-1.1

position	oligo	duplex			target	Intra-	Inter-
		total binding	form- ation	Tm of Duplex	struc- ture	molecular oligo	molecular oligo
476	AGCTTCTTAGCTGACATTGT SEQ ID NO:271	-14.6	-23.4	70.8	-6.8	-2	-7.7
711	GTAAGGGGAGGGCACAGGCT SEQ ID NO:272	-14.6	-28.1	79.4	-12.1	-1.3	-4
994	ATGAGTGAAAGATGAACAAG SEQ ID NO:273	-14.5	-15.7	50.7	-1.1	0	-2.9
968	AATGGAGACAGAGTGAGGGT SEQ ID NO:274	-14.4	-22.6	67.5	-7.3	-0.8	-3.7
1070	TAAGACCGTGTCTGGTTCAT SEQ ID NO:275	-14.4	-23.9	69.5	-8.1	-1.3	-8.3
1071	ATAAGACCGTGTCTGGTTCA SEQ ID NO:276	-14.4	-23.9	69.5	-8.1	-1.3	-8.3
145	TAGAACTTTTCATCGCAACTG SEQ ID NO:277	-14.3	-20.1	60	-5.8	0	-4.2
431	AATGCTTGTTTGGCTTTCTG SEQ ID NO:278	-14.3	-22.9	68.4	-7.7	-0.7	-3.7
712	GGTAAGGGGAGGGCACAGGC SEQ ID NO:279	-14.3	-28.4	80	-13.4	-0.5	-4
4	CAGCGTTCCCATTTGAGGGC SEQ ID NO:280	-14.2	-28.7	78.6	-13.2	-1.2	-9.2
101	AGAAATATAATGGAAGGTTCC SEQ ID NO:281	-14.2	-18.6	57.2	-3.7	-0.4	-6.7
844	TTTGTGATCTGTGACATTAA SEQ ID NO:282	-14.2	-18.1	57.3	-3.9	0	-4.9
907	CAGTGAATAGGGTAAATGG SEQ ID NO:283	-14.2	-17.9	55.3	-3.7	0	-3.1
89	AAGGTTCCCTGCTGGAGGCT SEQ ID NO:284	-14.1	-29.5	81.8	-14	-1.3	-8
93	ATGGAAGGTTCCCTGCTGGA SEQ ID NO:285	-14.1	-27.4	76.3	-12.4	-0.8	-7.1
688	ACTGACGAGAGAAGAAGACA SEQ ID NO:286	-14.1	-19.2	57.8	-5.1	0	-3.4
869	GGCAGACCCCATTTGAAGGA SEQ ID NO:287	-14.1	-27.1	73.5	-13	0	-4
979	ACAAGTAGGCCAATGGAGAC SEQ ID NO:288	-14.1	-22.7	65.8	-8.1	0	-7.7
491	ACAAAGGCAGAGCAAAGCTT SEQ ID NO:289	-13.9	-21.7	62.9	-6.8	-0.9	-7.5
676	AGAAGACACTAGAGAGAGCA SEQ ID NO:290	-13.9	-20.5	62.6	-6.6	0	-4.5
95	TAATGGAAGGTTCCCTGCTG SEQ ID NO:291	-13.8	-24.6	69.6	-9.9	-0.8	-7.1
269	CTTCCTGGAGCCATCTCCTA SEQ ID NO:292	-13.8	-28.9	80.6	-11.9	-3.2	-7.4
489	AAAGGCAGAGCAAAGCTTCT SEQ ID NO:293	-13.8	-22.1	64.5	-7.3	-0.9	-7.7
864	ACCCCATTTGAAGGAAACAA SEQ ID NO:294	-13.8	-21.6	60.5	-7.8	0	-3.4
1078	ATCTTTAATAAGACCGTGTC SEQ ID NO:295	-13.8	-19.9	60.3	-4.8	-1.2	-6.8
148	GATTAGAACTTTCATCGCAA SEQ ID NO:296	-13.7	-19.7	59.3	-6	0	-3.6
394	TGTTTTCTTCACATTGCCCT SEQ ID NO:297	-13.7	-25.7	74.2	-12	0	-3
719	AAGCCTGGGTAAGGGGAGGG SEQ ID NO:298	-13.7	-27.2	75.7	-12.1	-1.3	-5.2
913	AGTCTGCAGTGAATAGGGTA SEQ ID NO:299	-13.7	-23.1	70.1	-8.8	0	-8.6
105	TTGAAGAATATAATGGAAGG SEQ ID NO:300	-13.6	-14.9	49.1	-1.2	0	-2.7
213	CCTGGATTCAAGCTGCTAGA SEQ ID NO:301	-13.6	-26.8	76.5	-11	-2.2	-9.4
216	ACCCCTGGATTCAAGCTGCT SEQ ID NO:302	-13.6	-30.7	83	-14.4	-2.7	-9.6

position	oligo	duplex		target	Intra- molecular	Inter- molecular
		total binding	form- ation Duplex			
272	CGCCTTCCTGGAGCCATCTC SEQ ID NO:303	-13.6	-30.9	83.1	-16.4	-0.7
363	CAGGGGCACTGCTTCTTTGG SEQ ID NO:304	-13.6	-27.4	78.2	-13.1	-0.5
368	GATCACAGGGGCACTGCTTC SEQ ID NO:305	-13.6	-27	77.8	-12.7	-0.5
492	TACAAAGGCAGAGCAAAGCT SEQ ID NO:306	-13.6	-21.3	62.1	-6.8	-0.7
557	GTAGGTGTGCTCACTGTCTT SEQ ID NO:307	-13.6	-26	79.4	-10.4	-2
677	AAGAAGACACTAGAGAGAGC SEQ ID NO:308	-13.6	-19.1	59.2	-5.5	0
998	TCGAATGAGTGAAAGATGAA SEQ ID NO:309	-13.6	-16.6	52.1	-3	0
1045	TGCTTTTTTTTTTTTGTCCC SEQ ID NO:310	-13.6	-23.4	69.9	-9.8	0
1056	GTTCATTGGTATGCTTTTTT SEQ ID NO:311	-13.6	-21.8	67.3	-7.7	-0.1
88	AGGTTCCCTGCTGGAGGCTC SEQ ID NO:312	-13.5	-30.6	86.6	-15.9	-1.1
128	CTGTCCGTGCAGCTGTAAGT SEQ ID NO:313	-13.5	-26.3	76.2	-12	-0.4
188	TGGACATCAGCATTAGTGGC SEQ ID NO:314	-13.5	-24.3	71.7	-10.8	0
274	GCCGCTTCCTGGAGCCATC SEQ ID NO:315	-13.5	-33.4	87	-19.2	-0.4
289	GCACTCACATTCTTGCCGC SEQ ID NO:316	-13.5	-28.7	78.9	-14.7	0
92	TGGAAGGTTCCCTGCTGGAG SEQ ID NO:317	-13.4	-27.4	76.6	-13.1	-0.8
601	GGTGGGTACAGTGGGAGAGT SEQ ID NO:318	-13.4	-26.6	79.1	-12.5	-0.4
602	GGGTGGGTACAGTGGGAGAG SEQ ID NO:319	-13.4	-26.6	78.1	-12.5	-0.4
617	ACTGGAATGATTAGGGGTG SEQ ID NO:320	-13.4	-21.5	64.2	-8.1	0
843	TTTGATCTGTGACATTAAA SEQ ID NO:321	-13.4	-17.3	55	-3.9	0
853	AGGAAACAATTTTGATCTGT SEQ ID NO:322	-13.3	-18	56.1	-4.7	0
67	TGATCCCTGGGGATGACTCA SEQ ID NO:323	-13.2	-26.9	75	-11.7	-1.4
179	GCATTAGTGCAGCAACAGG SEQ ID NO:324	-13.2	-25.1	72.2	-11.9	0
366	TCACAGGGGCACTGCTTCTT SEQ ID NO:325	-13.2	-27.4	78.9	-12.7	-1.4
397	TCTTGTTTTCTTCACATTGC SEQ ID NO:326	-13.2	-22.2	68.6	-9	0
857	TTGAAGGAAACAATTTTGAT SEQ ID NO:327	-13.2	-15.5	50.2	-2.3	0
62	CCTGGGGATGACTCAGGTCA SEQ ID NO:328	-13.1	-27.4	77.8	-11.7	-2.6
97	TATAATGGAAGGTTCCCTGC SEQ ID NO:329	-13.1	-23.4	67.2	-9.4	-0.8
367	ATCACAGGGGCACTGCTTCT SEQ ID NO:330	-13.1	-27.3	78.5	-12.7	-1.4
710	TAAGGGGAGGGCACAGGCTA SEQ ID NO:331	-13.1	-26.6	75.2	-12.1	-1.3
882	CTGTTGTGAATTGGCAGAC SEQ ID NO:332	-13.1	-23.1	68.1	-10	0
1079	TATCTTTAATAAGACCGTGT SEQ ID NO:333	-13.1	-19.2	58.4	-4.8	-1.2
393	GTTTTCTTCACATGCCCTT SEQ ID NO:334	-13	-25.8	74.7	-12.8	0

position	oligo	total binding	duplex form- ation	Tm of Duplex	target struc- ture	Intra- molecular oligo	Inter- molecular oligo
570	AGAAGAGTGTCTGGTAGGTG SEQ ID NO:335	-13	-22.7	70	-9.7	0	-2.9
859	ATTGAAGGAAACAATTTTG SEQ ID NO:336	-13	-15	49.3	-2	0	-3.9
914	CAGTCTGCAGTGAATAGGGT SEQ ID NO:337	-13	-24.1	71.9	-10.5	0	-8.6
395	TTGTTTTCTTCACATTGCCC SEQ ID NO:338	-12.9	-24.9	72.6	-12	0	-3
931	TGTGTAGAATCTGGATTTCAG SEQ ID NO:339	-12.9	-20.3	63	-5.6	-1.7	-11
976	AGTAGGCCAATGGAGACAGA SEQ ID NO:340	-12.9	-23.8	69	-9.9	-0.8	-9.2
1004	GATTGTGCGAATGAGTGAAA SEQ ID NO:341	-12.9	-18.1	55.8	-5.2	0	-5
1067	GACCGTGTCTGGTTCATTGG SEQ ID NO:342	-12.9	-26.2	75.1	-11.9	-1.3	-7.8
129	ACTGTGCGGTGCAGCTGTAAG SEQ ID NO:343	-12.8	-25.3	73.3	-11	-1.3	-9.9
845	ATTTTGATCTGTGACATTTA SEQ ID NO:344	-12.8	-18.8	59.3	-6	0	-4.2
852	GGAACAATTTTGATCTGTG SEQ ID NO:345	-12.8	-18	55.9	-4.7	-0.2	-5.8
870	TGGCAGACCCCATTTGAAGG SEQ ID NO:346	-12.8	-26.5	72.1	-13	-0.5	-4.4
988	GAAAGATGAACAAGTAGGCC SEQ ID NO:347	-12.8	-19.8	58.9	-7	0	-6.4
573	AGAAGAAGAGTGTCTGGTAG SEQ ID NO:348	-12.7	-20.2	63.1	-7.5	0	-2.9
930	GTGTAGAATCTGGATTTCAGT SEQ ID NO:349	-12.7	-21.5	66.5	-7.4	-1.1	-10.2
1044	GCTTTTTTTTTTTTGTCCCA SEQ ID NO:350	-12.7	-24.1	71.2	-11.4	0	-2.8
75	GAGGCTCCTGATCCCTGGGG SEQ ID NO:351	-12.6	-31.3	84.9	-18.1	-0.2	-8.2
238	TCGGTCCCTGTGGC2CTGG SEQ ID NO:352	-12.6	-32.5	87.6	-18.3	-1.5	-7.2
795	TCCTGATTGCATTT3AGGTT SEQ ID NO:353	-12.6	-22.2	66	-9.1	-0.1	-5.4
796	TTCTGATTGCATT4AAGGT SEQ ID NO:354	-12.6	-22.2	66	-9.1	-0.1	-5.4
842	TTGATCTGTGACAT5TAAAA SEQ ID NO:355	-12.6	-16.5	52.9	-3.9	0	-5
865	GACCCCATTTGAAG6AAACA SEQ ID NO:356	-12.6	-22.9	63.5	-10.3	0	-3.4
943	TGGGGATAAGTATGTGTAGA SEQ ID NO:357	-12.6	-20.8	63.8	-8.2	0	-1.6
989	TGAAAGATGAACAAGTAGGC SEQ ID NO:358	-12.6	-17.8	55.2	-5.2	0	-2.9
999	GTCGAATGAGTGAAAGATGA SEQ ID NO:359	-12.6	-18.5	56.6	-5.9	0	-5
9	CAGGCCAGCGTTCCCATTTG SEQ ID NO:360	-12.5	-29.6	79.2	-16.6	0	-7.7
215	CCCCTGGATTTCAGGCTGCTA SEQ ID NO:361	-12.5	-30.2	81.8	-15	-2.7	-9.6
8	AGGCCAGCGTTCCCATTTGA SEQ ID NO:362	-12.4	-29.5	79.5	-16.6	0	-7.7
96	ATAATGGAAGGTTCCCTGCT SEQ ID NO:363	-12.4	-24.6	69.7	-11.5	-0.4	-6.4
369	TGATCACAGGGGCACTGCTT SEQ ID NO:364	-12.4	-26.6	75.8	-12.7	-1.4	-7.5
391	TTTCTTCACATTGCCCTTGA SEQ ID NO:365	-12.4	-25.1	72.1	-12.7	0	-3
479	CAAAGCTTCTTAGCTGACAT SEQ ID NO:366	-12.4	-21.4	63.8	-6.6	-2.4	-7

position	oligo	duplex			target	Intra-	Inter-
		total binding	form- ation	Tm of Duplex	struc- ture	molecular oligo	molecular oligo
522	TTAATTGGAAGAGTGGGCGC SEQ ID NO:367	-12.4	-22.9	65.9	-10.5	0	-7.2
794	CCTGATTGCATTTAAGGTTA SEQ ID NO:368	-12.4	-21.5	63.9	-9.1	0	-5.1
27	TGGTCTATGCTTTAGTCCCA SEQ ID NO:369	-12.3	-26.3	76.6	-13	-0.9	-5.7
370	ATGATCACAGGGGCACTGCT SEQ ID NO:370	-12.3	-26.5	75.4	-12.7	-1.4	-8.7
551	GTGCTCACTGTCTTCTTGGC SEQ ID NO:371	-12.3	-27.1	81.3	-14.8	0	-4.7
912	GTCCTGCAGTGAATAGGGTAA SEQ ID NO:372	-12.3	-22.4	67.4	-9.5	0	-8.6
74	AGGCTCCTGATCCCTGGGGA SEQ ID NO:373	-12.2	-31.3	84.9	-18.1	-0.2	-9.9
110	GTTGCTTGAAGAATATAATG SEQ ID NO:374	-12.2	-16.6	53.1	-4.4	0	-3.6
111	AGTTGCTTGAAGAATATAAT SEQ ID NO:375	-12.2	-16.6	53.3	-4.4	0	-3.6
187	GGACATCAGCATTAGTGGCA SEQ ID NO:376	-12.2	-25	73	-11.9	-0.8	-4.1
234	TCCCTGTGGCCTCTGGCGAC SEQ ID NO:377	-12.2	-32.3	85.8	-17.6	-2.5	-8.6
521	TAATTGGAAGAGTGGGCGCT SEQ ID NO:378	-12.2	-23.7	67.4	-11	-0.1	-8.1
689	GACTGACGAGAGAAGAAGAC SEQ ID NO:379	-12.2	-19.1	57.8	-6.9	0	-3.5
868	GCAGACCCCATTTGAAGGAA SEQ ID NO:380	-12.2	-25.2	69	-13	0	-3.4
878	TTGTGAATTGGCAGACCCCA SEQ ID NO:381	-12.2	-26.5	72.4	-13.6	-0.5	-4
969	CAATGGAGACAGAGTGGGG SEQ ID NO:382	-12.2	-22.1	65.4	-9	-0.8	-4.5
1076	CTTTAATAAGACCGTGTCTG SEQ ID NO:383	-12.2	-20.4	60.8	-6.8	-1.3	-8.3
275	GGCCGCCTTCCTGGAGCCAT SEQ ID NO:384	-12.1	-34.2	87.6	-19.2	-2.9	-9.6
364	ACAGGGGCACTGCTTCTTTG SEQ ID NO:385	-12.1	-26.4	76.2	-12.8	-1.4	-6.5
675	GAAGACACTAGAGAGAGCAA SEQ ID NO:386	-12.1	-19.8	60.3	-7.7	0	-4.5
690	AGACTGACGAGAGAAGAAGA SEQ ID NO:387	-12.1	-18.9	57.5	-6.8	0	-3.5
877	TGTGAATTGGCAGACCCCAT SEQ ID NO:388	-12.1	-26.4	72.1	-13.6	-0.5	-4
940	GGATAAGTATGTGTAGAATC SEQ ID NO:389	-12.1	-18.1	57.8	-6	0	-2.7
549	GCTCACTGTCTTCTTGGCTG SEQ ID NO:390	-12	-26.8	79.5	-14.8	0	-3.7
553	GTGTGCTCACTGTCTTCTTG SEQ ID NO:391	-12	-25.3	77.2	-12	-1.2	-3.3
978	CAAGTAGGCCAATGGAGACA SEQ ID NO:392	-12	-23.2	66.4	-10.3	-0.6	-8.9
1080	TTATCTTTAATAAGACCGTG SEQ ID NO:393	-12	-18.1	55.9	-4.8	-1.2	-6
1081	ATTATCTTTAATAAGACCGT SEQ ID NO:394	-12	-18.1	55.9	-4.8	-1.2	-6
113	TAAGTTGCTTGAAGAATATA SEQ ID NO:395	-11.9	-16.3	52.7	-4.4	0	-4.3
273	CCGCCTTCCTGGAGCCATCT SEQ ID NO:396	-11.9	-32.5	84.6	-20	-0.3	-6.7
874	GAATTGGCAGACCCCATTTG SEQ ID NO:397	-11.9	-25.4	69.8	-13	-0.2	-4
520	AATTGGAAGAGTGGGCGCTC SEQ ID NO:398	-11.8	-24.4	69.5	-11	-1.6	-8.3

position	oligo	total binding	duplex form- ation	Tm of Duplex	target struc- ture	Intra- molecular oligo	Inter- molecular oligo
840	GATCTGTGACATTTAAAAAT SEQ ID NO:399	-11.8	-15.7	51	-3.9	0	-5
841	TGATCTGTGACATTTAAAAA SEQ ID NO:400	-11.8	-15.7	50.9	-3.9	0	-5
29	GGTGGTCTATGCTTTAGTCC SEQ ID NO:401	-11.7	-26	78.2	-14.3	0	-3.9
87	GGTTCCTGCTGGAGGCTCC SEQ ID NO:402	-11.7	-32.6	89.7	-19.7	-1.1	-8
106	CTTGAGAATATAATGGAAG SEQ ID NO:403	-11.7	-14.6	48.5	-2.9	0	-2.7
181	CAGCATAGTGGCAGCAACA SEQ ID NO:404	-11.7	-24.6	70.8	-12	-0.8	-2.4
189	ATGGACATCAGCATTAGTGG SEQ ID NO:405	-11.7	-22.5	67.2	-10.8	0	-4.1
290	TGCACTCACATTCTTGCCG SEQ ID NO:406	-11.7	-26.9	74.5	-14.7	0	-7.6
750	GTTTCCTGGAATCTTTCAGG SEQ ID NO:407	-11.7	-23.6	70.2	-10.1	-1.8	-8.8
871	TTGGCAGACCCCATTTGAAG SEQ ID NO:408	-11.7	-25.4	70.1	-13	-0.5	-4
872	ATTGGCAGACCCCATTTGAA SEQ ID NO:409	-11.7	-25.4	69.8	-13	-0.5	-4
873	AATTGGCAGACCCCATTTGA SEQ ID NO:410	-11.7	-25.4	69.8	-13	-0.5	-4
996	GAATGAGTGAAAGATGAACA SEQ ID NO:411	-11.7	-16.3	51.8	-4.6	0	-2.9
1005	AGATTTGTGGAATGAGTGAA SEQ ID NO:412	-11.7	-18.8	57.8	-6.2	-0.7	-5
304	CAGGAACCAATCTTTGCACT SEQ ID NO:413	-11.6	-23.1	66	-11	-0.1	-7.8
390	TTCTTCACATTGCCCTTGAA SEQ ID NO:414	-11.6	-24.3	69.4	-12.7	0	-3.5
571	AAGAAGAGTGTCTGGTAGGT SEQ ID NO:415	-11.6	-22	67.7	-10.4	0	-2.9
645	GATCTTGAAAAACATGCTTT SEQ ID NO:416	-11.6	-17.6	54.6	-6	0	-5
724	AGCCTAAGCCTGGGTAAAGG SEQ ID NO:417	-11.6	-27.4	75.8	-14.4	-1.3	-8.2
846	AATTTTGATCTGTGACATTT SEQ ID NO:418	-11.6	-18.4	57.9	-6.8	0	-4.9
1008	GAAAGATTTGTCGAATGAGT SEQ ID NO:419	-11.6	-18.1	56	-5.6	-0.7	-5
112	AAGTTGCTTGAAGAATATAA SEQ ID NO:420	-11.5	-15.9	51.5	-4.4	0	-2.9
214	CCCTGGATTCAGGCTGCTAG SEQ ID NO:421	-11.5	-28.2	78.7	-14	-2.7	-9.6
396	CTTGTTTTCTTCACATTGCC SEQ ID NO:422	-11.5	-23.8	70.8	-12.3	0	-3
550	TGCTCACTGTCTTCTTGGCT SEQ ID NO:423	-11.5	-26.8	79.5	-14.8	-0.1	-3.7
908	GCAGTGAATAGGGTAAAATG SEQ ID NO:424	-11.5	-18.5	56.7	-7	0	-4.2
127	TGTCGGTGCAGCTGTAAGTT SEQ ID NO:425	-11.4	-25.5	74.6	-13.4	0	-8.9
182	TCAGCATTAGTGGCAGCAAC SEQ ID NO:426	-11.4	-24.3	71.3	-12	-0.8	-5.8
276	TGGCCGCCTTCTTGGAGCCA SEQ ID NO:427	-11.4	-34.2	87.4	-19.2	-3.6	-10.7
621	GAGCACTGGAATGATTTAGG SEQ ID NO:428	-11.4	-21	62.9	-9.6	0	-4.1
709	AAGGGGAGGGCACAGGCTAA SEQ ID NO:429	-11.4	-26.2	73.4	-13.4	-1.3	-4
749	TTTCCTGGAATCTTTCAGGT SEQ ID NO:430	-11.4	-23.6	70.2	-10.1	-2.1	-8.9

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex	struc- ture	molecular oligo	molecular oligo
851	GAAACAATTTTGATCTGTGA SEQ ID NO:431	-11.4	-17.4	54.7	-5.5	-0.2	-5.8
921	CTGGATTTCAGTCTGCAGTGA SEQ ID NO:432	-11.4	-24.7	73.9	-11.8	-0.5	-10.9
997	CGAATGAGTGAAAGATGAAC SEQ ID NO:433	-11.4	-16.4	51.5	-5	0	-2
68	CTGATCCCTGGGGATGACTC SEQ ID NO:434	-11.3	-27.1	75.9	-13.8	-1.4	-11.9
277	TTGGCCGCTTCTTGGAGCC SEQ ID NO:435	-11.3	-33.6	86.9	-19.8	-2.5	-10
303	AGGAACCAATCTTTGCACTC SEQ ID NO:436	-11.3	-22.8	66.3	-11	-0.1	-7.8
352	CTTCTTTTGGCAGCCAGACA SEQ ID NO:437	-11.3	-28.2	78.5	-15.8	-1	-8.1
362	AGGGGCACTGCTTCTTTGGC SEQ ID NO:438	-11.3	-28.5	81.7	-16.5	-0.4	-6.3
876	GTGAATTGGCAGACCCCATTT SEQ ID NO:439	-11.3	-26.5	72.6	-14.5	-0.5	-4
26	GGTCTATGCTTTAGTCCCAG SEQ ID NO:440	-11.2	-26.3	77.2	-14.6	-0.2	-4.6
264	TGGAGCCATCTCCTAGAAGC SEQ ID NO:441	-11.2	-26.3	74.8	-11.9	-3.2	-8.6
262	GAGCCATCTCCTAGAAGCCT SEQ ID NO:442	-11.1	-28	77.9	-15.9	-0.9	-5.6
456	TTGAGAAATTGCTGGCAGGC SEQ ID NO:443	-11.1	-23.4	67.6	-11.5	-0.3	-9
478	AAAGCTTCTTAGCTGACATT SEQ ID NO:444	-11.1	-20.8	62.9	-7.3	-2.4	-7
705	GGAGGGCACAGGCTAAGACT SEQ ID NO:445	-11.1	-26.2	74.5	-14.4	-0.5	-4.3
5	CCAGCGTTCCCATTTGAGGG SEQ ID NO:446	-11	-28.9	77.8	-16.8	-1	-9.2
40	ATACTCAGCCTGGTGGTCTA SEQ ID NO:447	-11	-26.4	77.5	-14.8	-0.3	-4.8
41	GATACTCAGCCTGGTGGTCT SEQ ID NO:448	-11	-27.3	79.6	-15.7	-0.3	-4.9
180	AGCATTAGTGGCAGCAACAG SEQ ID NO:449	-11	-23.9	69.9	-12	-0.8	-2.4
345	GGCAGCCAGACACTGTCAT SEQ ID NO:450	-11	-29.1	80.5	-16.6	-1.4	-8.9
357	CACTGCTTCTTTGGCAGCCC SEQ ID NO:451	-11	-29.6	81.9	-15.5	-3.1	-8.1
446	GCTGGCAGGCTCTGGAATGC SEQ ID NO:452	-11	-28.5	80.1	-16.6	-0.7	-6
490	CAAAGGCAGAGCAAAGCTTC SEQ ID NO:453	-11	-21.9	63.8	-9.9	-0.9	-7.7
748	TTCCTGGAATCTTTTCAGGTA SEQ ID NO:454	-11	-23.2	69.3	-10.1	-2.1	-8.9
1007	AAAGATTTGTCTGAATGAGTG SEQ ID NO:455	-11	-17.5	54.7	-5.6	-0.7	-5
473	TTCTTAGCTGACATTGTTTG SEQ ID NO:456	-10.9	-20.9	64.6	-10	0	-5.1
523	TTTAATTGGAAGAGTGGGCG SEQ ID NO:457	-10.9	-21.2	62.2	-10.3	0	-4
720	TAAGCCTGGGTAAGGGGAGG SEQ ID NO:458	-10.9	-25.7	72.5	-13.4	-1.3	-4.9
838	TCTGTGACATTTAAAAATAT SEQ ID NO:459	-10.9	-14.8	49.2	-3.9	0	-5
839	ATCTGTGACATTTAAAAATA SEQ ID NO:460	-10.9	-14.8	49.2	-3.9	0	-5
922	TCTGGATTTCAGTCTGCAGTG SEQ ID NO:461	-10.9	-24.5	74.3	-11.8	-1.1	-11.7
923	ATCTGGATTTCAGTCTGCAGT SEQ ID NO:462	-10.9	-24.5	74.5	-11.8	-1.1	-11.7

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex	struc- ture	molecular oligo	molecular oligo
960	CAGAGTGAGGGTCTTGGTGG SEQ ID NO:463	-10.9	-25.7	76.6	-14.8	0	-2.6
970	CCAATGGAGACAGAGTGAGG SEQ ID NO:464	-10.9	-22.9	66.5	-11.1	-0.8	-5.2
1068	AGACCGTGTCTGGTTCATTG SEQ ID NO:465	-10.9	-25	72.7	-12.7	-1.3	-7.5
1082	TATTATCTTTAATAAGACCG SEQ ID NO:466	-10.9	-16.6	52.7	-4.8	-0.7	-4.7
32	CCTGGTGGTCTATGCTTTAG SEQ ID NO:467	-10.8	-25.3	74.5	-14.5	0	-3.6
330	GTCATGAATTTCTTCTCGG SEQ ID NO:468	-10.8	-21.6	65.2	-10.8	0.1	-6.7
432	GAATGCTTGTTTGGCTTTCT SEQ ID NO:469	-10.8	-23.5	69.9	-11	-1.7	-5.4
494	CCTACAAAGGCAGAGCAAAG SEQ ID NO:470	-10.8	-21.5	61.8	-9.8	-0.7	-4.6
691	AAGACTGACGAGAGAAGAAG SEQ ID NO:471	-10.8	-17.6	54.4	-6.8	0	-3.5
114	GTAAGTTGCTTGAAGAATAT SEQ ID NO:472	-10.7	-17.8	56.2	-7.1	0	-4.3
263	GGAGCCATCTCCTAGAAGCC SEQ ID NO:473	-10.7	-28.3	78.6	-15.1	-2.5	-8.2
358	GCACTGCTTCTTTGGCAGCC SEQ ID NO:474	-10.7	-29.4	82.9	-15.6	-3.1	-9.8
371	AATGATCACAGGGGCACTGC SEQ ID NO:475	-10.7	-24.9	71	-12.7	-1.4	-8.4
455	TGAGAAATTGCTGGCAGGCT SEQ ID NO:476	-10.7	-24.2	69.2	-12.3	-1.1	-7.5
647	ATGATCTTGAAAACATGCT SEQ ID NO:477	-10.7	-17.4	54	-6.7	0	-5
755	CTACAGTTTCTTGAATCTT SEQ ID NO:478	-10.7	-22.7	67.6	-10.6	-1.3	-4.6
797	TTTCTGATTGCATTTAAGG SEQ ID NO:479	-10.7	-21.1	63.2	-10.4	0	-5.1
1006	AAGATTGTGCGAATGAGTGA SEQ ID NO:480	-10.7	-18.8	57.8	-7.2	-0.7	-5
239	CTCGGTCCCTGTGGCCTCTG SEQ ID NO:481	-10.6	-32.2	86.9	-20	-1.5	-7.2
267	TCCTGGAGCCATCTCCTAGA SEQ ID NO:482	-10.6	-28.5	80	-14.7	-3.2	-7.9
291	TTGCACTCACATTCTTGGCC SEQ ID NO:483	-10.6	-26.2	75	-15.6	0	-6.2
361	GGGGCACTGCTTCTTTGGCA SEQ ID NO:484	-10.6	-29.2	82.4	-17.3	-1.2	-7.2
365	CACAGGGGCACTGCTTCTTT SEQ ID NO:485	-10.6	-27.1	77.5	-15	-1.4	-6.5
519	ATTGGAAGAGTGGGCGCTCA SEQ ID NO:486	-10.6	-25.8	72.9	-12.5	-2.7	-10
644	ATCTTGAAAAACATGCTTTT SEQ ID NO:487	-10.6	-17.1	53.7	-6	-0.2	-7.1
856	TGAAGGAACAATTTTGATC SEQ ID NO:488	-10.6	-15.8	51	-5.2	0	-5.8
881	TGGTTGTGAATTGGCAGACC SEQ ID NO:489	-10.6	-24.2	69.9	-12.9	-0.4	-4.7
147	ATTAGAACTTTCATCGCAAC SEQ ID NO:490	-10.5	-19.3	58.6	-8.8	0	-4.2
346	TGGCAGCCCAGACACTGTCA SEQ ID NO:491	-10.5	-29.1	80.3	-16.6	-2	-9.6
351	TTCTTTGGCAGCCCAGACAC SEQ ID NO:492	-10.5	-27.5	77.1	-16.1	-0.7	-8.1
708	AGGGGAGGGCACAGGCTAAG SEQ ID NO:493	-10.5	-26.9	76.1	-15	-1.3	-4
743	GGAATCTTTCAGGTAATTAA SEQ ID NO:494	-10.5	-18.2	57.1	-6.8	-0.8	-5.8

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex ture	molecular oligo	molecular oligo	
760	GGAAGCTACAGTTTCCTGGA SEQ ID NO:495	-10.5	-24.9	72.3	-12.9	-1.4	-9.1
1014	ACCTCAGAAAGATTGTGCGA SEQ ID NO:496	-10.5	-21.2	62.4	-9.8	-0.7	-4.8
6	GCCAGCGTTCCTCATTTGAGG SEQ ID NO:497	-10.4	-29.5	79.5	-19.1	0	-4.1
39	TACTCAGCCTGGTGGTCTAT SEQ ID NO:498	-10.4	-26.4	77.5	-15.5	-0.2	-4.9
72	GCTCCTGATCCCTGGGGATG SEQ ID NO:499	-10.4	-30.1	81.7	-17.7	-1.4	-11.9
124	CGGTGCAGCTGTAAGTTGCT SEQ ID NO:500	-10.4	-26.6	75.8	-12.2	-4	-9.4
574	GAGAAGAAGAGTGCTCTGGTA SEQ ID NO:501	-10.4	-20.8	64.3	-10.4	0	-2.9
728	ATTAAGCCTAAGCCTGGGTA SEQ ID NO:502	-10.4	-24.8	70.3	-14.4	0	-5.4
10	CCAGGCCAGCGTTCCTCATTT SEQ ID NO:503	-10.3	-31.6	82.7	-20.8	0	-7.7
265	CTGGAGCCATCTCCTAGAAG SEQ ID NO:504	-10.3	-25.4	72.4	-11.9	-3.2	-7.4
389	TCTTCACATTGCCCTTGAAA SEQ ID NO:505	-10.3	-23.5	66.9	-12.7	-0.2	-3.6
746	CCTGGAATCTTTTCAGGTAAT SEQ ID NO:506	-10.3	-22	65	-10.1	-1.5	-7.7
860	CATTTGAAGGAAACAATTTT SEQ ID NO:507	-10.3	-15.7	50.6	-5.4	0	-3.2
493	CTACAAAGGCAGAGCAAAGC SEQ ID NO:508	-10.2	-21.3	62.1	-10.2	-0.7	-4.6
548	CTCACTGTCTTCTTGGCTGA SEQ ID NO:509	-10.2	-25.6	76.2	-15.4	0	-3.7
747	TCCTGGAATCTTTTCAGGTAA SEQ ID NO:510	-10.2	-22.4	66.6	-10.1	-2.1	-8.9
987	AAAGATGAACAAGTAGGCCA SEQ ID NO:511	-10.2	-19.9	58.8	-9.2	0	-7.7
209	GATTCAGGCTGCTAGAGACC SEQ ID NO:512	-10.1	-25.5	74.3	-14.9	-0.1	-6.1
356	ACTGCTTCTTTGGCAGCCCA SEQ ID NO:513	-10.1	-29.6	81.9	-16.4	-3.1	-8.1
725	AAGCCTAAGCCTGGGTAAGG SEQ ID NO:514	-10.1	-25.5	71	-14.4	-0.9	-7.5
764	GCTAGGAAGCTACAGTTTCC SEQ ID NO:515	-10.1	-24.6	72.5	-12.9	-1.5	-9.1
855	GAAGGAAACAATTTGATCT SEQ ID NO:516	-10.1	-16.7	52.9	-6.6	0	-5.8
76	GGAGGCTCCTGATCCCTGGG SEQ ID NO:517	-10	-31.3	84.9	-20.5	-0.5	-8.6
208	ATTCAGGCTGCTAGAGACCA SEQ ID NO:518	-10	-25.6	74	-14.9	-0.4	-6.1
268	TTCCTGGAGCCATCTCCTAG SEQ ID NO:519	-10	-28	79	-15.5	-2.5	-7.3
288	CACTCACATTCTTGGCCGCC SEQ ID NO:520	-10	-28.9	78.1	-18.4	0	-7.6
344	GCAGCCCAGACACTGTCATG SEQ ID NO:521	-10	-27.9	77.7	-16.6	-1.2	-8.9
354	TGCTTCTTTGGCAGCCCAGA SEQ ID NO:522	-10	-29.1	81	-18	-1	-8.1
472	TCTTAGCTGACATTGTTTGA SEQ ID NO:523	-10	-21.4	65.6	-11.4	0	-5.4
848	ACAATTTTGATCTGTGACAT SEQ ID NO:524	-10	-19.1	59	-9.1	0	-4.9
880	GGTTGTGAATTGGCAGACCC SEQ ID NO:525	-10	-26.2	73.6	-15.5	-0.5	-4.1
925	GAATCTGGATTGAGTCTGCA SEQ ID NO:526	-10	-23.2	69.4	-11.8	-1.1	-10.3

position	oligo	total binding	duplex form- ation	Tm of Duplex	target struc- ture	Intra- molecular oligo	Inter- molecular oligo
146	TTAGAACTTTTCATCGCAACT SEQ ID NO:527	-9.9	-20.2	60.4	-10.3	0	-4.2
167	GCAACAGGAGGAGGGAAGAG SEQ ID NO:528	-9.9	-23.2	67.2	-13.3	0	-3.4
355	CTGCTTCTTTGGCAGCCCAG SEQ ID NO:529	-9.9	-29.4	81.6	-17.3	-2.2	-7.9
388	CTTCACATTGCCCTTGAAAT SEQ ID NO:530	-9.9	-23.1	65.4	-12.7	-0.2	-3.6
692	TAAGACTGACGAGAGAAGAA SEQ ID NO:531	-9.9	-17.3	53.8	-7.4	0	-3.5
693	CTAAGACTGACGAGAGAAGA SEQ ID NO:532	-9.9	-18.9	57.4	-9	0	-3.5
757	AGCTACAGTTTCTCGGAATC SEQ ID NO:533	-9.9	-23.5	69.8	-12.9	-0.4	-8.3
849	AACAATTTTGATCTGTGACA SEQ ID NO:534	-9.9	-18.4	57.1	-8	-0.2	-4.9
866	AGACCCCATTTGAAGGAAAC SEQ ID NO:535	-9.9	-22.2	62.6	-12.3	0	-3.4
1009	AGAAAGATTTGTGGAATGAG SEQ ID NO:536	-9.9	-16.9	53.4	-7	0.1	-5
1098	TTTTTTTTTAAACCTATATT SEQ ID NO:537	-9.9	-15.7	51.6	-5.8	0	-4.4
1099	TTTTTTTTTAAACCTATAT SEQ ID NO:538	-9.9	-15.7	51.6	-5.8	0	-4.4
212	CTGGATTTCAGGCTGCTAGAG SEQ ID NO:539	-9.8	-24.8	73.1	-14.2	-0.6	-7.6
235	GTCCCTGTGGCCTCTGGCGA SEQ ID NO:540	-9.8	-33.3	88.8	-21	-2.5	-7.7
302	GGAACCAATCTTTGCACTCA SEQ ID NO:541	-9.8	-23.5	67.2	-13.2	-0.1	-5.1
353	GCTTCTTTGGCAGCCAGAC SEQ ID NO:542	-9.8	-29.3	81.9	-18.4	-1	-8.1
556	TAGGTGTGCTCACTGTCTTC SEQ ID NO:543	-9.8	-25.2	77.4	-13.4	-2	-4.2
600	GTGGGTACAGTGGGAGAGTG SEQ ID NO:544	-9.8	-25.4	76	-15.6	0	-5.2
646	TGATCTTGAAAAACATGCTT SEQ ID NO:545	-9.8	-17.5	54.3	-7.7	0	-5
785	ATTTAAGGTAAATGACACT SEQ ID NO:546	-9.8	-16.6	53.1	-6.2	-0.3	-6.5
920	TGGATTCACTCTGCACTGAA SEQ ID NO:547	-9.8	-23.1	69.3	-11.8	-0.5	-10.8
13	GTCCCAGGCCAGCGTTCCCA SEQ ID NO:548	-9.7	-35	90.5	-24.8	0	-7.7
35	CAGCCTGGTGGTCTATGCTT SEQ ID NO:549	-9.7	-28	80.4	-17.7	-0.3	-4.9
73	GGCTCCTGATCCCTGGGGAT SEQ ID NO:550	-9.7	-31.3	84.5	-19.7	-1.2	-11.9
123	GGTGCAGCTGTAAGTTGCTT SEQ ID NO:551	-9.7	-25.9	76.4	-12.2	-4	-11.4
166	CAACAGGAGGAGGGAAGAGA SEQ ID NO:552	-9.7	-22	64.4	-12.3	0	0
329	TCATGAATTTCTTCTCGGG SEQ ID NO:553	-9.7	-21.6	64.6	-11.1	-0.6	-5.9
552	TGTGCTCACTGTCTTCTTGG SEQ ID NO:554	-9.7	-25.3	76.2	-15.6	0	-5.5
674	AAGACACTAGAGAGAGCAAC SEQ ID NO:555	-9.7	-19.4	59.5	-9.7	0	-4.5
744	TGGAATCTTTTCAAGTAATTA SEQ ID NO:556	-9.7	-18.9	59.1	-8.3	-0.8	-5.6
915	TCAGTCTGCACTGAATAGGG SEQ ID NO:557	-9.7	-23.3	70.1	-13	0	-8.4
1083	ATATTATCTTTAATAAGACC SEQ ID NO:558	-9.7	-15.8	51.8	-4.8	-1.2	-5.2

position	oligo	total binding	duplex form- ation	Tm of Duplex	target struc- ture	Intra- molecular oligo	Inter- molecular oligo
107	GCTTGAAGATATAATGGAA SEQ ID NO:559	-9.6	-16.4	52.1	-6.8	0	-2.8
305	TCAGGAACCAATCTTTGCAC SEQ ID NO:560	-9.6	-22.6	65.6	-12.5	-0.1	-7.8
392	TTTTCTTCACATTGCCCTTG SEQ ID NO:561	-9.6	-24.6	71.1	-15	0	-3
721	CTAAGCCTGGGTAAGGGGAG SEQ ID NO:562	-9.6	-25.4	71.9	-15	-0.6	-4.7
850	AAACAATTTTGATCTGTGAC SEQ ID NO:563	-9.6	-17	54	-6.9	-0.2	-4.9
1013	CCTCAGAAAGATTGTGCGAA SEQ ID NO:564	-9.6	-20.3	59.9	-9.8	-0.7	-5
1015	TACCTCAGAAAGATTGTGCG SEQ ID NO:565	-9.6	-20.3	60.6	-9.8	-0.7	-3.2
328	CATGAATTTTCTTCTCGGGG SEQ ID NO:566	-9.5	-22.4	65.7	-12.1	-0.6	-4.4
752	CAGTTTCCTGGAATCTTTCA SEQ ID NO:567	-9.5	-23.1	68.7	-12.7	-0.8	-4.6
924	AATCTGGATTTCAGTCTGCAG SEQ ID NO:568	-9.5	-22.6	68.3	-11.8	-1.1	-9.9
941	GGGATAAGTATGTGTAGAAT SEQ ID NO:569	-9.5	-18.9	59	-9.4	0	-1.8
207	TTCAGGCTGCTAGAGACCAT SEQ ID NO:570	-9.4	-25.6	74	-14.9	-1.2	-6.7
445	CTGGCAGGCTCTGGAATGCT SEQ ID NO:571	-9.4	-27.6	77.7	-16.6	-1.5	-6.7
702	GGGCACAGGCTAAGACTGAC SEQ ID NO:572	-9.4	-25.2	72.1	-14.4	-1.3	-5.6
875	TGAATTGGCAGACCCATTT SEQ ID NO:573	-9.4	-25.4	69.8	-15.3	-0.5	-4
33	GCCTGGTGGTCTATGCTTTA SEQ ID NO:574	-9.3	-27.1	78.8	-17.2	-0.3	-4.7
240	CCTCGGTCCCTGTGGCCTCT SEQ ID NO:575	-9.3	-34.2	90.5	-23.3	-1.5	-7.2
247	AGCCTGGCCTCGGTCCCTGT SEQ ID NO:576	-9.3	-34.7	91.5	-24.6	0	-9.2
301	GAACCAATCTTTGCACTCAC SEQ ID NO:577	-9.3	-22.5	65.3	-13.2	0	-5
377	CCTTGAAATGATCACAGGGG SEQ ID NO:578	-9.3	-22.4	64.2	-11.5	-1.6	-7.1
787	GCATTTAAGGTTAAATGACA SEQ ID NO:579	-9.3	-18	55.8	-6	-2.7	-11
986	AAGATGAACAAGTAGGCCAA SEQ ID NO:580	-9.3	-19.9	58.8	-10.1	0	-7.7
61	CTGGGGATGACTCAGGTCAG SEQ ID NO:581	-9.2	-25.4	74.4	-13.8	-2.4	-6.6
71	CTCCTGATCCCTGGGGATGA SEQ ID NO:582	-9.2	-28.9	78.7	-17.7	-1.4	-11.9
84	TCCCTGCTGGAGGCTCCTGA SEQ ID NO:583	-9.2	-31.6	85.9	-21.1	-1.2	-7.1
86	GTTCCCTGCTGGAGGCTCCT SEQ ID NO:584	-9.2	-32.3	89	-21.8	-1.2	-8
116	CTGTAAGTTGCTTGAAGAAT SEQ ID NO:585	-9.2	-19	58.6	-9.8	0	-4.3
477	AAGCTTCTTAGCTGACATTG SEQ ID NO:586	-9.2	-21.5	65	-9.9	-2.4	-7.1
703	AGGGCACAGGCTAAGACTGA SEQ ID NO:587	-9.2	-25	71.7	-14.4	-1.3	-5.6
704	GAGGGCACAGGCTAAGACTG SEQ ID NO:588	-9.2	-25	71.7	-14.4	-1.3	-5.3
739	TCTTTCAGGTAATTAAGCCT SEQ ID NO:589	-9.2	-21.8	65.5	-12	-0.3	-5.4
761	AGGAAGCTACAGTTTCTGG SEQ ID NO:590	-9.2	-24.3	71.2	-12.9	-2.2	-10.6

position	oligo	total binding	duplex form- ation	Tm of Duplex	target struc- ture	Intra- molecular oligo	Inter- molecular oligo
246	GCCTGGCCTCGGTCCCTGTG SEQ ID NO:591	-9.1	-34.7	90.8	-25.1	0	-8
648	AATGATCTTGAAAAACATGC SEQ ID NO:592	-9.1	-15.8	50.6	-6.7	0	-5
707	GGGAGGGCACAGGCTAAGA SEQ ID NO:593	-9.1	-27.5	77.2	-17	-1.3	-4
729	AATTAAGCCTAAGCCTGGGT SEQ ID NO:594	-9.1	-24.4	68.6	-14.4	-0.8	-5.4
745	CTGGAATCTTTCAGGTAATT SEQ ID NO:595	-9.1	-20.1	61.6	-10.1	-0.8	-4.3
11	CCCAGGCCAGCGTTCCCATT SEQ ID NO:596	-9	-33.5	85.5	-24	0	-7.7
14	AGTCCAGGCCAGCGTTCCC SEQ ID NO:597	-9	-34.3	90	-24.8	0	-7.7
31	CTGGTGGTCTATGCTTAGT SEQ ID NO:598	-9	-24.5	74.3	-15.5	0	-3.9
190	CATGGACATCAGCATTAGTG SEQ ID NO:599	-9	-22	65.8	-13	0	-4.1
701	GGCACAGGCTAAGACTGACG SEQ ID NO:600	-9	-24.8	69.5	-14.4	-1.3	-5.4
722	CCTAAGCCTGGGTAAGGGGA SEQ ID NO:601	-9	-27.4	75.1	-17	-1.3	-6.9
753	ACAGTTTCCTGGAATCTTTC SEQ ID NO:602	-9	-22.6	68.1	-12.2	-1.3	-4.6
38	ACTCAGCCTGGTGGTCTATG SEQ ID NO:603	-8.9	-26.7	77.9	-17.2	-0.3	-4.9
70	TCCTGATCCCTGGGATGAC SEQ ID NO:604	-8.9	-28.2	77.4	-17.7	-0.8	-11.3
464	GACATTGTTTGAGAAATTGC SEQ ID NO:605	-8.9	-18.7	57.8	-9.8	0	-5.5
673	AGACACTAGAGAGAGCAACA SEQ ID NO:606	-8.9	-20.8	62.8	-11.9	0	-4.1
742	GAATCTTTCAGGTAATTAAG SEQ ID NO:607	-8.9	-17	54.7	-8.1	0	-5
754	TACAGTTTCCTGGAATCTTT SEQ ID NO:608	-8.9	-21.9	66	-11.6	-1.3	-4.6
861	CCATTTGAAGGAAACAATTT SEQ ID NO:609	-8.9	-17.6	53.8	-8.7	0	-3.2
919	GGATTCACTCTGCAGTGAAT SEQ ID NO:610	-8.9	-23.1	69.4	-11.8	-1.5	-12.8
926	AGAATCTGGATTCACTCTGC SEQ ID NO:611	-8.9	-22.5	68.5	-11.8	-1.7	-11
995	AATGAGTGAAAGATGAACAA SEQ ID NO:612	-8.9	-15	49	-6.1	0	-2.5
83	CCCTGCTGGAGGCTCCTGAT SEQ ID NO:613	-8.8	-31.2	84	-21.1	-1.2	-7.1
211	TGGATTCAAGCTGCTAGAGA SEQ ID NO:614	-8.8	-24.5	72.4	-15.7	0	-6.6
331	TGTCATGAATTTCTTCTCG SEQ ID NO:615	-8.8	-20.4	62.5	-10.8	-0.6	-6.7
386	TCACATTGCCCTTGAAATGA SEQ ID NO:616	-8.8	-22.7	64.4	-12.7	-1.1	-4.3
643	TCTTGAAAAACATGCTTTTT SEQ ID NO:617	-8.8	-17.2	54	-7.5	-0.7	-8.5
700	GCACAGGCTAAGACTGACGA SEQ ID NO:618	-8.8	-24.2	68.3	-14.4	-0.9	-5.4
727	TTAAGCCTAAGCCTGGGTAA SEQ ID NO:619	-8.8	-24.1	68.1	-14.4	-0.8	-4.9
740	ATCTTTTCAGGTAATTAAGCC SEQ ID NO:620	-8.8	-20.9	63.5	-12.1	0	-5
798	CTTTCCTGATTGCATTTAAG SEQ ID NO:621	-8.8	-20.8	62.5	-12	0	-5.1
1075	TTTAATAAGACCGTGTCTGG SEQ ID NO:622	-8.8	-20.7	61.4	-10.5	-1.3	-8.3

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex structure	molecular oligo	molecular oligo	
12	TCCCAGGCCAGCGTTCCCAT SEQ ID NO:623	-8.7	-33.8	86.9	-25.1	0	-6.9
69	CCTGATCCCTGGGGATGACT SEQ ID NO:624	-8.7	-28.7	77.6	-18	-1.4	-11.9
266	CCTGGAGCCATCTCCTAGAA SEQ ID NO:625	-8.7	-27.4	75.7	-15.5	-3.2	-7.7
360	GGGCACTGCTTCTTTGGCAG SEQ ID NO:626	-8.7	-28	80.1	-17.3	-2	-9.7
378	CCCTTGAAATGATCACAGGG SEQ ID NO:627	-8.7	-23.2	65.3	-11.5	-3	-7.9
726	TAAGCCTAAGCCTGGGTAAG SEQ ID NO:628	-8.7	-24	68	-14.4	-0.8	-4.9
759	GAAGCTACAGTTTCCTGGAA SEQ ID NO:629	-8.7	-23	67.3	-12.9	-1.3	-8.6
867	CAGACCCCATTTGAAGGAAA SEQ ID NO:630	-8.7	-22.7	63.2	-14	0	-3.4
1034	TTTTGTGCCACCTCGCTCTT SEQ ID NO:631	-8.7	-29	79.9	-20.3	0	-3.1
1035	TTTTGTGCCACCTCGCTCT SEQ ID NO:632	-8.7	-29	79.9	-20.3	0	-3.1
348	TTTGGCAGCCCAGACACTGT SEQ ID NO:633	-8.6	-28.2	78.3	-18.5	-1	-9.1
381	TTGCCCTTGAAATGATCACA SEQ ID NO:634	-8.6	-22.7	64.4	-13.4	-0.5	-6.8
387	TTACATTGCCCTTGAAATG SEQ ID NO:635	-8.6	-22.2	63.5	-12.7	-0.7	-4
444	TGGCAGGCTCTGGAATGCTT SEQ ID NO:636	-8.6	-26.8	76.1	-16.6	-1.5	-6.7
454	GAGAAATTGCTGGCAGGCTC SEQ ID NO:637	-8.6	-24.6	70.9	-14.8	-1.1	-7.5
496	CTCCTACAAAGGCAGAGCAA SEQ ID NO:638	-8.6	-23.5	66.7	-13.7	-1.1	-6.3
575	GGAGAAGAAGAGTGTCTGGT SEQ ID NO:639	-8.6	-22.3	67.6	-13.7	0	-2.9
738	CTTTCAGGTAATTAAGCCTA SEQ ID NO:640	-8.6	-21.1	63.4	-12	-0.2	-5.3
763	CTAGGAAGCTACAGTTTCCT SEQ ID NO:641	-8.6	-23.7	70.1	-12.9	-2.2	-10.7
788	TGCATTTAAGGTTAAATGAC SEQ ID NO:642	-8.6	-17.3	54.6	-6	-2.7	-11
929	TGTAGAATCTGGATTTCAGTC SEQ ID NO:643	-8.6	-20.7	64.7	-10.3	-1.7	-11
115	TGTAAGTTGCTTGAAGAATA SEQ ID NO:644	-8.5	-17.8	56.1	-9.3	0	-4.3
119	CAGCTGTAAGTTGCTTGAAG SEQ ID NO:645	-8.5	-21.6	65	-12.2	-0.6	-8.8
122	GTGCAGCTGTAAGTTGCTTG SEQ ID NO:646	-8.5	-24.7	73.5	-12.2	-4	-11.4
350	TCTTTGGCAGCCCAGACACT SEQ ID NO:647	-8.5	-28.3	78.7	-18.7	-1	-7.7
380	TGCCCTTGAAATGATCACAG SEQ ID NO:648	-8.5	-22.6	64.3	-13.4	-0.5	-6.8
789	TTGCATTTAAGGTTAAATGA SEQ ID NO:649	-8.5	-17.2	54.4	-6	-2.7	-11
1016	TTACCTCAGAAAGATTTGTC SEQ ID NO:650	-8.5	-19.6	60.4	-11.1	0	-2.5
117	GCTGTAAGTTGCTTGAAGAA SEQ ID NO:651	-8.4	-20.8	62.7	-12.4	0	-4.3
385	CACATTGCCCTTGAATGAT SEQ ID NO:652	-8.4	-22.3	63.1	-12.7	-1.1	-4.3
463	ACATTGTTTGAGAAATTGCT SEQ ID NO:653	-8.4	-19	58.5	-10.6	0	-4
524	GTTTAATTGGAAGAGTGGGC SEQ ID NO:654	-8.4	-21.6	65	-13.2	0	-2.9

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex structure	molecular oligo	molecular oligo	
622	AGAGCACTGGAAATGATTTAG SEQ ID NO:655	-8.4	-19.8	60.5	-11.4	0	-4.1
756	GCTACAGTTTCTCTGGAATCT SEQ ID NO:656	-8.4	-24.4	71.6	-14.6	-1.3	-8.3
786	CATTTAAGGTTAAATGACAC SEQ ID NO:657	-8.4	-16.4	52.5	-6	-2	-9.9
25	GTCTATGCTTTAGTCCCAGG SEQ ID NO:658	-8.3	-26.3	77.2	-18	0	-3.9
283	ACATTCTTGGCCGCTTCCT SEQ ID NO:659	-8.3	-30.3	81.1	-21.5	0	-8
300	AACCAATCTTTGCACACACA SEQ ID NO:660	-8.3	-22.6	65.2	-14.3	0	-5
349	CTTTGGCAGCCCAGACACTG SEQ ID NO:661	-8.3	-27.9	76.8	-18.5	-1	-8.5
1033	TTTGTCCCACCTCGCTCTTA SEQ ID NO:662	-8.3	-28.6	79	-20.3	0	-3.1
1043	CTTTTTTTTTTTTGTCCCAC SEQ ID NO:663	-8.3	-22.5	67.4	-14.2	0	-1.6
287	ACTCACATTCTTGGCCGCT SEQ ID NO:664	-8.2	-29.1	78.9	-20.4	0	-8
332	CTGTCATGAATTTCTTCTC SEQ ID NO:665	-8.2	-20.5	64.1	-11.5	-0.6	-6.7
433	GGAATGCTTGTTTGGCTTTC SEQ ID NO:666	-8.2	-23.8	70.6	-13.9	-1.7	-5.4
460	TTGTTTGAGAAATGCTGGC SEQ ID NO:667	-8.2	-21.1	63.2	-12.9	0	-5.5
510	GTGGGCGCTCAGAGCTCCTA SEQ ID NO:668	-8.2	-30.3	84.5	-20.8	1.5	-10.6
511	AGTGGGCGCTCAGAGCTCCT SEQ ID NO:669	-8.2	-30.6	85.5	-21.1	1.5	-10.6
1092	TTTAAACCTATATTATCTTT SEQ ID NO:670	-8.2	-16.3	52.9	-8.1	0	-4
1093	TTTTAAACCTATATTATCTT SEQ ID NO:671	-8.2	-16.3	52.9	-8.1	0	-4.4
108	TGCTTGAAGAATATAATGGA SEQ ID NO:672	-8.1	-17.1	53.7	-9	0	-3.6
284	CACATTCTTGGCCGCTTCC SEQ ID NO:673	-8.1	-30.1	80.2	-21.5	0	-8
374	TGAAATGATCACAGGGGCAC SEQ ID NO:674	-8.1	-22.1	64.1	-13.4	-0.3	-6.3
384	ACATTGCCCTTGAAATGATC SEQ ID NO:675	-8.1	-22	63.3	-12.7	-1.1	-4.3
461	ATTGTTTGAGAAATGCTGG SEQ ID NO:676	-8.1	-19.3	59.2	-11.2	0	-4
624	TGAGAGCACTGGAATGATTT SEQ ID NO:677	-8.1	-20.7	62.1	-12.6	0	-3.4
625	TTGAGAGCACTGGAATGATT SEQ ID NO:678	-8.1	-20.7	62.1	-12.6	0	-4.2
758	AAGCTACAGTTTCCTGGAAT SEQ ID NO:679	-8.1	-22.4	66	-12.9	-1.3	-8.6
928	GTAGAATCTGGATTCACTCT SEQ ID NO:680	-8.1	-21.6	66.9	-11.7	-1.7	-11
299	ACCAATCTTTGCACTCACAT SEQ ID NO:681	-8	-23.3	67.3	-15.3	0	-5
572	GAAGAAGAGTGTCTGGTAGG SEQ ID NO:682	-8	-21.4	65.6	-13.4	0	-2.9
120	GCAGCTGTAAGTTGCTTGAA SEQ ID NO:683	-7.9	-23.4	69	-12.2	-3.3	-11.4
121	TGCAGCTGTAAGTTGCTTGA SEQ ID NO:684	-7.9	-24.1	71.3	-12.2	-4	-11.4
359	GGCACTGCTTCTTTGGCAGC SEQ ID NO:685	-7.9	-28.6	82	-17.6	-3.1	-10.1
375	TTGAAATGATCACAGGGGCA SEQ ID NO:686	-7.9	-22	63.9	-13.4	-0.5	-6.8

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex	struc- ture	molecular oligo	molecular oligo
631	TGCTTTTTTGAGAGCACTGGA SEQ ID NO:687	-7.9	-23.7	70	-13.8	-2	-5.9
741	AATCTTTTCAGGTAATTAAGC SEQ ID NO:688	-7.9	-18.2	57.5	-10.3	0	-5
17	TTTAGTCCCAGGCCAGCGTT SEQ ID NO:689	-7.8	-29.8	81.7	-21.5	0	-7.7
294	TCTTTGCACTCACATTCTTG SEQ ID NO:690	-7.8	-22.6	68.2	-14.8	0	-5
295	ATCTTTGCACTCACATTCTT SEQ ID NO:691	-7.8	-22.6	68.4	-14.8	0	-4.7
630	GCTTTTGTGAGAGCACTGGAA SEQ ID NO:692	-7.8	-23	67.8	-13.8	-1.3	-4.6
771	GACACTAGCTAGGAAGCTAC SEQ ID NO:693	-7.8	-22.4	66.9	-11.8	-2.8	-9.9
780	AGGTTAAATGACACTAGCTA SEQ ID NO:694	-7.8	-19.5	59.8	-11.2	-0.1	-5.6
1091	TTAAACCTATATTATCTTTA SEQ ID NO:695	-7.8	-15.9	52	-8.1	0	-2.3
1097	TTTTTTTAAACCTATATTA SEQ ID NO:696	-7.8	-15.3	50.7	-7.5	0	-4.1
278	CTTGCCCGCCTTCCTGGAGC SEQ ID NO:697	-7.7	-32.5	85.5	-23.6	-0.8	-10
306	CTCAGGAACCAATCTTTGCA SEQ ID NO:698	-7.7	-23.3	66.9	-15.6	0.2	-6.3
335	ACACTGTCATGAATTTTCTT SEQ ID NO:699	-7.7	-19.9	61.5	-12.2	0	-6.7
507	GGCGCTCAGAGCTCCTACAA SEQ ID NO:700	-7.7	-28.1	77.5	-19.8	2.3	-9.1
599	TGGGTACAGTGGGAGAGTGA SEQ ID NO:701	-7.7	-24.8	73.7	-17.1	0	-5.2
697	CAGGCTAAGACTGACGAGAG SEQ ID NO:702	-7.7	-22.1	64.4	-14.4	0	-4.9
1074	TTAATAAGACCGTGTCTGGT SEQ ID NO:703	-7.7	-21.8	64.1	-12.7	-1.3	-8.3
34	AGCCTGGTGGTCTATGCTTT SEQ ID NO:704	-7.6	-27.4	79.8	-19.2	-0.3	-4.9
36	TCAGCCTGGTGGTCTATGCT SEQ ID NO:705	-7.6	-28.3	82	-20.1	-0.3	-4.9
373	GAAATGATCACAGGGCACT SEQ ID NO:706	-7.6	-23	66.1	-14.9	-0.2	-7
449	ATTGCTGGCAGGCTCTGGAA SEQ ID NO:707	-7.6	-26.8	76.1	-18	-1.1	-7.5
694	GCTAAGACTGACGAGAGAAG SEQ ID NO:708	-7.6	-20.1	60	-12.5	0	-3.5
730	TAATTAAGCCTAAGCCTGGG SEQ ID NO:709	-7.6	-22.9	65.1	-14.4	-0.8	-5.8
126	GTCGGTGCAGCTGTAAGTTG SEQ ID NO:710	-7.5	-25.5	74.6	-16.9	-1	-8.9
184	CATCAGCATTAGTGGCAGCA SEQ ID NO:711	-7.5	-25.5	74.3	-18	0	-5.3
437	CTCTGGAATGCTTGTTTGGC SEQ ID NO:712	-7.5	-24.5	71.7	-17	0	-3.6
518	TTGGAAGAGTGGGCGCTCAG SEQ ID NO:713	-7.5	-25.8	73.2	-15.6	-2.7	-10.1
762	TAGGAAGCTACAGTTTCCTG SEQ ID NO:714	-7.5	-22.8	67.9	-12.9	-2.4	-11.1
879	GTTGTGAATTGGCAGACCCC SEQ ID NO:715	-7.5	-27	74.6	-18.8	-0.5	-4
319	TCTTCTCGGGGCTCTCAGGA SEQ ID NO:716	-7.4	-28.4	82	-21	0	-4.1
327	ATGAATTTTCTTCTCGGGGC SEQ ID NO:717	-7.4	-23.5	68.7	-15.3	-0.6	-4.1
457	TTTGAGAAATTGCTGGCAGG SEQ ID NO:718	-7.4	-21.7	63.9	-13.6	0	-9

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex	struc- ture	molecular oligo	molecular oligo
629	CTTTTTGAGAGCACTGGAAT SEQ ID NO:719	-7.4	-21.2	63.5	-13.8	0	-4.2
765	AGCTAGGAAGCTACAGTTTC SEQ ID NO:720	-7.4	-22.6	68.9	-12.9	-2.3	-7.8
779	GGTTAAATGACACTAGCTAG SEQ ID NO:721	-7.4	-19.5	59.8	-11.2	-0.1	-9.5
781	AAGGTTAAATGACACTAGCT SEQ ID NO:722	-7.4	-19.1	58.4	-11.2	-0.1	-5.1
1084	TATATTATCTTTAATAAGAC SEQ ID NO:723	-7.4	-13.5	47.3	-4.8	-1.2	-5.2
286	CTCACATTCTTGGCCGCCTT SEQ ID NO:724	-7.3	-29	78.7	-21.2	0	-8
341	GCCCAGACACTGTCATGAAT SEQ ID NO:725	-7.3	-25.3	71	-17.3	-0.4	-7.1
517	TGGAAGAGTGGGCGCTCAGA SEQ ID NO:726	-7.3	-26.3	74.2	-17.1	-1.9	-10.1
672	GACACTAGAGAGAGCAACAA SEQ ID NO:727	-7.3	-20.1	60.5	-12.8	0	-4.5
778	GTTAAATGACACTAGCTAGG SEQ ID NO:728	-7.3	-19.5	59.8	-11.2	0	-9.9
791	GATTGCATTTAAGGTTAAAT SEQ ID NO:729	-7.3	-17.2	54.4	-9.3	-0.3	-6.5
918	GATTCAGTCTGCAGTGAATA SEQ ID NO:730	-7.3	-21.6	66.1	-11.8	-1.7	-12.9
191	CCATGGACATCAGCATTAGT SEQ ID NO:731	-7.2	-24	69.7	-16.8	0	-7.3
347	TTGGCAGCCCAGACACTGTC SEQ ID NO:732	-7.2	-28.5	79.7	-20.1	-1.1	-8.7
379	GCCCTTGAAATGATCACAGG SEQ ID NO:733	-7.2	-23.8	66.8	-14.9	-1.7	-6.8
434	TGGAATGCTTGTGGCTTT SEQ ID NO:734	-7.2	-23.4	68.8	-15.3	-0.7	-4
442	GCAGGCTCTGGAATGCTTGT SEQ ID NO:735	-7.2	-26.8	77	-18.5	-1	-6.7
784	TTTAAGGTTAAATGACACTA SEQ ID NO:736	-7.2	-16.3	52.6	-8.6	-0.1	-4.7
916	TTCAGTCTGCAGTGAATAGG SEQ ID NO:737	-7.2	-22.2	67.7	-13.9	-0.2	-10.2
917	ATTCAGTCTGCAGTGAATAG SEQ ID NO:738	-7.2	-21	64.9	-11.8	-1.1	-12
7	GGCCAGCGTCCCATTGAG SEQ ID NO:739	-7.1	-29.5	79.5	-22.4	0	-7
495	TCCTACAAAGGCAGAGCAAA SEQ ID NO:740	-7.1	-21.9	62.9	-13.6	-1.1	-6.2
626	TTTGAGAGCACTGGAATGAT SEQ ID NO:741	-7.1	-20.7	62.1	-13.6	0	-4.2
751	AGTTTCCTGGAATCTTTCAG SEQ ID NO:742	-7.1	-22.4	67.8	-14.4	-0.8	-8.3
884	ATCTGGTTGTGAATTGGCAG SEQ ID NO:743	-7.1	-22.7	67.7	-15.6	0	-4
37	CTCAGCCTGGTGGTCTATGC SEQ ID NO:744	-7	-28.3	82	-20.7	-0.3	-4.9
497	GCTCCTACAAAGGCAGAGCA SEQ ID NO:745	-7	-26	73.1	-16.6	-2.4	-7.9
699	CACAGGCTAAGACTGACGAG SEQ ID NO:746	-7	-22.4	64.6	-14.4	-0.9	-5.4
723	GCCTAAGCCTGGGTAAGGGG SEQ ID NO:747	-7	-28.6	78	-20.2	-1.3	-8.2
772	TGACACTAGCTAGGAAGCTA SEQ ID NO:748	-7	-22.2	66.2	-12.4	-2.8	-9
790	ATTGCATTTAAGGTTAAATG SEQ ID NO:749	-7	-16.6	53.1	-7.3	-2.3	-10.5
1090	TAAACCTATATTATCTTTAA SEQ ID NO:750	-7	-15.1	50	-8.1	0	-2.2

position	oligo	total binding	duplex form- ation	Tm of Duplex	target struc- ture	Intra- molecular oligo	Inter- molecular oligo
206	TCAGGCTGCTAGAGACCATG SEQ ID NO:751	-6.9	-25.5	73.5	-17.3	-1.2	-6.7
320	TTCTTCTCGGGCTCTCAGG SEQ ID NO:752	-6.9	-27.9	81	-21	0	-4.1
698	ACAGGCTAAGACTGACGAGA SEQ ID NO:753	-6.9	-22.3	64.7	-14.4	-0.9	-5.4
883	TCTGTTTGTGAATTGGCAGA SEQ ID NO:754	-6.9	-23.3	69.1	-15.7	-0.5	-4.2
334	CACGTGCATGAATTTCTTC SEQ ID NO:755	-6.8	-20.1	62.4	-13.3	0	-6.2
448	TTGCTGGCAGGCTCTGGAAT SEQ ID NO:756	-6.8	-26.8	76.1	-18.8	-1.1	-7.5
637	AAAACATGCTTTTGTAGAGC SEQ ID NO:757	-6.8	-18.9	57.8	-11.1	-0.9	-6.3
767	CTAGCTAGGAAGCTACAGTT SEQ ID NO:758	-6.8	-22.7	68.3	-12.9	-3	-8.5
59	GGGGATGACTCAGGTCAGGA SEQ ID NO:759	-6.7	-26.3	76.7	-17.7	-1.9	-6.1
450	AATTGCTGGCAGGCTCTGGA SEQ ID NO:760	-6.7	-26.8	76.1	-18.9	-1.1	-7.5
777	TTAAATGACACTAGCTAGGA SEQ ID NO:761	-6.7	-18.9	58.1	-11.2	0	-9.9
30	TGGTGGTCTATGCTTTAGTC SEQ ID NO:762	-6.6	-24	74	-17.4	0	-3.9
77	TGGAGGCTCCTGATCCCTGG SEQ ID NO:763	-6.6	-30.1	82.1	-22.2	-1.2	-7
109	TTGCTTGAAGAATATAATGG SEQ ID NO:764	-6.6	-16.6	52.8	-10	0	-3.6
376	CTTGAAATGATCACAGGGGC SEQ ID NO:765	-6.6	-22.2	64.6	-14.9	-0.5	-6.8
436	TCTGGAATGCTTGTGTTGGCT SEQ ID NO:766	-6.6	-24.5	71.7	-17	-0.7	-4
770	ACACTAGCTAGGAAGCTACA SEQ ID NO:767	-6.6	-22.5	66.7	-12.9	-3	-9.9
773	ATGACACTAGCTAGGAAGCT SEQ ID NO:768	-6.6	-22.5	66.7	-13.6	-2.3	-9.9
1032	TTGTCCACCTCGCTCTTAC SEQ ID NO:769	-6.6	-28.7	79.2	-22.1	0	-3.1
799	ACTTTCCTGATTGCATTAA SEQ ID NO:770	-6.5	-21	62.9	-14.5	0	-5.1
854	AAGGAAACAATTTTGATCTG SEQ ID NO:771	-6.5	-16.1	51.6	-9.6	0	-5.8
1010	CAGAAAGATTGTGCAATGA SEQ ID NO:772	-6.5	-17.6	54.4	-10.2	-0.7	-5
118	AGCTGTAAGTTGCTTGAAGA SEQ ID NO:773	-6.4	-21.5	65.1	-14.4	-0.5	-6.2
326	TGAATTTCTTCTCGGGGCT SEQ ID NO:774	-6.4	-24.4	70.7	-17.2	-0.6	-4.3
336	GACACTGTCATGAATTTCT SEQ ID NO:775	-6.4	-20.4	62.5	-13.3	-0.4	-6.9
382	ATTGCCCTTGAAATGATCAC SEQ ID NO:776	-6.4	-22	63.3	-14.9	-0.5	-6.8
465	TGACATTGTTTGAGAAATTG SEQ ID NO:777	-6.4	-16.9	53.8	-10.5	0	-5.5
471	CTTAGCTGACATTGTTTGAG SEQ ID NO:778	-6.4	-21	64.3	-14.6	0	-5.4
1073	TAATAAGACCGTGTCTGGTT SEQ ID NO:779	-6.4	-21.8	64.1	-14	-1.3	-7.8
186	GACATCAGCATTAGTGGCAG SEQ ID NO:780	-6.3	-23.8	70.6	-16.6	-0.8	-4.1
241	GCCTCGGTCCCTGTGGCCTC SEQ ID NO:781	-6.3	-35.1	93.1	-26.8	-2	-7.2
261	AGCCATCTCCTAGAAGCCTG SEQ ID NO:782	-6.3	-27.4	76.4	-20.1	-0.9	-4.3

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex structure	molecular oligo	molecular oligo	
318	CTTCTCGGGGCTCTCAGGAA SEQ ID NO:783	-6.3	-27.3	77.4	-21	0	-4.1
627	TTTTGAGAGCACTGGAATGA SEQ ID NO:784	-6.3	-20.8	62.5	-14.5	0	-4.2
737	TTTCAGGTAATTAAGCCTAA SEQ ID NO:785	-6.3	-19.5	59.4	-12.5	-0.4	-5.5
1085	CTATATTATCTTTAATAAGA SEQ ID NO:786	-6.3	-14.2	48.7	-6.8	-1	-5.2
298	CCAATCTTTGCACTCACATT SEQ ID NO:787	-6.2	-23.2	67.1	-17	0	-5
462	CATTGTTTGAGAAATGCTG SEQ ID NO:788	-6.2	-18.8	57.9	-12.6	0	-4
623	GAGAGCACTGGAATGATTTA SEQ ID NO:789	-6.2	-20.4	61.6	-14.2	0	-4.2
766	TAGCTAGGAAGCTACAGTTT SEQ ID NO:790	-6.2	-21.9	66.6	-12.9	-2.8	-8.3
833	GACATTTAAAAATATTTATT SEQ ID NO:791	-6.2	-12.3	44.2	-5.4	-0.4	-6.7
1096	TTTTTTTAAACCTATATTAT SEQ ID NO:792	-6.2	-15.2	50.4	-9	0	-4.4
42	GGATACTCAGCCTGGTGGTC SEQ ID NO:793	-6.1	-27.6	80.2	-20.9	-0.3	-4.9
245	CCTGGCCTCGGTCCCTGTGG SEQ ID NO:794	-6.1	-34.1	88.9	-28	0.3	-7.2
909	TGCAGTGAATAGGGTAAAAAT SEQ ID NO:795	-6.1	-18.5	56.7	-12.4	0	-4.7
942	GGGGATAAGTATGTGTAGAA SEQ ID NO:796	-6.1	-20.1	61.7	-14	0	-1.8
1042	TTTTTTTTTTTTTGTCACC SEQ ID NO:797	-6.1	-23.6	69.2	-17.5	0	-1.7
16	TTAGTCCCAGGCCAGCGTTC SEQ ID NO:798	-6	-30.1	83.1	-23.6	0	-7.7
506	GCGCTCAGAGCTCCTACAAA SEQ ID NO:799	-6	-26.2	72.6	-18.7	-1.4	-9.6
642	CTTGAAAAACATGCTTTTTG SEQ ID NO:800	-6	-16.8	52.8	-9.2	-1.5	-9.1
649	AAATGATCTTGAAAAACATG SEQ ID NO:801	-6	-13.3	45.6	-7.3	0	-4.9
816	ATTGACTTCTGTTTGCTACT SEQ ID NO:802	-6	-22.1	67.4	-16.1	0	-3.6
834	TGACATTTAAAAATATTTAT SEQ ID NO:803	-6	-12.2	43.9	-5.5	-0.4	-6.7
836	TGTGACATTTAAAAATATTT SEQ ID NO:804	-6	-13.7	46.9	-7.7	0	-6.4
439	GGCTCTGGAATGCTTGTTTG SEQ ID NO:805	-5.9	-24.5	71.7	-17.9	-0.5	-4
441	CAGGCTCTGGAATGCTTGTT SEQ ID NO:806	-5.9	-25.1	72.9	-18.5	-0.5	-5.4
776	TAAATGACACTAGCTAGGAA SEQ ID NO:807	-5.9	-18.1	55.9	-11.2	0	-9.9
783	TTAAGGTTAAATGACACTAG SEQ ID NO:808	-5.9	-16.2	52.4	-10.3	0.7	-4
1072	AATAAGACCGTGTCTGGTTC SEQ ID NO:809	-5.9	-22.5	66.1	-15.2	-1.3	-8.3
85	TTCCCTGCTGGAGGCTCCTG SEQ ID NO:810	-5.8	-31.1	85	-24	-1.2	-8
321	TTTCTTCTCGGGGCTCTCAG SEQ ID NO:811	-5.8	-26.8	78.7	-21	0	-4.1
829	TTTAAAAATATTTATTGACT SEQ ID NO:812	-5.8	-12.5	44.7	-6	-0.4	-6.2
248	AAGCCTGGCCTCGGTCCCTG SEQ ID NO:813	-5.7	-32.8	85.1	-26.3	0	-9.2
323	ATTTTCTTCTCGGGGCTCTC SEQ ID NO:814	-5.7	-26.2	77.5	-20.5	0	-4.1

position	oligo	total binding	duplex form- ation	Tm of Duplex	target struc- ture	Intra- molecular oligo	Inter- molecular oligo
325	GAATTTTCTCTCGGGGCTC SEQ ID NO:815	-5.7	-24.8	72.5	-19.1	0	-3.9
466	CTGACATTGTTTGAGAAAT SEQ ID NO:816	-5.7	-17.8	55.8	-12.1	0	-5.5
800	TACTTTCTGATTGCATTTA SEQ ID NO:817	-5.7	-21.4	64.4	-15.7	0	-5.1
830	ATTTAAAAATATTTATTGAC SEQ ID NO:818	-5.7	-11.6	42.9	-5.2	-0.4	-6.7
210	GGATTCAGGCTGCTAGAGAC SEQ ID NO:819	-5.6	-24.7	73.2	-19.1	0	-6.1
638	AAAAACATGCTTTTGTGAGAG SEQ ID NO:820	-5.6	-16.4	52.2	-9.8	-0.9	-8.3
1039	TTTTTTTTTGTCCACCTCG SEQ ID NO:821	-5.6	-25.4	71.7	-19.8	0	-2.4
24	TCTATGCTTTAGTCCAGGC SEQ ID NO:822	-5.5	-26.9	78.1	-21.4	0	-3.6
183	ATCAGCATTAGTGGCAGCAA SEQ ID NO:823	-5.5	-24.1	70.6	-17.7	-0.8	-5.3
185	ACATCAGCATTAGTGGCAGC SEQ ID NO:824	-5.5	-25	73.8	-18.6	-0.8	-4.7
202	GCTGCTAGAGACCATGGACA SEQ ID NO:825	-5.5	-25.9	73.4	-19.7	0	-8.8
296	AATCTTTGCACTCACATTCT SEQ ID NO:826	-5.5	-21.8	65.6	-16.3	0	-5
525	TGTTTAATTGGAAGAGTGGG SEQ ID NO:827	-5.5	-19.8	60.7	-14.3	0	-2.6
547	TCACTGTCTTCTTGGCTGAG SEQ ID NO:828	-5.5	-24.7	74.4	-19.2	0	-4.2
632	ATGCTTTTTGAGAGCACTGG SEQ ID NO:829	-5.5	-23.1	68.6	-15.2	-2.4	-6.7
768	ACTAGCTAGGAAGCTACAGT SEQ ID NO:830	-5.5	-22.8	68.5	-14.3	-3	-9.9
835	GTGACATTTAAAAATATTTA SEQ ID NO:831	-5.5	-13.4	46.4	-7.4	-0.2	-6.7
279	TCTTGCGCCCTTCTGAGAG SEQ ID NO:832	-5.4	-31.1	83.1	-24.6	-0.3	-10
534	GGCTGAGAATGTTTAATTGG SEQ ID NO:833	-5.4	-20.1	60.9	-14.7	0	-3.7
576	GGGAGAGAAGAGTGTCTGG SEQ ID NO:834	-5.4	-22.3	67	-16.9	0	-2.9
636	AAACATGCTTTTTGAGAGCA SEQ ID NO:835	-5.4	-20.3	61	-13.2	-1.7	-5.9
911	TCTGCAGTGAATAGGGTAAA SEQ ID NO:836	-5.4	-20.5	61.9	-14.5	0	-8.6
1031	TGTCCACCTCGCTCTTACC SEQ ID NO:837	-5.4	-30.6	82.2	-25.2	0	-3.1
60	TGGGGATGACTCAGGTCAGG SEQ ID NO:838	-5.3	-25.7	75.1	-18	-2.4	-6.6
769	CACTAGCTAGGAAGCTACAG SEQ ID NO:839	-5.3	-22.3	66.4	-14	-3	-9.9
910	CTGCAGTGAATAGGGTAAAA SEQ ID NO:840	-5.3	-19.4	58.6	-14.1	0	-7.4
1041	TTTTTTTTTTTGTCCACCT SEQ ID NO:841	-5.3	-24.4	70.8	-19.1	0	-1.7
342	AGCCAGACACTGTCATGAA SEQ ID NO:842	-5.2	-25.3	71.3	-18.8	-1.2	-7.6
503	CTCAGAGCTCCTACAAAGGC SEQ ID NO:843	-5.2	-24.8	71.3	-18.4	-1.1	-8.4
792	TGATTGCATTAAAGGTAA SEQ ID NO:844	-5.2	-17.2	54.4	-12	0	-5.3
793	CTGATTGCATTAAAGGTAA SEQ ID NO:845	-5.2	-18.8	58.1	-13.6	0	-4.8
440	AGGCTCTGGAATGCTTGTTT SEQ ID NO:846	-5.1	-24.5	72.1	-18.7	-0.5	-4

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex	structure	molecular oligo	molecular oligo
443	GGCAGGCTCTGGAATGCTTG SEQ ID NO:847	-5.1	-26.8	76.1	-20.1	-1.5	-6.7
501	CAGAGCTCCTACAAAGGCAG SEQ ID NO:848	-5.1	-24.2	69.2	-17.9	-1.1	-8.4
826	AAAAATATTTATTGACTTCT SEQ ID NO:849	-5.1	-14	47.7	-8.9	0	-6.7
58	GGGATGACTCAGGTCAGGAT SEQ ID NO:850	-5	-25.1	73.9	-17.7	-2.4	-6.6
201	CTGCTAGAGACCATGGACAT SEQ ID NO:851	-5	-24.1	69.2	-18.4	0	-8.8
340	CCCAGACACTGTTCATGAATT SEQ ID NO:852	-5	-23.6	67.2	-17.3	-1.2	-7.6
467	GCTGACATTGTTTGAGAAAT SEQ ID NO:853	-5	-19.5	59.4	-14.5	0	-5.5
468	AGCTGACATTGTTTGAGAAA SEQ ID NO:854	-5	-19.5	59.6	-14.5	0	-4.9
695	GGCTAAGACTGACGAGAGAA SEQ ID NO:855	-5	-21.3	62.2	-16.3	0	-3.7
15	TAGTCCCAGGCCAGCGTCC SEQ ID NO:856	-4.9	-32	86.2	-26.6	0	-7.7
435	CTGGAATGCTTGTTTGGCTT SEQ ID NO:857	-4.9	-24.2	70.4	-18.4	-0.7	-4
509	TGGGCGCTCAGAGCTCCTAC SEQ ID NO:858	-4.9	-29.3	81.5	-23.1	1.5	-10.6
512	GAGTGGGCGCTCAGAGCTCC SEQ ID NO:859	-4.9	-30.3	84.9	-23.1	-1.9	-12.4
706	GGGAGGGCACAGGCTAAGAC SEQ ID NO:860	-4.9	-26.5	75.2	-20.2	-1.3	-4
1011	TCAGAAAGATTGTGCGAATG SEQ ID NO:861	-4.9	-17.4	54.4	-11.6	-0.7	-5
1040	TTTTTTTTTTGTCCACCTC SEQ ID NO:862	-4.9	-24.7	72.1	-19.8	0	-1.7
828	TTAAAAATATTTATTGACTT SEQ ID NO:863	-4.8	-12.5	44.7	-7	-0.4	-6.7
458	GTTTGAGAAATGCTGGCAG SEQ ID NO:864	-4.7	-21.7	64.4	-15.9	0	-10.1
546	CACTGTCTTCTTGGCTGAGA SEQ ID NO:865	-4.7	-24.9	74.1	-20.2	0	-6
774	AATGACACTAGCTAGGAAGC SEQ ID NO:866	-4.7	-20.9	62.6	-14.6	-1.5	-9.9
1020	GCTCTTACCTCAGAAAAGATT SEQ ID NO:867	-4.7	-21.9	65.1	-16.5	-0.4	-3.6
1030	GTCCACCTCGCTCTTACCT SEQ ID NO:868	-4.7	-31.5	84.3	-26.8	0	-3.1
1038	TTTTTTTTGTCCACCTCGC SEQ ID NO:869	-4.7	-27.1	75.5	-22.4	0	-2.7
256	TCTCCTAGAAGCCTGGCCTC SEQ ID NO:870	-4.6	-29.2	81.4	-23.5	0	-10.1
322	TTTTCTTCTCGGGGCTCTCA SEQ ID NO:871	-4.6	-26.9	78.7	-22.3	0	-4.1
324	AATTTTCTTCTCGGGGCTCT SEQ ID NO:872	-4.6	-25.1	73.1	-20.5	0	-4.1
200	TGCTAGAGACCATGGACATC SEQ ID NO:873	-4.5	-23.6	68.8	-18.4	0	-8.8
650	AAAATGATCTTGAAAAACAT SEQ ID NO:874	-4.5	-12.6	44.2	-8.1	0	-4.2
671	ACACTAGAGAGAGCAACAAA SEQ ID NO:875	-4.5	-18.8	57.3	-14.3	0	-4.5
736	TTCAGGTAATTAAGCCTAAG SEQ ID NO:876	-4.5	-19.4	59.3	-14.2	-0.4	-5.5
977	AAGTAGGCCAATGGAGACAG SEQ ID NO:877	-4.5	-22.5	65.4	-17.1	-0.8	-8.4
18	CTTTAGTCCCAGGCCAGCGT SEQ ID NO:878	-4.4	-30.6	83.2	-25.7	0	-7.7

position	oligo	duplex		target	Intra-	Inter-
		total binding	form- ation	Tm of Duplex structure	molecular oligo	molecular oligo
333	ACTGTCATGAATTTTCTTCT SEQ ID NO:879	-4.4	-20.3	63.1	-15.1	-0.6
337	AGACACTGTCATGAATTTTC SEQ ID NO:880	-4.4	-19.5	60.7	-13.8	-1.2
500	AGAGCTCCTACAAAGGCAGA SEQ ID NO:881	-4.4	-24.1	69.3	-18.5	-1.1
514	AAGAGTGGGCGCTCAGAGCT SEQ ID NO:882	-4.4	-27.2	77.1	-20.1	-2.7
598	GGGTACAGTGGGAGAGTGAG SEQ ID NO:883	-4.4	-24.8	74.3	-20.4	0
43	AGGATACTCAGCCTGGTGGT SEQ ID NO:884	-4.3	-27.2	78.7	-21.8	-1
438	GCTCTGGAATGCTTGTTTGG SEQ ID NO:885	-4.3	-24.5	71.7	-20.2	0
628	TTTTTTGAGAGCACTGGAATG SEQ ID NO:886	-4.3	-20.3	61.5	-16	0
639	GAAAAACATGCTTTTGTGAGA SEQ ID NO:887	-4.3	-17	53.3	-11.1	-1.5
731	GTAATTAAGCCTAAGCCTGG SEQ ID NO:888	-4.3	-22.9	65.6	-17.7	-0.8
257	ATCTCCTAGAAGCCTGGCCT SEQ ID NO:889	-4.2	-28.8	79.5	-23.5	0
260	GCCATCTCCTAGAAGCCTGG SEQ ID NO:890	-4.2	-28.6	78.6	-23.7	-0.5
292	TTTGCACTCACATTCTTGGC SEQ ID NO:891	-4.2	-24.3	71.7	-20.1	0
505	CGCTCAGAGCTCCTACAAAG SEQ ID NO:892	-4.2	-24.4	68.8	-18.7	-1.4
535	TGGCTGAGAAATGTTTAATTG SEQ ID NO:893	-4.2	-18.9	58.3	-14.7	0
827	TAAAAATATTATTGACTTC SEQ ID NO:894	-4.2	-12.8	45.4	-8.1	-0.1
1086	CCTATATTATCTTTAATAAG SEQ ID NO:895	-4.2	-15.6	51.3	-10.5	-0.8
199	GCTAGAGACCATGGACATCA SEQ ID NO:896	-4.1	-24.3	70.1	-19.5	0
383	CATTGCCCTTGAAATGATCA SEQ ID NO:897	-4.1	-22.5	63.9	-17.8	-0.3
451	AAATTGCTGGCAGGCTCTGG SEQ ID NO:898	-4.1	-25.5	72.3	-20.7	-0.5
499	GAGCTCCTACAAAGGCAGAG SEQ ID NO:899	-4.1	-24.1	69.3	-18.8	-1.1
515	GAAGAGTGGGCGCTCAGAGC SEQ ID NO:900	-4.1	-26.9	76.4	-20.1	-2.7
498	AGCTCCTACAAAGGCAGAGC SEQ ID NO:901	-4	-25.3	72.3	-19.2	-2.1
125	TCGGTGCAGCTGTAAGTTGC SEQ ID NO:902	-3.9	-26.1	75.5	-19.7	-2.5
205	CAGGCTGCTAGAGACCATGG SEQ ID NO:903	-3.9	-26.3	74.4	-21.1	-1.2
285	TCACATTCTTGGCCGCTTC SEQ ID NO:904	-3.9	-28.5	78.5	-24.1	0
1037	TTTTTTTGTCCACCTCGCT SEQ ID NO:905	-3.9	-27.9	77	-24	0
23	CTATGCTTTAGTCCCAGGCC SEQ ID NO:906	-3.8	-28.5	79.9	-24.7	0
502	TCAGAGCTCCTACAAAGGCA SEQ ID NO:907	-3.8	-24.6	70.5	-19.6	-1.1
459	TGTTTGAGAAATTGCTGGCA SEQ ID NO:908	-3.7	-21.7	64.1	-17.4	0
696	AGGCTAAGACTGACGAGAGA SEQ ID NO:909	-3.7	-22	64.5	-18.3	0
837	CTGTGACATTAAAAATATT SEQ ID NO:910	-3.7	-14.5	48.4	-10.8	0

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation Duplex	Tm of struc- ture	molecular oligo	molecular oligo	
1021	CGCTCTTACCTCAGAAAGAT SEQ ID NO:911	-3.7	-22.6	65	-18.2	-0.4	-3.6
78	CTGGAGGCTCCTGATCCCTG SEQ ID NO:912	-3.6	-29.8	81.5	-24.9	-1.2	-7
508	GGGCGCTCAGAGCTCCTACA SEQ ID NO:913	-3.6	-30	82.7	-25.5	1.5	-9.9
825	AAAATATTTATTGACTTCTG SEQ ID NO:914	-3.6	-14.7	49.3	-11.1	0	-6.7
1012	CTCAGAAAGATTTGTGCGAAT SEQ ID NO:915	-3.6	-18.3	56.3	-13.8	-0.7	-5
1094	TTTTTAAACCTATATTATCT SEQ ID NO:916	-3.6	-16.3	52.9	-12.7	0	-4.4
1095	TTTTTTAAACCTATATTATC SEQ ID NO:917	-3.6	-15.5	51.3	-11.9	0	-4.4
57	GGATGACTCAGGTCAGGATA SEQ ID NO:918	-3.5	-23.6	70.5	-17.7	-2.4	-6.6
81	CTGCTGGAGGCTCCTGATCC SEQ ID NO:919	-3.5	-29.6	82.4	-24.9	-1.1	-6.3
293	CTTTGCACTCACATTCTTGG SEQ ID NO:920	-3.5	-23.4	69.3	-19.9	0	-5
536	TTGGCTGAGAATGTTTAATT SEQ ID NO:921	-3.5	-19	58.7	-15.5	0	-3.7
82	CCTGCTGGAGGCTCCTGATC SEQ ID NO:922	-3.4	-29.6	82.4	-24.9	-1.2	-7.1
249	GAAGCCTGGCCTCGGTCCCT SEQ ID NO:923	-3.4	-33.4	86.6	-29.2	0	-9.2
635	AACATGCTTTTGTAGAGCAC SEQ ID NO:924	-3.4	-21.2	63.6	-15.4	-2.4	-6.7
832	ACATTTAAAAATATTTATTG SEQ ID NO:925	-3.4	-11.7	43	-7.6	-0.4	-6.7
927	TAGAATCTGGATTCACTCTG SEQ ID NO:926	-3.4	-20.4	63.4	-15.2	-1.7	-11
309	GCTCTCAGGAACCAATCTTT SEQ ID NO:927	-3.3	-23.9	69.4	-20.1	-0.1	-4.6
372	AAATGATCACAGGGGCACTG SEQ ID NO:928	-3.3	-22.4	64.7	-17.8	-1.2	-8.5
447	TGCTGGCAGGCTCTGGAATG SEQ ID NO:929	-3.3	-26.7	75.5	-22.2	-1.1	-7
526	ATGTTTAATTGGAAGAGTGG SEQ ID NO:930	-3.3	-18.6	58.1	-15.3	0	-2.9
192	ACCATGGACATCAGCATTAG SEQ ID NO:931	-3.2	-23	67	-19.1	0	-8.8
244	CTGGCCTCGGTCCCTGTGGC SEQ ID NO:932	-3.2	-33.9	90.1	-28.3	-2.4	-7.2
343	CAGCCCAGACACTGTCAATGA SEQ ID NO:933	-3.2	-26.7	74.7	-22.2	-1.2	-7.6
782	TAAGGTTAAATGACACTAGC SEQ ID NO:934	-3.2	-17.9	56	-14.2	-0.1	-4.5
824	AAATATTTATTGACTTCTGT SEQ ID NO:935	-3.2	-16.6	53.9	-13.4	0	-5.8
339	CCAGACACTGTCAATGAATTT SEQ ID NO:936	-3.1	-21.7	64	-17.3	-1.2	-7.6
823	AATATTTATTGACTTCTGTT SEQ ID NO:937	-3.1	-17.4	56.1	-14.3	0	-3.8
651	CAAAATGATCTTGAAAAACA SEQ ID NO:938	-3	-13.3	45.4	-10.3	0	-4.9
504	GCTCAGAGCTCCTACAAAGG SEQ ID NO:939	-2.9	-24.8	71.3	-20.1	-1.8	-10.2
19	GCTTTAGTCCCAGGCCAGCG SEQ ID NO:940	-2.8	-31.2	84	-27.9	-0.2	-7.7
670	CACTAGAGAGAGCAACAAAC SEQ ID NO:941	-2.8	-18.8	57.3	-16	0	-4.5
735	TCAGGTAATTAAGCCTAAGC SEQ ID NO:942	-2.8	-21.1	63	-17.6	-0.4	-5.5

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex	struc- ture	molecular oligo	molecular oligo
45	TCAGGATACTCAGCCTGGTG SEQ ID NO:943	-2.6	-25.9	75.3	-21.1	-2.2	-6.6
577	TGGGAGAAGAAGAGTGTCTG SEQ ID NO:944	-2.6	-21.1	64.2	-18.5	0	-2.9
453	AGAAATTGCTGGCAGGCTCT SEQ ID NO:945	-2.5	-24.9	71.5	-21.2	-1.1	-7.5
1028	CCCACCTCGCTCTTACCTCA SEQ ID NO:946	-2.5	-31	81.8	-28.5	0	-3.1
1087	ACCTATATTATCTTTAATAA SEQ ID NO:947	-2.5	-15.8	51.7	-12.7	-0.3	-3.3
313	CGGGGCTCTCAGGAACCAAT SEQ ID NO:948	-2.4	-26.8	72.7	-23.4	-0.9	-4.6
802	GCTACTTTCTGATTGCATT SEQ ID NO:949	-2.4	-24.3	70.9	-21.9	0	-5.1
312	GGGGCTCTCAGGAACCAATC SEQ ID NO:950	-2.3	-26.4	74.4	-23.1	-0.9	-4.6
811	CTTCTGTTTGCTACTTTTCCT SEQ ID NO:951	-2.3	-24.7	73.6	-22.4	0	-3.6
1019	CTCTTACCTCAGAAAGATTT SEQ ID NO:952	-2.3	-20.2	61.3	-17.2	-0.4	-3.6
46	GTCAGGATACTCAGCCTGGT SEQ ID NO:953	-2.2	-27.1	79.2	-22.7	-2.2	-6.6
307	TCTCAGGAACCAATCTTTGC SEQ ID NO:954	-2.1	-23	67.3	-20.4	-0.1	-4.1
280	TTCTTGCCCGCCTTCCTGGA SEQ ID NO:955	-2	-31.2	83.1	-28.1	-0.3	-10
338	CAGACACTGTCATGAATTTT SEQ ID NO:956	-2	-19.8	60.5	-16.5	-1.2	-7.6
633	CATGCTTTTTGAGAGCACTG SEQ ID NO:957	-2	-22.6	67.1	-18.2	-2.4	-6.7
663	GAGAGCAACAAACAAAATGA SEQ ID NO:958	-2	-15.9	50.2	-13.9	0	-4.1
665	GAGAGAGCAACAAACAAAAT SEQ ID NO:959	-2	-15.9	50.4	-13.9	0	-4.1
666	AGAGAGAGCAACAAACAAA SEQ ID NO:960	-2	-15.9	50.5	-13.9	0	-4.1
813	GACTTCTGTTTGCTACTTTC SEQ ID NO:961	-2	-22.6	69.7	-20.6	0	-3.6
55	ATGACTCAGGTCAGGATACT SEQ ID NO:962	-1.9	-22.9	69.1	-18.1	-2.9	-7.2
259	CCATCTCCTAGAAGCCTGGC SEQ ID NO:963	-1.9	-28.6	78.6	-26	0	-8.8
530	GAGAATGTTTAAATTGGAAGA SEQ ID NO:964	-1.9	-16.7	53.4	-14.8	0	-2.9
775	AAATGACACTAGCTAGGAAG SEQ ID NO:965	-1.9	-18.4	56.7	-15.5	0	-9.9
831	CATTTAAAAATATTTATTGA SEQ ID NO:966	-1.9	-12.1	43.7	-9.5	-0.4	-6.7
801	CTACTTTCCTGATTGCATTT SEQ ID NO:967	-1.8	-22.6	67	-20.8	0	-5.1
80	TGCTGGAGGCTCCTGATCCC SEQ ID NO:968	-1.7	-30.7	83.9	-27.7	-1.2	-7
203	GGCTGCTAGAGACCATGGAC SEQ ID NO:969	-1.7	-26.4	74.9	-23.9	-0.4	-8.8
314	TCGGGGCTCTCAGGAACCAA SEQ ID NO:970	-1.7	-27.2	74.3	-24.5	-0.9	-4.6
1017	CTTACCTCAGAAAGATTTGT SEQ ID NO:971	-1.7	-20.1	60.9	-18.4	0	-2.5
242	GGCCTCGGTCCCTGTGGCCT SEQ ID NO:972	-1.6	-35.9	93.6	-30.1	-4.2	-10.8
21	ATGCTTTAGTCCCAGGCCAG SEQ ID NO:973	-1.5	-28.6	79.9	-26.6	0	-7.7
805	TTTGCTACTTTCCTGATTGC SEQ ID NO:974	-1.5	-23.7	70	-22.2	0	-3.6

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex	struc- ture	molecular oligo	molecular oligo
281	ATTCTTGGCCGCTTCCTGG SEQ ID NO:975	-1.4	-30.6	81.8	-28.2	0	-10
597	GGTACAGTGGGAGAGTGAGG SEQ ID NO:976	-1.4	-24.8	74.3	-23.4	0	-5.2
662	AGAGCAACAACAAAATGAT SEQ ID NO:977	-1.4	-15.3	49.1	-13.9	0	-4.1
664	AGAGAGCAACAACAAAATG SEQ ID NO:978	-1.4	-15.3	49.2	-13.9	0	-3.3
732	GGTAATTAAGCCTAAGCCTG SEQ ID NO:979	-1.4	-22.9	65.6	-20.6	-0.8	-6.5
812	ACTTCTGTTTGCTACTTTCC SEQ ID NO:980	-1.4	-24	72.2	-22.6	0	-3.6
529	AGAATGTTTAAATGGAAGAG SEQ ID NO:981	-1.3	-16.1	52.3	-14.8	0	-2.9
593	CAGTGGGAGAGTGAGGTGGG SEQ ID NO:982	-1.3	-26.1	76.8	-24.8	0	-3.1
1022	TCGCTCTTACCTCAGAAAGA SEQ ID NO:983	-1.3	-23	66.5	-21.2	-0.2	-3.5
1036	TTTTTTGTCCCACCTCGCTC SEQ ID NO:984	-1.3	-28.2	78.4	-26.9	0	-3.1
315	CTCGGGGCTCTCAGGAACCA SEQ ID NO:985	-1.2	-28.8	78.5	-26.6	-0.9	-4.6
44	CAGGATACTCAGCCTGGTGG SEQ ID NO:986	-1.1	-26.7	76.2	-24	-1.6	-6.7
79	GCTGGAGGCTCCTGATCCCT SEQ ID NO:987	-1.1	-31.6	86.1	-29.2	-1.2	-7
1029	TCCCACCTCGCTCTTACCTC SEQ ID NO:988	-1.1	-30.7	82.6	-29.6	0	-3.1
255	CTCCTAGAAGCCTGGCCTCG SEQ ID NO:989	-1	-29.6	79.2	-27.7	-0.3	-9.5
310	GGCTCTCAGGAACCAATCTT SEQ ID NO:990	-1	-25	71.6	-23.5	-0.1	-4.6
578	GTGGGAGAAGAAGAGTGTCT SEQ ID NO:991	-1	-22.3	67.6	-21.3	0	-2.9
1088	AACCTATATTATCTTTAATA SEQ ID NO:992	-1	-15.8	51.7	-14	-0.6	-3.1
282	CATTCTTGGCCGCTTCCTG SEQ ID NO:993	-0.9	-30.1	80.3	-28.7	0	-8
452	GAAATTGCTGGCAGGCTCTG SEQ ID NO:994	-0.9	-24.9	71.1	-22.8	-1.1	-7.2
533	GCTGAGAATGTTTAAATTGGA SEQ ID NO:995	-0.9	-19.5	59.6	-18.6	0	-2.9
804	TTGCTACTTTCCTGATTGCA SEQ ID NO:996	-0.9	-24.3	70.8	-22.9	-0.2	-4.8
20	TGCTTTAGTCCCAGGCCAGC SEQ ID NO:997	-0.8	-30.4	84.5	-29.1	0	-7.7
470	TTAGCTGACATTGTTTGAGA SEQ ID NO:998	-0.8	-20.7	63.6	-19.9	0	-5.4
542	GTCTTCTTGGCTGAGAATGT SEQ ID NO:999	-0.7	-23.6	71.1	-22	-0.8	-8.1
661	GAGCAACAACAAAATGATC SEQ ID NO:1000	-0.7	-15.7	50	-15	0	-4.1
810	TTCTGTTTGCTACTTTCCTG SEQ ID NO:1001	-0.7	-23.8	71.4	-23.1	0	-3.6
198	CTAGAGACCATGGACATCAG SEQ ID NO:1002	-0.6	-22.5	66.1	-21.2	0	-8.8
308	CTCTCAGGAACCAATCTTTG SEQ ID NO:1003	-0.6	-22.1	65.1	-21	-0.1	-4.6
669	ACTAGAGAGCAACAAACA SEQ ID NO:1004	-0.6	-18.8	57.3	-18.2	0	-4.5
803	TGCTACTTTCCTGATTGCAT SEQ ID NO:1005	-0.6	-24.2	70.4	-23.1	-0.2	-5.1
814	TGACTTCTGTTTGCTACTTT SEQ ID NO:1006	-0.6	-22.2	67.8	-21.6	0	-3.6

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex	struc- ture	molecular oligo	molecular oligo
56	GATGACTCAGGTCAGGATAC SEQ ID NO:1007	-0.5	-22.6	68.4	-19.7	-2.4	-6.6
818	TTATTGACTTCTGTTTGCTA SEQ ID NO:1008	-0.5	-20.8	64.5	-20.3	0	-3.6
1023	CTCGCTCTTACCTCAGAAAG SEQ ID NO:1009	-0.5	-23.3	67.1	-22.8	0	-3.1
311	GGGCTCTCAGGAACCAATCT SEQ ID NO:1010	-0.4	-26.1	73.8	-25.2	-0.1	-4.6
532	CTGAGAATGTTTAATTGGAA SEQ ID NO:1011	-0.3	-17	53.8	-16.7	0	-2.9
806	GTTTGCTACTTTCCTGATTG SEQ ID NO:1012	-0.2	-23.1	69	-22.9	0	-3.6
1089	AAACCTATATTATCTTTAAT SEQ ID NO:1013	-0.2	-15.4	50.5	-15.2	0	-2.5
54	TGACTCAGGTCAGGATACTC SEQ ID NO:1014	-0.1	-23.3	70.8	-20.5	-2.7	-6.8
808	CTGTTTGCTACTTTCCTGAT SEQ ID NO:1015	-0.1	-23.9	70.7	-23.8	0	-3.6
596	GTACAGTGGGAGAGTGAGGT SEQ ID NO:1016	0	-24.8	75.2	-24.8	0	-4.6
654	AAACAAAATGATCTTGAAAA SEQ ID NO:1017	0	-11.9	42.9	-11.9	0	-5
297	CAATCTTTGCACTCACATTC SEQ ID NO:1018	0.1	-21.6	64.9	-21.7	0	-5
469	TAGCTGACATTGTTTGAGAA SEQ ID NO:1019	0.1	-19.9	61.1	-20	0	-5.3
819	TTTATTGACTTCTGTTTGCT SEQ ID NO:1020	0.2	-21.2	65.5	-21.4	0	-3.6
53	GACTCAGGTCAGGATACTCA SEQ ID NO:1021	0.3	-24	72.2	-22.2	-2.1	-5.1
516	GGAAGAGTGGGCGCTCAGAG SEQ ID NO:1022	0.3	-26.3	74.7	-23.9	-2.7	-10.1
531	TGAGAATGTTTAATTGGAAG SEQ ID NO:1023	0.3	-16.1	52.1	-16.4	0	-2.9
655	CAAACAAAATGATCTTGAAA SEQ ID NO:1024	0.3	-13.3	45.4	-13.6	0	-5
815	TTGACTTCTGTTTGCTACTT SEQ ID NO:1025	0.3	-22.2	67.8	-22.5	0	-3.6
1018	TCTTACCTCAGAAAGATTG SEQ ID NO:1026	0.3	-19.3	59.3	-19.1	-0.2	-3.5
537	CTTGCTGAGAATGTTTAAT SEQ ID NO:1027	0.4	-19.8	60.3	-20.2	0	-4
541	TCTTCTTGGCTGAGAATGTT SEQ ID NO:1028	0.4	-22.5	68	-22	-0.8	-8.1
317	TTCTCGGGCTCTCAGGAAC SEQ ID NO:1029	0.5	-26.6	76.1	-27.1	0	-4.1
204	AGGCTGCTAGAGACCATGGA SEQ ID NO:1030	0.6	-26.2	74.6	-25.5	-1.2	-8.8
251	TAGAAGCCTGGCCTCGGTCC SEQ ID NO:1031	0.6	-30.2	81.3	-29.9	-0.3	-9.5
668	CTAGAGAGAGCAACAAACAA SEQ ID NO:1032	0.8	-17.9	55	-18.7	0	-4.1
316	TCTCGGGCTCTCAGGAACC SEQ ID NO:1033	0.9	-28.5	79.3	-29.4	0	-3.3
809	TCTGTTTGCTACTTTCCTGA SEQ ID NO:1034	0.9	-24.3	72.4	-25.2	0	-3.6
528	GAATGTTTAATTGGAAGAGT SEQ ID NO:1035	1	-17.3	55	-18.3	0	-2.9
538	TCTTGGCTGAGAATGTTTAA SEQ ID NO:1036	1	-20.2	61.7	-21.2	0	-5.8
652	ACAAAATGATCTTGAAAAAC SEQ ID NO:1037	1	-12.8	44.6	-13.8	0	-5
653	AACAAAATGATCTTGAAAAA SEQ ID NO:1038	1.1	-11.9	42.9	-13	0	-5

		total	duplex	Tm of	target	Intra-	Inter-
position	oligo	binding	formation	Duplex	structure	molecular oligo	molecular oligo
660	AGCAACAACAAAATGATCT SEQ ID NO:1039	1.1	-16	50.6	-17.1	0	-4.9
807	TGTTTGCTACTTTCCTGATT SEQ ID NO:1040	1.2	-23.1	69	-24.3	0	-3.4
250	AGAAGCCTGGCCTCGGTCCC SEQ ID NO:1041	1.4	-32.5	85.2	-33	-0.3	-9.5
822	ATATTTATTGACTTCTGTTT SEQ ID NO:1042	1.4	-18.2	58.5	-19.6	0	-2.5
47	GGTCAGGATACTCAGCCTGG SEQ ID NO:1043	1.6	-27.1	78.2	-26.5	-2.2	-7
539	TTCTTGGCTGAGAATGTTTA SEQ ID NO:1044	1.6	-21	64.2	-21.8	-0.6	-7.8
50	TCAGGTCAGGATACTCAGCC SEQ ID NO:1045	1.7	-26.1	76.9	-26.7	-1	-4.6
820	ATTATTGACTTCTGTTTGC SEQ ID NO:1046	1.7	-20.3	63.4	-22	0	-2.6
258	CATCTCCTAGAAGCCTGGCC SEQ ID NO:1047	1.8	-28.6	78.6	-29.3	0	-10.1
656	ACAAACAACAAAATGATCTGAA SEQ ID NO:1048	1.8	-14.2	47.2	-16	0	-5
49	CAGGTCAGGATACTCAGCCT SEQ ID NO:1049	1.9	-26.6	77.1	-26.7	-1.8	-4.9
243	TGGCCTCGGTCCCCTGTGGCC SEQ ID NO:1050	1.9	-35	91.4	-32.8	-4.1	-10.6
513	AGAGTGGGCGCTCAGAGCTC SEQ ID NO:1051	1.9	-28.3	81.6	-27.5	-2.7	-12.3
579	GGTGGGAGAAGAAGAGTGTC SEQ ID NO:1052	2	-22.6	68.3	-24.6	0	-1.8
817	TATTGACTTCTGTTTGCTAC SEQ ID NO:1053	2	-20.9	64.7	-22.9	0	-3.6
527	AATGTTTAATTGGAAGAGTG SEQ ID NO:1054	2.1	-16.7	53.6	-18.8	0	-2.9
545	ACTGTCTTCTTGGCTGAGAA SEQ ID NO:1055	2.2	-23.5	70.3	-24.9	-0.6	-7.8
52	ACTCAGGTCAGGATACTCAG SEQ ID NO:1056	2.4	-23.4	71.1	-24.9	-0.8	-3.8
197	TAGAGACCATGGACATCAGC SEQ ID NO:1057	2.4	-23.4	68.4	-25.1	0	-8.8
1024	CCTCGCTCTTACCTCAGAAA SEQ ID NO:1058	2.4	-25.3	70.4	-27.7	0	-3.1
821	TATTTATTGACTTCTGTTTG SEQ ID NO:1059	2.5	-18.2	58.4	-20.7	0	-2.5
51	CTCAGGTCAGGATACTCAGC SEQ ID NO:1060	2.6	-25	75.1	-26.7	-0.8	-4.2
544	CTGTCTTCTTGGCTGAGAAT SEQ ID NO:1061	2.6	-23.3	69.7	-25.1	-0.6	-7.9
641	TTGAAAAACATGCTTTTTTGA SEQ ID NO:1062	2.6	-16.5	52.2	-17.5	-1.5	-9.1
657	AACAAACAACAAAATGATCTTGA SEQ ID NO:1063	2.6	-14.2	47.2	-16.8	0	-5
1026	CACCTCGCTCTTACCTCAGA SEQ ID NO:1064	2.6	-27.6	76.7	-30.2	0	-3.1
634	ACATGCTTTTTTGAGAGCACT SEQ ID NO:1065	2.8	-22.8	67.8	-23.2	-2.4	-6.7
1025	ACCTCGCTCTTACCTCAGAA SEQ ID NO:1066	3.2	-26.2	73.2	-29.4	0	-2.7
733	AGGTAATTAAGCCTAAGCCT SEQ ID NO:1067	3.4	-22.9	66	-25.4	-0.8	-6.6
196	AGAGACCATGGACATCAGCA SEQ ID NO:1068	3.5	-24.4	70.1	-27.3	0	-8.5
640	TGAAAAACATGCTTTTTTGAG SEQ ID NO:1069	3.5	-16.4	52.1	-18.3	-1.5	-9.1
658	CAACAAACAACAAAATGATCTTG SEQ ID NO:1070	3.5	-14.3	47.3	-17.8	0	-4.9

position	oligo	duplex		target	Intra-	Inter-	
		total binding	form- ation	Tm of Duplex structure	molecular oligo	molecular oligo	
667	TAGAGAGAGCAACAAACAAA SEQ ID NO:1071	3.8	-16.3	51.6	-20.1	0	-4.1
734	CAGGTAATTAAGCCTAAGCC SEQ ID NO:1072	3.8	-22.7	65.2	-25.6	-0.8	-6.8
1027	CCACCTCGCTCTTACCTCAG SEQ ID NO:1073	3.8	-29	78.8	-32.8	0	-3.1
543	TGTCTTCTTGGCTGAGAATG SEQ ID NO:1074	3.9	-22.4	67.5	-25.4	-0.8	-8.1
580	AGGTGGGAGAGAAGAGTGT SEQ ID NO:1075	4	-22.2	67	-26.2	0	0
587	GAGAGTGAGGTGGGAGAAGA SEQ ID NO:1076	4	-22.9	68.7	-26.9	0	0
254	TCCTAGAAGCCTGGCCTCGG SEQ ID NO:1077	4.1	-29.9	79.8	-33.4	0.2	-8.7
253	CCTAGAAGCCTGGCCTCGGT SEQ ID NO:1078	4.3	-30.7	81.4	-34.1	-0.3	-9.5
540	CTTCTTGGCTGAGAATGTTT SEQ ID NO:1079	4.3	-22.2	66.8	-25.6	-0.8	-8.1
592	AGTGGGAGAGTGAGGTGGGA SEQ ID NO:1080	4.3	-26	77.1	-30.3	0	0
595	TACAGTGGGAGAGTGAGGTG SEQ ID NO:1081	4.5	-23.6	71.3	-28.1	0	-4.6
193	GACCATGGACATCAGCATT SEQ ID NO:1082	4.7	-23.6	68.1	-27.6	0	-8.8
194	AGACCATGGACATCAGCATT SEQ ID NO:1083	4.9	-23.9	68.9	-28.1	0	-8.8
581	GAGGTGGGAGAAGAAGAGTG SEQ ID NO:1084	5.3	-21.6	65	-26.9	0	0
586	AGAGTGAGGTGGGAGAAGAA SEQ ID NO:1085	5.3	-21.6	65	-26.9	0	0
252	CTAGAAGCCTGGCCTCGGTC SEQ ID NO:1086	5.6	-29.1	79.8	-33.8	-0.3	-9.5
22	TATGCTTTAGTCCCAGGCCA SEQ ID NO:1087	5.7	-28.3	79	-33.5	0	-7.7
589	GGGAGAGTGAGGTGGGAGAA SEQ ID NO:1088	5.8	-24.7	72.5	-30.5	0	0
590	TGGGAGAGTGAGGTGGGAGA SEQ ID NO:1089	6.1	-25.4	74.8	-31.5	0	0
195	GAGACCATGGACATCAGCAT SEQ ID NO:1090	6.2	-24.4	69.8	-29.9	0	-8.8
594	ACAGTGGGAGAGTGAGGTGG SEQ ID NO:1091	6.4	-25.1	74.7	-31.5	0	-4.6
588	GGAGAGTGAGGTGGGAGAAG SEQ ID NO:1092	7	-23.5	70	-30.5	0	0
591	GTGGGAGAGTGAGGTGGGAG SEQ ID NO:1093	7.3	-26	77.1	-33.3	0	0
659	GCAACAAACAAAATGATCTT SEQ ID NO:1094	9	-16.1	50.7	-25.1	0	-4.9
582	TGAGGTGGGAGAAGAGAGT SEQ ID NO:1095	9.4	-21.6	65	-31	0	-0.1
48	AGGTCAGGATACTCAGCCTG SEQ ID NO:1096	9.5	-25.9	75.8	-33.6	-1.8	-7
584	AGTGAGGTGGGAGAAGAAGA SEQ ID NO:1097	9.6	-21.6	65	-31.2	0	0
583	GTGAGGTGGGAGAAGAAGAG SEQ ID NO:1098	11.4	-21.6	65	-33	0	0
585	GAGTGAGGTGGGAGAAGAAG SEQ ID NO:1099	11.9	-21.6	65	-33.5	0	0

Example 15**Western blot analysis of VCC-1 protein levels**

[00226] Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100
5 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to VCC-1 is used, with a radiolabeled or fluorescently labeled secondary antibody directed against the
10 primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

WHAT IS CLAIMED IS:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding VCC-1, wherein said antisense
5 compound specifically hybridizes with and inhibits the expression of VCC-1.
2. The antisense compound of claim 1 which is an antisense oligonucleotide.
3. The antisense oligonucleotide of claim 2 comprising a nucleic acid
10 sequence selected from the group consisting of at least eight contiguous bases of SEQ ID NO:1 – SEQ ID NO:1099.
4. The antisense oligonucleotide of claim 2 comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:1 – SEQ ID NO:1099.
5. The antisense compound of claim 2, 3, or 4 wherein the antisense
15 oligonucleotide comprises at least one modified internucleoside linkage.
6. The antisense compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage.
7. The antisense compound of claim 2, 3, or 4 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 20 8. The antisense compound of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
9. The antisense compound of claim 2, 3, or 4 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
10. The antisense compound of claim 9 wherein the modified nucleobase
25 is a 5-methylcytosine.
11. The antisense compound of claim 2, 3, or 4 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

12. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
13. The composition of claim 12 further comprising a colloidal dispersion system.
- 5 14. The composition of claim 13 wherein the antisense compound is an antisense oligonucleotide.
15. A method of inhibiting the expression of VCC-1 in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of VCC-1 is inhibited.
- 10 16. A method of treating a human having a disease or condition associated with VCC-1 comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of VCC-1 is inhibited.
- 15 17. The method of claim 16 wherein the disease or condition is diabetes.
18. The method of claim 16 wherein the disease or condition is an immunological disorder.
19. The method of claim 16 wherein the disease or condition is a cardiovascular disorder.
- 20 20. The method of claim 16 wherein the disease or condition is a neurologic disorder.
21. The method of claim 16 wherein the disease or condition is ischemia/reperfusion injury.
22. The method of claim 16 wherein the disease or condition is any
25 form of cancer.
23. The method of claim 16 wherein the disease or condition is an angiogenic disorder.

10/525116

Figure 1

GATTCCCATAAAGCACATGGTCTAATCTGTACGTAACAGCAAGACAGCGTCACCTCACCTGTTCT 66
CGCCCTCAAATGGGAAOGCTGGCCTGGGACTAAAGCATAGACCACCAGGCTGAGTATCCTGACCTGAGTCATCCC 141
CAGGGATCAGGAGCCTCCAGCAGGGAACCTTCCATTATATTCTTCAAGCAACTTACAGCTGCACCGACAGTTGCG 216

ATGAAAGTTCTAATCTCTTCCCTCCTCCTGTGTGCTGCCACTAATGCTGATGTCCATGGTCTCTAGCAGCCTGAAT 291
M K V L I S S L L L L L P L M L M S M V S S S L N 25

CCAGGGGTCGCCAGAGGCCACAGGGACCGAGGCCAGGCTTCTAGGAGATGGCTCCAGGAAGGCGGCCAAGAATGT 366
P G V A R G H R D R G Q A S R R W L Q E G G Q E C 50

GAGTGCAAAGATTGGTTCTGAGAGCCCCGAGAAGAAAATTCATGACAGTGTCTGGGCTGCCAAAGAAGCAGTGC 441
E C K D W F L R A P R R K F M T V S G L P K K Q C 75

CCCTGTGATCATTTCAAGGGCAATGTGAAGAAAAACAAGACACCAAAGGCACCACAGAAAGCCAAACAAGCATTCC 516
P C D H F K G N V K K T R H Q R H H R K P N K H S 100

AGAGCCTGCCAGCAATTTCTCAAACAATGTCAGCTAAGAAGCTTTGCTCTGCCTTTGTAGGAGCTCTGAGCGCCC 591
R A C Q Q F L K Q C Q L R S F A L P L * SEQ ID 1106 119

ACTCTTCCAATTAAACATTCTCAGCCAAGAAGACAGTGAGCACACCTACCAGACACTCTTCTTCTCCACCTCAC 666
TCTCCCACTGTACCCACCCCTAAATCATTCCAGTGCTCTCAAAAAGCATGTTTTTCAAGATCATTTTGTGTTG 741
CTCTCTCTAGTGTCTTCTTCTCTCGTCAGTCTTAGCCTGTGCCCTCCCTTACCCAGGCTTAGGCTTAATTACCT 816
GAAAGATTCCAGGAAACTGTAGCTTCCTAGCTAGTGTCAATTAACCTTAAATGCAATCAGGAAAGTAGCAAACAG 891
AAGTCAATAAATATTTTTAAATGTCACAGATCAAAATTGTTTCCTTCAAATGGGGTCTGCCAATTCACAACCAGA 966
TGACCCATTTTACCCTATTCACTGCAGACTGAATCCAGATTCTACACATACTTATCCCCACCAAGACCCTCACTC 1041
TGTCTCCATTGGCCTACTTGTTCATCTTTCATCATTGACAAATCTTCTGAGGTAAGAGCGAGGTGGGACAAA 1116
AAAAAAAAGCATACCAATGAACCAGACACGGTCTTATTAAAGATAATATAGGTTT SEQ ID NO:1107 1172

SEQUENCE LISTING

10/525116
DT01 Rec'd PCT/PTC 18 FEB 2005

<110> Pharmacia Corporation
Weinstein, Edward

<120> ANTISENSE MODULATION OF VEGF CO-REGULATED CHEMOKINE-1 EXPRESSION

<130> 01055/1/PCT

<150> 60/404,484

<151> 2002-08-19

<160> 1107

<170> PatentIn version 3.2

<210> 1

<211> 20

<212> DNA

<213> artificial

<220>

<223> human VCC-1 antisense

<400> 1

ctgtggtgcc tttggtgtct

20

<210> 2

<211> 20

<212> DNA

<213> artificial

<220>

<223> human VCC-1 antisense

<400> 2

gctttctgtg gtgcctttgg

20

<210> 3

<211> 20

<212> DNA

<213> artificial

<220>

<223> human VCC-1 antisense

<400> 3

tctgtggtgc ctttggtgtc

20

<210> 4

<211> 20

<212> DNA

<213> artificial

<220>

<223> human VCC-1 antisense

<400> 4
ggtgcctttg gtgtcttggt 20

<210> 5
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 5
tggtgccttt ggtgtcttgt 20

<210> 6
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 6
gtggtgcctt tggtgtcttg 20

<210> 7
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 7
tgtggtgcct ttggtgtctt 20

<210> 8
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 8
ttctgtggtg cctttggtgt 20

<210> 9
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 9
ctttctgtgg tgcctttggt 20

<210> 10
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 10
gtttggcttt ctgtggtgcc 20

<210> 11
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 11
gtgaggtct tggtagggat 20

<210> 12
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 12
gtgcctttgg tgtcttggtt 20

<210> 13
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 13
ggctttctgt ggtgcctttg 20

<210> 14
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 14
tttctgtggt gcctttggtg 20

<210> 15
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 15
tgtttggtt tctgtggtgc 20

<210> 16
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 16
tggttttctg tggtgccttt 20

<210> 17
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 17
ttggctttct gtggtgcctt 20

<210> 18
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 18
tttggctttc tgtggtgcct 20

<210> 19
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 19
gcctttggtg tcttggttttc

20

<210> 20
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 20
agtgaggggc ttggtgggga

20

<210> 21
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 21
tgcctttggt gtcttggtttt

20

<210> 22
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 22
tgagggtcctt ggtggggata

20

<210> 23
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 23
gggtcttggt ggggataagt

20

<210> 24
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 24
ggcagcaaca ggaggagggga 20

<210> 25
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 25
gagtgtcttg taggtgtgct 20

<210> 26
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 26
gaggggtcttg gtggggataa 20

<210> 27
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 27
ttgtttggct ttctgtggtg 20

<210> 28
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 28
agtgtctggt aggtgtgctc 20

<210> 29
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 29
ttggtgtctt gttttcttca 20

<210> 30
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 30
tttgggtgtct tgttttcttc 20

<210> 31
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 31
gaatgattta ggggtgggta 20

<210> 32
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 32
tggcagcaac aggaggaggg 20

<210> 33
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 33
ggaatgattt aggggtgggt 20

<210> 34
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 34
gggtcatctg gttgtgaatt

20

<210> 35
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 35
agggtcttgg tggggataag

20

<210> 36
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 36
cgttcccatt tgagggcgag

20

<210> 37
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 37
tgggtcatct ggttgtgaat

20

<210> 38
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 38
atgggtcatc tggttgtgaa

20

<210> 39
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 39
aatgggtcat ctggttgtga

20

<210> 40
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 40
agagtgtctg gtaggtgtgc

20

<210> 41
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 41
ggtcttggtg gggataagta

20

<210> 42
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 42
ctgggtaagg ggagggcaca

20

<210> 43
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 43
gagtgagggt cttggtgggg

20

<210> 44
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 44
ctttggtgtc ttgttttctt 20

<210> 45
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 45
agtggcagca acaggaggag 20

<210> 46
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 46
gtctggtagg tgtgctcact 20

<210> 47
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 47
gtggcagcaa caggaggagg 20

<210> 48
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 48
ggaggagga agagattaga 20

<210> 49
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 49
gcagcaacag gaggaggaa 20

<210> 50
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 50
tagtggcagc aacaggagga 20

<210> 51
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 51
ggcatctgg ttgtgaattg 20

<210> 52
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 52
tgggtaaggg gagggcacag 20

<210> 53
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 53
ggtaaatgg gtcattggt 20

<210> 54
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 54
gggtaaaatg ggcatctctgg 20

<210> 55
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 55
ggcctctggc gacccttgga 20

<210> 56
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 56
gtgtctggta ggtgtgctca 20

<210> 57
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 57
aaatgggtca tctggttg 20

<210> 58
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 58
gtcttggtgg ggataagtat 20

<210> 59
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 59
tggtggggat aagtatgtgt

20

<210> 60
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 60
aggaggaggg aagagattag

20

<210> 61
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 61
gcctctggcg acccctggat

20

<210> 62
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 62
aatgatttag ggggtgggtac

20

<210> 63
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 63
cttgggtgggg ataagtatgt

20

<210> 64
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 64
tggcctctgg cgacccctgg 20

<210> 65
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 65
gtggcctctg gcgacccctg 20

<210> 66
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 66
tggtgtcttg ttttcttcac 20

<210> 67
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 67
cttgtttggc tttctgtggt 20

<210> 68
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 68
ctggtagggt tgctcactgt 20

<210> 69
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 69
ggtggggata agtatgtgta 20

<210> 70
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 70
atcgcaactg tgggtgcagc 20

<210> 71
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 71
cctttggtgt cttgttttct 20

<210> 72
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 72
ttaggggtgg gtacagtggg 20

<210> 73
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 73
aaaatgggtc atctggttgt 20

<210> 74
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 74
gcgttcccat ttgagggcga 20

<210> 75
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 75
ggtgtcttgt tttcttcaca 20

<210> 76
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 76
tctggtaggt gtgctcactg 20

<210> 77
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 77
cctctggcga cccctggatt 20

<210> 78
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 78
tcatcgcaac tgtcggtgca 20

<210> 79
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 79
taggggtggg tacagtggga 20

<210> 80
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 80
gtaaaatggg tcatctggtt 20

<210> 81
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 81
gtatgctttt ttttttttgt 20

<210> 82
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 82
ggtatgcttt tttttttttg 20

<210> 83
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 83
tggtatgctt tttttttttt 20

<210> 84
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 84
ttggtatgct tttttttttt 20

<210> 85
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 85
gcaactgtcg gtgcagctgt 20

<210> 86
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 86
agggtaaaat gggtcacatctg 20

<210> 87
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 87
ctttcatcgc aactgtcggt 20

<210> 88
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 88
ggaggggaaga gattagaact 20

<210> 89
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 89
ggagacagag tgagggtctt 20

<210> 90
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 90
ttcatcgcaa ctgtcgggtgc 20

<210> 91
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 91
ttagtggcag caacaggagg 20

<210> 92
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 92
tcttggtggg gataagtatg 20

<210> 93
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 93
agacagagtg aggggtcttgg 20

<210> 94
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 94
gtgtcttggt ttcttcacat 20

<210> 95
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 95
atgatttagg ggtgggtaca 20

<210> 96
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 96
tggaatgatt taggggtggg 20

<210> 97
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 97
tagggtaaaa tgggtcatct 20

<210> 98
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 98
ttggtgggga taagtatgtg 20

<210> 99
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 99
gacagagtga gggctcttggt 20

<210> 100
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 100
cagcaacagg aggagggaag 20

<210> 101
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 101
gaggagggaa gagattagaa 20

<210> 102
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 102
agcaacagga ggagggaaga 20

<210> 103
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 103
gtcatctggt tgtgaattgg 20

<210> 104
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 104
ccgtgtcttggtttcattggta 20

<210> 105
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 105
tccctgggga tgactcaggt 20

<210> 106
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 106
catcgcaact gtcggtgcag 20

<210> 107
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 107
tttaggggtg ggtacagtgg 20

<210> 108
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 108
gtctgggttca ttggtatgct 20

<210> 109
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 109
aagagtgtct ggtagggtgtg 20

<210> 110
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 110
gacgagagaa gaagacacta 20

<210> 111
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 111
tggagacaga gtgagggtct 20

<210> 112
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 112
attggtatgc tttttttttt 20

<210> 113
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 113
cgtgtctggt tcattggtat 20

<210> 114
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 114
aggaggaag agattagaac 20

<210> 115
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 115
tgacgagaga agaagacact 20

<210> 116
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 116
tatgcttttt tttttttgtc 20

<210> 117
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 117
actttcatcg caactgtcgg 20

<210> 118
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 118
cgagagaaga agacactaga 20

<210> 119
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 119
taaaatgggt catctggttg

20

<210> 120
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 120
agcgttccca ttgagggcg

20

<210> 121
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 121
gagggaagag attagaactt

20

<210> 122
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 122
tgtctggtag gtgtgctcac

20

<210> 123
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 123
atagggtaaa atggggtcatc

20

<210> 124
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 124
gggaagagat tagaactttc 20

<210> 125
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 125
gagacagagt gagggctcttg 20

<210> 126
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 126
cctgggtaag gggagggcac 20

<210> 127
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 127
gtatgtgtag aatctggatt 20

<210> 128
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 128
ccctgtggcc tctggcgacc 20

<210> 129
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 129
acgagagaag aagacactag 20

<210> 130
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 130
agtatgtgta gaatctggat 20

<210> 131
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 131
atccctgggg atgactcagg 20

<210> 132
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 132
ctctggcgac ccctggattc 20

<210> 133
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 133
gccttcctgg agccatctcc 20

<210> 134
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 134
tgtcttggtt tcttcacatt 20

<210> 135
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 135
gcagagcaaa gcttcttagc 20

<210> 136
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 136
gggtaagggg agggcacagg 20

<210> 137
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 137
gtgaataggg taaaatgggt 20

<210> 138
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 138
tgtctgggtc attggtatgc 20

<210> 139
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 139
agagattaga actttcatcg

20

<210> 140
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 140
aggggaagaga ttagaacttt

20

<210> 141
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 141
cctgtggcct ctggcgaccc

20

<210> 142
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 142
gaatagggta aaatgggtca

20

<210> 143
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 143
agagtgaggg tcttggtggg

20

<210> 144
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 144
gtgtctgggt cattgggtatg

20

<210> 145
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 145
tttcatcgca actgtcgggtg

20

<210> 146
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 146
tctggcgacc cctggattca

20

<210> 147
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 147
gcttgtttgg ctttctgtgg

20

<210> 148
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 148
ggcagagcaa agcttcttag

20

<210> 149
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 149
tctggttcat tggtatgctt

20

<210> 150
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 150
aggcagagca aagcttctta

20

<210> 151
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 151
atttaggggt gggtagagt

20

<210> 152
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 152
gagaagaaga cactagagag

20

<210> 153
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 153
agagaagaag acactagaga

20

<210> 154
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 154
gagagaagaa gacactagag 20

<210> 155
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 155
gaacaagtag gccaatggag 20

<210> 156
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 156
tgaacaagta ggccaatgga 20

<210> 157
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 157
cattggtatg cttttttttt 20

<210> 158
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 158
caggaggagg gaagagatta 20

<210> 159
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 159
ggcgacccct ggattcaggc 20

<210> 160
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 160
cccatttgaa ggaaacaatt 20

<210> 161
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 161
ctggttcatt ggtatgcttt 20

<210> 162
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 162
caactgtcgg tgcagctgta 20

<210> 163
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 163
aagtatgtgt agaatctgga 20

<210> 164
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 164
acagagtgag ggtcttggtg 20

<210> 165
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 165
tgtggcctct ggcgaccctt 20

<210> 166
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 166
aatagggttaa aatgggtcat 20

<210> 167
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 167
ggccaatgga gacagagtga 20

<210> 168
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 168
gcgacccttg gattcaggct 20

<210> 169
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 169
ctggcgaccc ctggattcag

20

<210> 170
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 170
ggtgtgctca ctgtcttctt

20

<210> 171
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 171
tgaatagggt aaaatgggtc

20

<210> 172
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 172
tggttcattg gtatgctttt

20

<210> 173
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 173
gagattagaa ctttcatcgc

20

<210> 174
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 174
ggaagagatt agaactttca 20

<210> 175
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 175
acaggaggag ggaagagatt 20

<210> 176
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 176
aggtgtgctc actgtcttct 20

<210> 177
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 177
gcactggaat gatttagggg 20

<210> 178
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 178
atggagacag agtgagggtc 20

<210> 179
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 179
atgaacaagt aggccaatgg 20

<210> 180
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 180
accgtgtctg gttcattggt 20

<210> 181
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 181
tgatttaggg gtgggtacag 20

<210> 182
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 182
agaagaagac actagagaga 20

<210> 183
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 183
agtgaatagg gtaaaatggg 20

<210> 184
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 184
ggttcattgg tatgcttttt 20

<210> 185
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 185
aactttcatc gcaactgtcg 20

<210> 186
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 186
gaagagatta gaactttcat 20

<210> 187
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 187
attagtggca gcaacaggag 20

<210> 188
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 188
ctgacgagag aagaagacac 20

<210> 189
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 189
aggccaatgg agacagagtg 20

<210> 190
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 190
agattagaac tttcatcgca 20

<210> 191
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 191
ctgtggcctc tggcgacccc 20

<210> 192
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 192
cggtcctgt ggcctctggc 20

<210> 193
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 193
tggtagggtg gtcactgtc 20

<210> 194
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 194
ctggaatgat ttaggggtgg 20

<210> 195
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 195
cactggaatg atttaggggt 20

<210> 196
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 196
atgtgtagaa tctggattca 20

<210> 197
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 197
taagtatgtg tagaatctgg 20

<210> 198
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 198
gatgaacaag taggccaatg 20

<210> 199
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 199
agatgaacaa gtaggccaat 20

<210> 200
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 200
tcattggtat gctttttttt 20

<210> 201
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 201
aatataatgg aaggttcct 20

<210> 202
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 202
gaactttcat cgcaactgtc 20

<210> 203
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 203
aagagattag aactttcatc 20

<210> 204
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 204
gacccttgga ttcaggctgc 20

<210> 205
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 205
tgcttgtttg gctttctgtg 20

<210> 206
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 206
atgcttgttt ggctttctgt 20

<210> 207
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 207
agcctgggta aggggagggc 20

<210> 208
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 208
tatgtgtaga atctggattc 20

<210> 209
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 209
gccaatggag acagagtgag 20

<210> 210
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 210
ccttcctgga gccatctcct 20

<210> 211
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 211
gtcttggttt cttcacattg 20

<210> 212
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 212
ggtaggtgtg ctcaactgtct 20

<210> 213
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 213
tcatctgggtt gtgaattggc 20

<210> 214
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 214
taggccaatg gagacagagt 20

<210> 215
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 215
gcaaagcttc ttagctgaca 20

<210> 216
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 216
gaagagtgtc tggtaggtgt 20

<210> 217
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 217
aggggtgggt acagtgggag 20

<210> 218
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 218
gaatataatg gaagggtccc 20

<210> 219
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 219
gatttagggg tgggtacagt 20

<210> 220
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 220
aactgtcggg gcagctgtaa 20

<210> 221
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 221
agaactttca tcgcaactgt 20

<210> 222
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 222
agcaaagctt cttagctgac 20

<210> 223
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 223
ccccatttga aggaaacaat 20

<210> 224
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 224
gaagaatata atggaagggt 20

<210> 225
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 225
cgacccctgg attcaggctg 20

<210> 226
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 226
tggcgacccc tggattcagg 20

<210> 227
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 227
gataagtatg tgtagaatct 20

<210> 228
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 228
gtggggataa gtatgtgtag 20

<210> 229
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 229
tgagtgaaag atgaacaagt 20

<210> 230
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 230
tttgtcgaat gagtgaaaga 20

<210> 231
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 231
ccctggggat gactcaggtc 20

<210> 232
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 232
tgaagaatat aatggaaggt 20

<210> 233
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 233
cgcaactgtc ggtgcagctg 20

<210> 234
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 234
ttgtcgaatg agtgaaagat 20

<210> 235
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 235
gcctgggtaa ggggagggca 20

<210> 236
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 236
gtgaaagatg aacaagtagg 20

<210> 237
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 237
tgtcgaatga gtgaaagatg 20

<210> 238
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 238
cattagtggc agcaacagga 20

<210> 239
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 239
ggtcacctgtg gcctctggcg 20

<210> 240
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 240
gcttcttagc tgacattggt 20

<210> 241
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 241
aacaagtagg ccaatggaga 20

<210> 242
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 242
gagtgaaga tgaacaagta 20

<210> 243
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 243
aatggaagg tccctgctgg 20

<210> 244
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 244
aaggcagagc aaagcttctt

20

<210> 245
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 245
ttcattggta tgcttttttt

20

<210> 246
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 246
gaaggttccc tgctggaggc

20

<210> 247
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 247
atataatgga aggttccctg

20

<210> 248
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 248
cagagcaaag cttcttagct

20

<210> 249
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 249
gggggtgggta cagtgggaga

20

<210> 250
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 250
ataagtatgt gtagaatctg

20

<210> 251
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 251
atttgctgaa tgagtgaaag

20

<210> 252
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 252
cttccttagct gacattgttt

20

<210> 253
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 253
gaagaagaca ctagagagag

20

<210> 254
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 254
gtaggccaat ggagacagag 20

<210> 255
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 255
gtggtctatg ctttagtccc 20

<210> 256
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 256
gatccctggg gatgactcag 20

<210> 257
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 257
gagcaaagct tcttagctga 20

<210> 258
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 258
caattttgat ctgtgacatt 20

<210> 259
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 259
tcgcaactgt cggtgcagct 20

<210> 260
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 260
agcactggaa tgatttaggg 20

<210> 261
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 261
tttgaaggaa acaattttga 20

<210> 262
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 262
agtgaagat gaacaagtag 20

<210> 263
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 263
atgctttttt ttttttgtcc 20

<210> 264
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 264
aagaccgtgt ctgggttcatt 20

<210> 265
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 265
tctttaataa gaccgtgtct 20

<210> 266
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 266
agagcaaagc ttcttagctg 20

<210> 267
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 267
catctggttg tgaattggca 20

<210> 268
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 268
ggaaggttcc ctgctggagg 20

<210> 269
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 269
aagaatataa tggaaggttc 20

<210> 270
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 270
aacaggagga gggaagagat 20

<210> 271
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 271
agcttcttag ctgacattgt 20

<210> 272
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 272
gtaaggggag ggcacaggct 20

<210> 273
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 273
atgagtgaaa gatgaacaag 20

<210> 274
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 274
aatggagaca gagtgagggt 20

<210> 275
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 275
taagaccgtg tctggttcat 20

<210> 276
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 276
ataagaccgt gtctggttca 20

<210> 277
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 277
tagaactttc atcgcaactg 20

<210> 278
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 278
aatgcttggt tggctttctg 20

<210> 279
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 279
ggtaagggga gggcacaggc 20

<210> 280
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 280
cagcgttccc atttgagggc 20

<210> 281
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 281
agaatataat ggaaggttcc 20

<210> 282
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 282
ttttgatctg tgacatttaa 20

<210> 283
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 283
cagtgaatag ggtaaaatgg 20

<210> 284
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 284
aaggttccct gctggaggct 20

<210> 285
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 285
atggaagggtt ccctgctgga 20

<210> 286
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 286
actgacgaga gaagaagaca 20

<210> 287
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 287
ggcagacccc atttgaagga 20

<210> 288
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 288
acaagtaggc caatggagac 20

<210> 289
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 289
acaaaggcag agcaaagctt

20

<210> 290
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 290
agaagacact agagagagca

20

<210> 291
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 291
taatggaagg ttccctgctg

20

<210> 292
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 292
cttcctggag ccatctccta

20

<210> 293
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 293
aaaggcagag caaagcttct

20

<210> 294
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 294
acccatttg aaggaaaca 20

<210> 295
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 295
atctttaata agaccgtgtc 20

<210> 296
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 296
gattagaact ttcacgcaa 20

<210> 297
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 297
tgttttcttc acattgccct 20

<210> 298
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 298
aagcctgggt aaggggaggg 20

<210> 299
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 299
agtctgcagt gaatagggtg 20

<210> 300
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 300
ttgaagaata taatggaagg 20

<210> 301
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 301
cctggattca ggctgctaga 20

<210> 302
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 302
acccttgat tcaggctgct 20

<210> 303
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 303
cgccttctg gagccatctc 20

<210> 304
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 304
caggggcact gcttcttttg 20

<210> 305
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 305
gatcacaggg gcactgcttc 20

<210> 306
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 306
tacaaaggca gagcaaagct 20

<210> 307
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 307
gtaggtgtgc tcactgtctt 20

<210> 308
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 308
aagaagacac tagagagagc 20

<210> 309
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 309
tcgaatgagt gaaagatgaa 20

<210> 310
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 310
tgcttttttt tttttgtccc 20

<210> 311
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 311
gttcattggg atgctttttt 20

<210> 312
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 312
aggttccctg ctggaggctc 20

<210> 313
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 313
ctgtcgggtgc agctgtaagt 20

<210> 314
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 314
tggacatcag cattagtggc 20

<210> 315
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 315
gccgccttcc tggagccatc 20

<210> 316
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 316
gcactcacat tcttggccgc 20

<210> 317
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 317
tggaagggtc cctgctggag 20

<210> 318
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 318
ggtgggtaca gtgggagagt 20

<210> 319
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 319
gggtgggtac agtgggagag 20

<210> 320
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 320
actggaatga tttaggggtg 20

<210> 321
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 321
tttgatctgt gacatttaaa 20

<210> 322
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 322
aggaaacaat tttgatctgt 20

<210> 323
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 323
tgatccctgg ggatgactca 20

<210> 324
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 324
gcattagtgg cagcaacagg 20

<210> 325
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 325
tcacaggggc actgcttctt 20

<210> 326
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 326
tcttgttttc ttcacattgc 20

<210> 327
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 327
ttgaaggaaa caattttgat 20

<210> 328
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 328
cctggggatg actcagggtca 20

<210> 329
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 329
tataatggaa ggttccttgc 20

<210> 330
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 330
atcacagggg cactgcttct 20

<210> 331
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 331
taaggggagg gcacaggcta 20

<210> 332
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 332
ctggttgtga attggcagac 20

<210> 333
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 333
tatctttaat aagaccgtgt 20

<210> 334
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 334
gtttttcttca cattgccctt 20

<210> 335
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 335
agaagagtgt ctggtaggtg 20

<210> 336
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 336
atttgaagga aacaattttg 20

<210> 337
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 337
cagtctgcag tgaatagggt 20

<210> 338
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 338
ttgttttctt cacattgccc 20

<210> 339
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 339
tgtgtagaat ctggattcag 20

<210> 340
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 340
agtaggccaa tggagacaga 20

<210> 341
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 341
gatttgtcga atgagtgaaa 20

<210> 342
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 342
gaccgtgtct ggttcattgg 20

<210> 343
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 343
actgtcgggtg cagctgtaag 20

<210> 344
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 344
attttgatct gtgacattta 20

<210> 345
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 345
ggaaacaatt ttgatctgtg 20

<210> 346
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 346
tggcagaccc catttgaagg 20

<210> 347
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 347
gaaagatgaa caagtaggcc 20

<210> 348
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 348
agaagaagag tgtctggtag 20

<210> 349
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 349
gtgtagaatc tggattcagt 20

<210> 350
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 350
gctttttttt ttttgtccca 20

<210> 351
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 351
gaggctcctg atccctgggg 20

<210> 352
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 352
tcggtccttg tggcctctgg 20

<210> 353
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 353
tcctgattgc atttaaggtt 20

<210> 354
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 354
ttcctgattg catttaaggt 20

<210> 355
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 355
ttgatctgtg acatttaaaa 20

<210> 356
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 356
gaccccatTT gaaggaaaca 20

<210> 357
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 357
tggggataag tatgtgtaga 20

<210> 358
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 358
tgaaagatga acaagtaggc 20

<210> 359
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 359
gtcgaatgag tgaaagatga 20

<210> 360
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 360
caggccagcg ttcccatttg 20

<210> 361
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 361
cccctggatt caggctgcta 20

<210> 362
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 362
aggccagcgt tcccatttga 20

<210> 363
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 363
ataatggaag gttccctgct 20

<210> 364
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 364
tgatcacagg ggcactgctt 20

<210> 365
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 365
tttcttcaca ttgcccttga 20

<210> 366
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 366
caaagcttct tagctgacat 20

<210> 367
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 367
ttaattggaa gagtgggcg 20

<210> 368
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 368
cctgattgca tttaagggtta 20

<210> 369
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 369
tgggtctatgc tttagtccca 20

<210> 370
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 370
atgatcacag gggcactgct 20

<210> 371
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 371
gtgctcactg tcttcttggc 20

<210> 372
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 372
gtctgcagtg aatagggtaa 20

<210> 373
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 373
aggctcctga tccctgggga 20

<210> 374
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 374
gttgcttgaa gaatataatg 20

<210> 375
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 375
agttgcttga agaataataat 20

<210> 376
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 376
ggacatcagc attagtggca 20

<210> 377
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 377
tccctgtggc ctctggcgac 20

<210> 378
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 378
taattggaag agtgggcgct 20

<210> 379
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 379
gactgacgag agaagaagac 20

<210> 380
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 380
gcagacccca tttgaaggaa 20

<210> 381
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 381
ttgtgaattg gcagacccca 20

<210> 382
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 382
caatggagac agagtgaggg 20

<210> 383
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 383
ctttaataag accgtgtctg 20

<210> 384
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 384
ggcgccttc ctggagccat 20

<210> 385
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 385
acaggggcac tgcttctttg 20

<210> 386
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 386
gaagacacta gagagagcaa 20

<210> 387
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 387
agactgacga gagaagaaga 20

<210> 388
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 388
tgtgaattgg cagaccccat 20

<210> 389
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 389
ggataagtat gtgtagaatc 20

<210> 390
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 390
gctcactgtc ttcttggtg 20

<210> 391
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 391
gtgtgctcac tgtcttcttg 20

<210> 392
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 392
caagtaggcc aatggagaca 20

<210> 393
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 393
ttatctttaa taagaccgtg 20

<210> 394
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 394
attatcttta ataagaccgt 20

<210> 395
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 395
taagttgctt gaagaatata 20

<210> 396
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 396
ccgccttcct ggagccatct 20

<210> 397
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 397
gaattggcag accccatttg 20

<210> 398
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 398
aattggaaga gtgggcgctc 20

<210> 399
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 399
gatctgtgac atttaaaaat 20

<210> 400
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 400
tgatctgtga catttaaaaa 20

<210> 401
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 401
ggtggtctat gctttagtcc 20

<210> 402
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 402
ggttccctgc tggaggctcc 20

<210> 403
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 403
cttgaagaat ataatggaag 20

<210> 404
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 404
cagcattagt ggcagcaaca 20

<210> 405
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 405
atggacatca gcattagtgg 20

<210> 406
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 406
tgcaactcaca ttcttgccg 20

<210> 407
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 407
gtttcctgga atctttcagg 20

<210> 408
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 408
ttggcagacc ccatttgaag 20

<210> 409
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 409
attggcagac cccatttgaa 20

<210> 410
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 410
aattggcaga ccccatTTga 20

<210> 411
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 411
gaatgagtga aagatgaaca 20

<210> 412
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 412
agatttgtcg aatgagtga 20

<210> 413
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 413
caggaaccaa tctttgcact 20

<210> 414
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 414
ttcttcacat tgcccttgaa

20

<210> 415
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 415
aagaagagtg tctggtaggt

20

<210> 416
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 416
gatcttgaaa aacatgcttt

20

<210> 417
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 417
agcctaagcc tgggtaaggg

20

<210> 418
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 418
aattttgatc tgtgacattt

20

<210> 419
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 419
gaaagatttg tcgaatgagt 20

<210> 420
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 420
aagttgcttg aagaatataa 20

<210> 421
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 421
ccctggattc aggctgctag 20

<210> 422
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 422
cttgttttct tcacattgcc 20

<210> 423
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 423
tgctcactgt cttcttggt 20

<210> 424
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 424
gcagtgaata gggtaaaatg 20

<210> 425
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 425
tgtcggtgca gctgtaagtt 20

<210> 426
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 426
tcagcattag tggcagcaac 20

<210> 427
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 427
tggccgcctt cctggagcca 20

<210> 428
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 428
gagcactgga atgatttagg 20

<210> 429
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 429
aaggggaggg cacaggctaa 20

<210> 430
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 430
tttcctggaa tctttcaggt 20

<210> 431
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 431
gaaacaattt tgatctgtga 20

<210> 432
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 432
ctggattcag tctgcagtga 20

<210> 433
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 433
cgaatgagtg aaagatgaac 20

<210> 434
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 434
ctgatccctg gggatgactc 20

<210> 435
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 435
ttggccgcct tcctggagcc 20

<210> 436
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 436
aggaaccaat ctttgactc 20

<210> 437
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 437
cttcctttggc agcccagaca 20

<210> 438
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 438
aggggcactg cttcctttggc 20

<210> 439
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 439
gtgaattggc agacccatt 20

<210> 440
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 440
ggtctatgct ttagtcccag 20

<210> 441
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 441
tggagccatc tcctagaagc 20

<210> 442
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 442
gagccatctc ctagaagcct 20

<210> 443
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 443
ttgagaaatt gctggcaggc 20

<210> 444
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 444
aaagcttctt agctgacatt 20

<210> 445
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 445
ggagggcaca ggctaagact 20

<210> 446
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 446
ccagcgttcc catttgaggg 20

<210> 447
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 447
atactcagcc tgggtggtcta 20

<210> 448
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 448
gatactcagc ctggtggtct 20

<210> 449
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 449
agcattagtgc gcagcaacag 20

<210> 450
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 450
ggcagcccag acactgtcat 20

<210> 451
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 451
cactgcttct ttggcagccc 20

<210> 452
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 452
gctggcaggc tctggaatgc 20

<210> 453
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 453
caaaggcaga gcaaagcttc 20

<210> 454
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 454
ttcctggaat ctttcaggta

20

<210> 455
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 455
aaagatttgt cgaatgagtg

20

<210> 456
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 456
ttcttagctg acattgtttg

20

<210> 457
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 457
tttaattgga agagtgggag

20

<210> 458
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 458
taagcctggg taaggggagg

20

<210> 459
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 459
tctgtgacat ttaaaaatat 20

<210> 460
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 460
atctgtgaca tttaaaaata 20

<210> 461
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 461
tctggattca gtctgcagtg 20

<210> 462
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 462
atctggattc agtctgcagt 20

<210> 463
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 463
cagagtgagg gtcttggtgg 20

<210> 464
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 464
ccaatggaga cagagtgagg 20

<210> 465
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 465
agaccgtgtc tggttcattg 20

<210> 466
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 466
tattatcttt aataagaccg 20

<210> 467
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 467
cctggtggtc tatgctttag 20

<210> 468
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 468
gtcatgaatt ttcttctcgg 20

<210> 469
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 469
gaatgcttgt ttggctttct

20

<210> 470
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 470
cctacaaagg cagagcaaag

20

<210> 471
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 471
aagactgacg agagaagaag

20

<210> 472
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 472
gtaagttgct tgaagaatat

20

<210> 473
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 473
ggagccatct cctagaagcc

20

<210> 474
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 474
gcactgcttc tttggcagcc 20

<210> 475
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 475
aatgatcaca ggggcactgc 20

<210> 476
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 476
tgagaaattg ctggcaggct 20

<210> 477
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 477
atgatcttga aaaacatgct 20

<210> 478
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 478
ctacagtttc ctggaatctt 20

<210> 479
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 479
tttcctgatt gcatttaagg 20

<210> 480
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 480
aagatttgtc gaatgagtga 20

<210> 481
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 481
ctcggtcct gtggcctctg 20

<210> 482
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 482
tcctggagcc atctcctaga 20

<210> 483
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 483
ttgcactcac attcttggcc 20

<210> 484
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 484
ggggcactgc ttctttggca 20

<210> 485
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 485
cacaggggca ctgcttcttt 20

<210> 486
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 486
attggaagag tgggcgctca 20

<210> 487
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 487
atcttgaaaa acatgctttt 20

<210> 488
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 488
tgaaggaaac aattttgatc 20

<210> 489
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 489
tggttgtgaa ttggcagacc

20

<210> 490
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 490
attagaactt tcatcgcaac

20

<210> 491
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 491
tggcagccca gacactgtca

20

<210> 492
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 492
ttctttggca gcccagacac

20

<210> 493
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 493
aggggagggc acaggctaag

20

<210> 494
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 494
ggaatctttc aggtaattaa

20

<210> 495
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 495
ggaagctaca gtttcctgga

20

<210> 496
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 496
acctcagaaa gatttgtcga

20

<210> 497
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 497
gccagcgttc ccatttgagg

20

<210> 498
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 498
tactcagcct ggtggtctat

20

<210> 499
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 499
gctcctgatc cctgggggatg 20

<210> 500
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 500
cggtgcagct gtaagttgct 20

<210> 501
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 501
gagaagaaga gtgtctggta 20

<210> 502
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 502
attaagccta agcctgggta 20

<210> 503
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 503
ccaggccagc gttcccattt 20

<210> 504
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 504
ctggagccat ctcctagaag 20

<210> 505
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 505
tcttcacatt gcccttgaaa 20

<210> 506
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 506
cctggaatct ttcaggtaat 20

<210> 507
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 507
catttgaagg aaacaatttt 20

<210> 508
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 508
ctacaaaggc agagcaaagc 20

<210> 509
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 509
ctcactgtct tcttggctga 20

<210> 510
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 510
tcctggaatc tttcaggtaa 20

<210> 511
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 511
aaagatgaac aagtaggcca 20

<210> 512
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 512
gattcaggct gctagagacc 20

<210> 513
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 513
actgcttctt tggcagccca 20

<210> 514
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 514
aagcctaagc ctgggtaagg 20

<210> 515
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 515
gctaggaagc tacagtttcc 20

<210> 516
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 516
gaaggaaaca attttgatct 20

<210> 517
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 517
ggaggctcct gatccctggg 20

<210> 518
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 518
attcaggctg ctagagacca 20

<210> 519
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 519
ttcctggagc catctcctag 20

<210> 520
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 520
cactcacatt cttggccgcc 20

<210> 521
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 521
gcagcccaga cactgtcatg 20

<210> 522
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 522
tgcttctttg gcagcccaga 20

<210> 523
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 523
tcttagctga cattgtttga 20

<210> 524
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 524
acaattttga tctgtgacat

20

<210> 525
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 525
ggtttgtgaat tggcagaccc

20

<210> 526
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 526
gaatctggat tcagtctgca

20

<210> 527
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 527
ttagaacttt catcgcaact

20

<210> 528
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 528
gcaacaggag gaggggaagag

20

<210> 529
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 529
ctgcttcttt ggcagcccag 20

<210> 530
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 530
cttcacattg cccttgaaat 20

<210> 531
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 531
taagactgac gagagaagaa 20

<210> 532
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 532
ctaagactga cgagagaaga 20

<210> 533
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 533
agctacagtt tcctggaatc 20

<210> 534
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 534
aacaattttg atctgtgaca 20

<210> 535
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 535
agacccatt tgaaggaaac 20

<210> 536
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 536
agaaagattt gtcgaatgag 20

<210> 537
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 537
ttttttttta aacctatatt 20

<210> 538
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 538
tttttttttt aaacctatat 20

<210> 539
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 539
ctggattcag gctgctagag 20

<210> 540
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 540
gtccctgtgg cctctggcga 20

<210> 541
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-i antisense

<400> 541
ggaaccaatc tttgcactca 20

<210> 542
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 542
gcttcttttg cagcccagac 20

<210> 543
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 543
taggtgtgct cactgtcttc 20

<210> 544
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 544
gtgggtacag tgggagagtg 20

<210> 545
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 545
tgatcttgaa aaacatgctt 20

<210> 546
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 546
atttaagggtt aaatgacact 20

<210> 547
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 547
tggattcagt ctgcagtgaa 20

<210> 548
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 548
gtcccaggcc agcggtccca 20

<210> 549
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 549
cagcctggtg gtctatgctt 20

<210> 550
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 550
ggctcctgat ccctggggat 20

<210> 551
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 551
ggtgcagctg taagttgctt 20

<210> 552
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 552
caacaggagg aggggaagaga 20

<210> 553
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 553
tcatgaattt tcttctcggg 20

<210> 554
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 554
tgtgctcact gtcttcttgg 20

<210> 555
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 555
aagacactag agagagcaac 20

<210> 556
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 556
tggaatcttt caggaatta 20

<210> 557
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 557
tcagtctgca gtgaataggg 20

<210> 558
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 558
atattatctt taataagacc 20

<210> 559
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 559
gcttgaagaa tataatggaa 20

<210> 560
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 560
tcaggaacca atctttgcac 20

<210> 561
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 561
ttttcttcac attgcccttg 20

<210> 562
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 562
ctaagcctgg gtaaggggag 20

<210> 563
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 563
aaacaatddd gatctgtgac 20

<210> 564
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 564
cctcagaaag atttgtcgaa

20

<210> 565
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 565
tacctcagaa agatttgtcg

20

<210> 566
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 566
catgaatttt cttctcgggg

20

<210> 567
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 567
cagtttctctg gaatctttca

20

<210> 568
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 568
aatctggatt cagtctgcag

20

<210> 569
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 569
gggataagta tgtgtagaat

20

<210> 570
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 570
ttcaggctgc tagagaccat

20

<210> 571
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 571
ctggcaggct ctggaatgct

20

<210> 572
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 572
gggcacaggc taagactgac

20

<210> 573
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 573
tgaattggca gaccccat

20

<210> 574
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 574
gcctggtggt ctatgcttta 20

<210> 575
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 575
cctcggtccc tgtggcctct 20

<210> 576
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 576
agcctggcct cggtcctgt 20

<210> 577
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 577
gaaccaatct ttgcactcac 20

<210> 578
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 578
ccttgaaatg atcacagggg 20

<210> 579
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 579
gcatttaagg ttaaagaca 20

<210> 580
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 580
aagatgaaca agtaggcaa 20

<210> 581
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 581
ctggggatga ctcaggtcag 20

<210> 582
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 582
ctcctgatcc ctggggatga 20

<210> 583
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 583
tccctgctgg aggctcctga 20

<210> 584
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 584
gttccctgct ggaggctcct 20

<210> 585
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 585
ctgtaagttg cttgaagaat 20

<210> 586
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 586
aagcttctta gctgacattg 20

<210> 587
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 587
agggcacagg ctaagactga 20

<210> 588
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 588
gagggcacag gctaagactg 20

<210> 589
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 589
tcttttcaggt aattaagcct 20

<210> 590
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 590
aggaagctac agtttcctgg 20

<210> 591
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 591
gcctggcctc ggtccctgtg 20

<210> 592
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 592
aatgatcttg aaaaacatgc 20

<210> 593
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 593
ggggagggca caggctaaga 20

<210> 594
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 594
aattaagcct aagcctgggt 20

<210> 595
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 595
ctggaatctt tcaggtaatt 20

<210> 596
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 596
cccaggccag cgttcccatt 20

<210> 597
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 597
agtcccaggc cagcgttccc 20

<210> 598
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 598
ctggtggtct atgctttagt 20

<210> 599
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 599
catggacatc agcattagtg 20

<210> 600
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 600
ggcacaggct aagactgacg 20

<210> 601
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 601
cctaagcctg ggtaagggga 20

<210> 602
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 602
acagtttcct ggaatctttc 20

<210> 603
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 603
actcagcctg gtggtctatg 20

<210> 604
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 604
tcctgatccc tggggatgac 20

<210> 605
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 605
gacattgttt gagaaattgc 20

<210> 606
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 606
agacactaga gagagcaaca 20

<210> 607
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 607
gaatctttca ggtaattaag 20

<210> 608
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 608
tacagtttcc tggaatcttt 20

<210> 609
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 609
ccatttgaag gaaacaattt 20

<210> 610
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 610
ggattcagtc tgcagtgaat 20

<210> 611
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 611
agaatctgga ttcagtctgc 20

<210> 612
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 612
aatgagtga agatgaacaa 20

<210> 613
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 613
ccctgctgga ggctcctgat 20

<210> 614
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 614
tggattcagg ctgctagaga 20

<210> 615
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 615
tgtcatgaat tttcttctcg 20

<210> 616
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 616
tcacattgcc cttgaaatga 20

<210> 617
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 617
tcttgaaaaa catgcttttt 20

<210> 618
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 618
gcacaggcta agactgacga 20

<210> 619
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 619
ttaagcctaa gcctgggtaa 20

<210> 620
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 620
atctttcagg taattaagcc 20

<210> 621
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 621
ctttcctgat tgcatttaag 20

<210> 622
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 622
tttaataaga ccgtgtctgg 20

<210> 623
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 623
tccaggcca gcgttcccat 20

<210> 624
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 624
cctgatccct ggggatgact 20

<210> 625
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 625
cctggagcca tctcctagaa 20

<210> 626
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 626
gggcactgct tctttggcag 20

<210> 627
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 627
cccttgaaat gatcacaggg 20

<210> 628
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 628
taagcctaag cctgggtaag 20

<210> 629
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 629
gaagctacag tttcctggaa 20

<210> 630
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 630
cagaccccat ttgaaggaaa 20

<210> 631
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 631
ttttgtccca cctcgctctt 20

<210> 632
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 632
tttttgtccc acctcgctct 20

<210> 633
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 633
tttggcagcc cagacactgt 20

<210> 634
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 634
ttgcccttga aatgatcaca 20

<210> 635
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 635
ttcacattgc ccttgaaatg 20

<210> 636
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 636
tggcaggctc tggaatgctt 20

<210> 637
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 637
gagaaattgc tggcaggctc 20

<210> 638
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 638
ctcctacaaa ggcagagcaa 20

<210> 639
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 639
ggagaagaag agtgtctggt 20

<210> 640
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 640
ctttcaggtta attaacgcta 20

<210> 641
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 641
ctaggaagct acagtttcct 20

<210> 642
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 642
tgcatttaag gttaaagac 20

<210> 643
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 643
tgtagaatct ggattcagtc 20

<210> 644
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 644
tgtaagttgc ttgaagaata 20

<210> 645
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 645
cagctgtaag ttgcttgaag 20

<210> 646
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 646
gtgcagctgt aagttgcttg 20

<210> 647
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 647
tctttggcag cccagacact 20

<210> 648
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 648
tgcccttgaa atgatcacag 20

<210> 649
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 649
ttgcatttaa ggttaaataga 20

<210> 650
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 650
ttacctcaga aagatttgct 20

<210> 651
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 651
gctgtaagtt gcttgaagaa 20

<210> 652
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 652
cacattgccc ttgaaatgat 20

<210> 653
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 653
acattgtttg agaaattgct 20

<210> 654
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 654
gtttaattgg aagagtgggc 20

<210> 655
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 655
agagcactgg aatgatttag 20

<210> 656
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 656
gctacagttt cctggaatct 20

<210> 657
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 657
catttaagggt taaatgacac 20

<210> 658
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 658
gtctatgctt tagtcccagg 20

<210> 659
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 659
acattcttgg ccgccttcct 20

<210> 660
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 660
aaccaatctt tgcactcaca 20

<210> 661
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 661
ctttggcagc ccagacactg 20

<210> 662
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 662
tttgtcccac ctcgctctta 20

<210> 663
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 663
cttttttttt ttgtcccac 20

<210> 664
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 664
actcacattc ttggccgcct

20

<210> 665
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 665
ctgtcatgaa ttttcttctc

20

<210> 666
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 666
ggaatgcttg tttggctttc

20

<210> 667
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 667
ttgtttgaga aattgctggc

20

<210> 668
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 668
gtgggcgctc agagctccta

20

<210> 669
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 669
agtgggcgct cagagctcct 20

<210> 670
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 670
tttaaaccta tattatcttt 20

<210> 671
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 671
ttttaaacct atattatctt 20

<210> 672
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 672
tgcttgaaga atataatgga 20

<210> 673
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 673
cacattcttg gccgccttcc 20

<210> 674
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 674
tgaaatgatc acaggggcac 20

<210> 675
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 675
acattgccct tgaaatgatc 20

<210> 676
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 676
attgtttgag aaattgctgg 20

<210> 677
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 677
tgagagcact ggaatgattt 20

<210> 678
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 678
ttgagagcac tggaatgatt 20

<210> 679
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 679
aagctacagt ttcctggaat 20

<210> 680
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 680
gtagaatctg gattcagtct 20

<210> 681
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 681
accaatcttt gcactcacat 20

<210> 682
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 682
gaagaagagt gtctggtagg 20

<210> 683
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 683
gcagctgtaa gttgcttgaa 20

<210> 684
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 684
tgcagctgta agttgcttga 20

<210> 685
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 685
ggcactgctt ctttggcagc 20

<210> 686
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 686
ttgaaatgat cacaggggca 20

<210> 687
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 687
tgctttttga gagcactgga 20

<210> 688
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 688
aatcttttcag gtaattaagc 20

<210> 689
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 689
tttagtccca ggccagcggt

20

<210> 690
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 690
tctttgcact cacattcttg

20

<210> 691
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 691
atctttgcac tcacattctt

20

<210> 692
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 692
gctttttgag agcactggaa

20

<210> 693
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 693
gacactagct aggaagctac

20

<210> 694
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 694
aggttaaatg acactagcta 20

<210> 695
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 695
ttaaacctat attatcttta 20

<210> 696
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 696
ttttttttaac acctatatatta 20

<210> 697
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 697
cttgccgccgccc ttcctggagc 20

<210> 698
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 698
ctcaggaacc aatctttgca 20

<210> 699
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 699
acactgtcat gaattttctt 20

<210> 700
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 700
ggcgctcaga gctcctacaa 20

<210> 701
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 701
tgggtacagt gggagagtga 20

<210> 702
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 702
caggctaaga ctgacgagag 20

<210> 703
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 703
ttaataagac cgtgtctggt 20

<210> 704
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 704
agcctggtgg tctatgcttt 20

<210> 705
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 705
tcagcctggt ggtctatgct 20

<210> 706
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 706
gaaatgatca caggggcact 20

<210> 707
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 707
attgctggca ggctctggaa 20

<210> 708
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 708
gctaagactg acgagagaag 20

<210> 709
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 709
taattaagcc taagcctggg 20

<210> 710
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 710
gtcgggtgcag ctgtaagttg 20

<210> 711
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 711
catcagcatt agtggcagca 20

<210> 712
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 712
ctctggaatg cttgtttggc 20

<210> 713
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 713
ttggaagagt gggcgctcag 20

<210> 714
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 714
taggaagcta cagtttcctg 20

<210> 715
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 715
gttgtgaatt ggcagacccc 20

<210> 716
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 716
tcttctcggg gctctcagga 20

<210> 717
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 717
atgaattttc ttctcggggc 20

<210> 718
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 718
tttgagaaat tgctggcagg 20

<210> 719
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 719
ctttttgaga gcactggaat 20

<210> 720
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 720
agctaggaag ctacagtttc 20

<210> 721
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 721
ggttaaatga cactagctag 20

<210> 722
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 722
aaggttaaat gacactagct 20

<210> 723
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 723
tatattatct ttaataagac 20

<210> 724
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 724
ctcacattct tggccgcctt 20

<210> 725
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 725
gccagacac tgatcatgaat 20

<210> 726
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 726
tggaagagtg ggcgctcaga 20

<210> 727
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 727
gacactagag agagcaacaa 20

<210> 728
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 728
gttaaagac actagctagg 20

<210> 729
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 729
gattgcattt aaggttaaat 20

<210> 730
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 730
gattcagtct gcagtgaata 20

<210> 731
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 731
ccatggacat cagcattagt 20

<210> 732
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 732
ttggcagccc agacactgtc 20

<210> 733
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 733
gcccttgaaa tgatcacagg 20

<210> 734
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 734
tggaatgctt gtttggcttt 20

<210> 735
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 735
gcaggctctg gaatgcttgt 20

<210> 736
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 736
tttaaggtta aatgacacta 20

<210> 737
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 737
ttcagtctgc agtgaatagg 20

<210> 738
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 738
attcagtctg cagtgaatag 20

<210> 739
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 739
ggccagcggtt cccatttgag

20

<210> 740
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 740
tcctacaaag gcagagcaaa

20

<210> 741
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 741
tttgagagca ctggaatgat

20

<210> 742
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 742
agtttcctgg aatctttcag

20

<210> 743
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 743
atctggttgt gaattggcag

20

<210> 744
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 744
ctcagcctgg tggctctatgc 20

<210> 745
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 745
gctcctacaa aggagagca 20

<210> 746
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 746
cacaggctaa gactgacgag 20

<210> 747
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 747
gcctaagcct gggttaagggg 20

<210> 748
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 748
tgacactagc taggaagcta 20

<210> 749
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 749
attgcattta aggttaaattg 20

<210> 750
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 750
taaacctata ttatctttaa 20

<210> 751
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 751
tcaggctgct agagaccatg 20

<210> 752
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 752
ttcttctcgg ggctctcagg 20

<210> 753
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 753
acaggctaag actgacgaga 20

<210> 754
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 754
tctggttgatg aattggcaga 20

<210> 755
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 755
cactgtcatg aattttcttc 20

<210> 756
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 756
ttgctggcag gctctggaat 20

<210> 757
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 757
aaaacatgct ttttgagagc 20

<210> 758
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 758
ctagctagga agctacagtt 20

<210> 759
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 759
ggggatgact caggtcagga 20

<210> 760
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 760
aattgctggc aggctctgga 20

<210> 761
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 761
ttaaagtaca ctagctagga 20

<210> 762
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 762
tggtgggtcta tgcttttagtc 20

<210> 763
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 763
tggaggctcc tgatccctgg 20

<210> 764
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 764
ttgcttgaag aatataatgg 20

<210> 765
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 765
cttgaaatga tcacaggggc 20

<210> 766
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 766
tctggaatgc ttgtttggct 20

<210> 767
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 767
acactagcta ggaagctaca 20

<210> 768
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 768
atgacactag ctaggaagct 20

<210> 769
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 769
ttgtcccacc tcgctcttac 20

<210> 770
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 770
actttcctga ttgcatttaa 20

<210> 771
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 771
aaggaaacaa ttttgatctg 20

<210> 772
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 772
cagaaagatt tgtcgaatga 20

<210> 773
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 773
agctgtaagt tgcttgaaga 20

<210> 774
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 774
tgaattttct tctcggggct 20

<210> 775
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 775
gacactgtca tgaattttct 20

<210> 776
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 776
attgcccttg aaatgatcac 20

<210> 777
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 777
tgacattggt tgagaaattg 20

<210> 778
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 778
cttagctgac attgtttgag 20

<210> 779
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 779
taataagacc gtgtctggtt 20

<210> 780
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 780
gacatcagca ttagtggcag 20

<210> 781
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 781
gcctcggtcc ctgtggcctc 20

<210> 782
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 782
agccatctcc tagaagcctg 20

<210> 783
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 783
cttctcgggg ctctcaggaa 20

<210> 784
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 784
ttttgagagc actggaatga 20

<210> 785
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 785
tttcaggtaa ttaagcctaa 20

<210> 786
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 786
ctatattatc ttttaataaga 20

<210> 787
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 787
ccaatctttg cactcacatt 20

<210> 788
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 788
cattgtttga gaaattgctg 20

<210> 789
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 789
gagagcactg gaatgattta 20

<210> 790
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 790
tagctaggaa gctacagttt 20

<210> 791
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 791
gacatttaaa aatatttatt 20

<210> 792
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 792
tttttttaaa cctatattat 20

<210> 793
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 793
ggatactcag cctggtggtc 20

<210> 794
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 794
cctggcctcg gtcctgtgg 20

<210> 795
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 795
tgcagtgaat agggtaaaat 20

<210> 796
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 796
ggggataagt atgtgtagaa 20

<210> 797
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 797
tttttttttt ttgtcccacc 20

<210> 798
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 798
ttagtcccag gccagcgttc 20

<210> 799
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 799
gcgctcagag ctcctacaaa

20

<210> 800
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 800
cttgaaaaac atgcttttttg

20

<210> 801
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 801
aaatgatctt gaaaaacatg

20

<210> 802
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 802
attgacttct gtttgctact

20

<210> 803
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 803
tgacatttaa aaatatttat

20

<210> 804
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 804
tgtgacattt aaaaatattt 20

<210> 805
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 805
ggctctggaa tgcttgtttg 20

<210> 806
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 806
caggctctgg aatgcttggt 20

<210> 807
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 807
taaattgacac tagctaggaa 20

<210> 808
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 808
ttaagggttaa atgacactag 20

<210> 809
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 809
aataagaccg tgtctgggttc 20

<210> 810
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 810
ttccctgctg gaggtcctg 20

<210> 811
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 811
tttcttctcg gggctctcag 20

<210> 812
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 812
tttaaaaata tttattgact 20

<210> 813
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 813
aagcctggcc tcggtccctg 20

<210> 814
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 814
attttcttct cggggctctc 20

<210> 815
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 815
gaattttctt ctcggggctc 20

<210> 816
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 816
ctgacattgt ttgagaaatt 20

<210> 817
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 817
tactttcctg attgcattta 20

<210> 818
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 818
atttaaaaat atttattgac 20

<210> 819
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 819
ggattcaggc tgctagagac

20

<210> 820
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 820
aaaaacatgc tttttgagag

20

<210> 821
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 821
tttttttttg tcccacctcg

20

<210> 822
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 822
tctatgcttt agtcccaggc

20

<210> 823
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 823
atcagcatta gtggcagcaa

20

<210> 824
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 824
acatcagcat tagtggcagc 20

<210> 825
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 825
gctgctagag accatggaca 20

<210> 826
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 826
aatctttgca ctcacattct 20

<210> 827
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 827
tgtttaattg gaagagtggg 20

<210> 828
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 828
tcactgtctt cttggctgag 20

<210> 829
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 829
atgctttttg agagcactgg 20

<210> 830
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 830
actagctagg aagctacagt 20

<210> 831
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 831
gtgacattta aaaatattta 20

<210> 832
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 832
tcttggecgc cttcctggag 20

<210> 833
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 833
ggctgagaat gtttaattgg 20

<210> 834
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 834
gggagaagaa gagtgtctgg 20

<210> 835
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 835
aaacatgctt tttgagagca 20

<210> 836
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 836
tctgcagtga atagggtaaa 20

<210> 837
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 837
tgtcccacct cgctcttacc 20

<210> 838
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 838
tggggatgac tcaggtcagg 20

<210> 839
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 839
cactagctag gaagctacag 20

<210> 840
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 840
ctgcagtgaa tagggtaaaa 20

<210> 841
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 841
tttttttttt tgtcccacct 20

<210> 842
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 842
agcccagaca ctgtcatgaa 20

<210> 843
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 843
ctcagagctc ctacaaaggc 20

<210> 844
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 844
tgattgcatt taagggttaa 20

<210> 845
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 845
ctgattgcat ttaagggttaa 20

<210> 846
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 846
aggctctgga atgcttggtt 20

<210> 847
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 847
ggcaggctct ggaatgcttg 20

<210> 848
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 848
cagagctcct acaaaggcag 20

<210> 849
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 849
aaaaatattt attgacttct 20

<210> 850
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 850
gggatgactc aggtcaggat 20

<210> 851
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 851
ctgctagaga ccatggacat 20

<210> 852
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 852
cccagacact gtcatgaatt 20

<210> 853
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 853
gctgacattg tttgagaaat 20

<210> 854
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 854
agctgacatt gtttgagaaa 20

<210> 855
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 855
ggctaagact gacgagagaa 20

<210> 856
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 856
tagtcccagg ccagcgttcc 20

<210> 857
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 857
ctggaatgct tgtttggctt 20

<210> 858
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 858
tgggcgctca gagtcctac 20

<210> 859
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 859
gagtgggcgc tcagagctcc 20

<210> 860
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 860
gggagggcac aggctaagac 20

<210> 861
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 861
tcagaaagat ttgtcgaatg 20

<210> 862
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 862
tttttttttt gtccacctc 20

<210> 863
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 863
ttaaaaatat ttattgactt 20

<210> 864
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 864
gtttgagaaa ttgctggcag 20

<210> 865
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 865
cactgtcttc ttggctgaga 20

<210> 866
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 866
aatgacacta gctaggaagc 20

<210> 867
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 867
gctcttacct cagaaagatt 20

<210> 868
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 868
gtcccacctc gctcttacct 20

<210> 869
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 869
ttttttttgt cccacctcgc 20

<210> 870
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 870
tctcctagaa gcctggcctc 20

<210> 871
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 871
ttttcttctc ggggctctca 20

<210> 872
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 872
aattttcttc tcggggctct 20

<210> 873
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 873
tgctagagac catggacatc 20

<210> 874
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 874
aaaatgatct tgaaaaacat 20

<210> 875
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 875
acactagaga gagcaacaaa 20

<210> 876
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 876
ttcaggtaat taagcctaag 20

<210> 877
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 877
aagtaggcca atggagacag 20

<210> 878
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 878
ctttagtccc aggccagcgt 20

<210> 879
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 879
actgtcatga attttcttct 20

<210> 880
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 880
agacactgtc atgaattttc 20

<210> 881
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 881
agagctccta caaaggcaga 20

<210> 882
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 882
aagagtgggc gctcagagct 20

<210> 883
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 883
gggtacagtg ggagagtgag 20

<210> 884
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 884
aggatactca gcctggtggt 20

<210> 885
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 885
gctctggaat gcttgtttgg 20

<210> 886
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 886
tttttgagag cactggaatg 20

<210> 887
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 887
gaaaaacatg ctttttgaga 20

<210> 888
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 888
gtaattaagc ctaagcctgg 20

<210> 889
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 889
atctcctaga agcctggcct 20

<210> 890
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 890
gccatctcct agaagcctgg 20

<210> 891
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 891
tttgactca cattcttggc 20

<210> 892
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 892
cgctcagagc tcctacaaag 20

<210> 893
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 893
tggctgagaa tgtttaattg 20

<210> 894
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 894
taaaaatatt tattgacttc 20

<210> 895
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 895
cctatattat ctttaataag 20

<210> 896
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 896
gctagagacc atggacatca 20

<210> 897
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 897
cattgccctt gaaatgatca 20

<210> 898
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 898
aaattgctgg caggctctgg 20

<210> 899
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 899
gagctcctac aaaggcagag 20

<210> 900
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 900
gaagagtggg cgctcagagc 20

<210> 901
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 901
agctcctaca aaggcagagc 20

<210> 902
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 902
tcggtgcagc tgtaagttgc 20

<210> 903
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 903
caggctgcta gagaccatgg 20

<210> 904
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 904
tcacattctt ggccgccttc 20

<210> 905
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 905
tttttttgtc ccacctcgct 20

<210> 906
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 906
ctatgcttta gtcccaggcc 20

<210> 907
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 907
tcagagctcc tacaaaggca 20

<210> 908
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 908
tgtttgagaa attgctggca 20

<210> 909
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 909
aggctaagac tgacgagaga 20

<210> 910
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 910
ctgtgacatt taaaaatatt 20

<210> 911
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 911
cgctcttacc tcagaaagat 20

<210> 912
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 912
ctggaggctc ctgatccctg 20

<210> 913
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 913
gggcgctcag agctcctaca 20

<210> 914
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 914
aaaatattta ttgacttctg 20

<210> 915
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 915
ctcagaaaga tttgtcgaat 20

<210> 916
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 916
tttttaaacc tatattatct 20

<210> 917
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 917
ttttttaaac ctatattatc 20

<210> 918
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 918
ggatgactca ggtcaggata 20

<210> 919
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 919
ctgctggagg ctctgatcc 20

<210> 920
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 920
ctttgcactc acattcttgg 20

<210> 921
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 921
ttggctgaga atgtttaatt 20

<210> 922
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 922
cctgctggag gctcctgatc 20

<210> 923
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 923
gaagcctggc ctcggtccct 20

<210> 924
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 924
aacatgcttt ttgagagcac 20

<210> 925
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 925
acatttaaaa atatttattg 20

<210> 926
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 926
tagaatctgg attcagtctg 20

<210> 927
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 927
gctctcagga accaatcttt 20

<210> 928
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 928
aatgatcac aggggcactg 20

<210> 929
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 929
tgctggcagg ctctggaatg

20

<210> 930
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 930
atgtttaatt ggaagagtgg

20

<210> 931
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 931
accatggaca tcagcattag

20

<210> 932
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 932
ctggcctcgg tccctgtggc

20

<210> 933
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 933
cagcccagac actgtcatga

20

<210> 934
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 934
taagggttaaa tgacactagc 20

<210> 935
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 935
aaatatttat tgacttctgt 20

<210> 936
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 936
ccagacactg tcatgaattt 20

<210> 937
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 937
aatattttatt gacttctgtt 20

<210> 938
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 938
caaatgatc ttgaaaaaca 20

<210> 939
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 939
gctcagagct cctacaaagg 20

<210> 940
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 940
gcttttagtcc caggccagcg 20

<210> 941
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 941
cactagagag agcaacaaac 20

<210> 942
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 942
tcaggtatt aagcctaagc 20

<210> 943
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 943
tcaggatact cagcctggtg 20

<210> 944
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 944
tgggagaaga agagtgtctg 20

<210> 945
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 945
agaaattgct ggcaggctct 20

<210> 946
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 946
cccacctcgc tcttacctca 20

<210> 947
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 947
acctatatta tctttaataa 20

<210> 948
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 948
cggggctctc aggaaccaat 20

<210> 949
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 949
gctactttcc tgattgcatt

20

<210> 950
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 950
ggggctctca ggaaccaatc

20

<210> 951
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 951
cttctgtttg ctactttcct

20

<210> 952
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 952
ctcttacctc agaaagattt

20

<210> 953
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 953
gtcaggatac tcagcctggt

20

<210> 954
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 954
tctcaggaac caatctttgc

20

<210> 955
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 955
ttcttggcgc ccttcctgga

20

<210> 956
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 956
cagacactgt catgaatttt

20

<210> 957
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 957
catgcttttt gagagcactg

20

<210> 958
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 958
gagagcaaca aacaaaatga

20

<210> 959
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 959
gagagagcaa caaacaaaat 20

<210> 960
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 960
agagagagca acaaacaaaa 20

<210> 961
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 961
gacttctgtt tgctactttc 20

<210> 962
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 962
atgactcagg tcaggatact 20

<210> 963
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 963
ccatctccta gaagcctggc 20

<210> 964
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 964
gagaatgttt aattggaaga 20

<210> 965
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 965
aaatgacact agctaggaag 20

<210> 966
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-i antisense

<400> 966
catttaaaaa tattttattga 20

<210> 967
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 967
ctactttcct gattgcattt 20

<210> 968
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 968
tgctggaggc tcctgatccc 20

<210> 969
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 969
ggctgctaga gaccatggac 20

<210> 970
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 970
tcggggctct caggaaccaa 20

<210> 971
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 971
cttacctcag aaagatttgt 20

<210> 972
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 972
ggcctcggtc cctgtggcct 20

<210> 973
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 973
atgctttagt cccaggccag 20

<210> 974
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 974
tttgctactt tcctgattgc

20

<210> 975
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 975
attccttggcc gccttcctgg

20

<210> 976
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 976
ggtacagtgg gagagtgagg

20

<210> 977
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 977
agagcaacaa acaaaatgat

20

<210> 978
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 978
agagagcaac aaacaaaatg

20

<210> 979
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 979
ggtaattaag cctaagcctg 20

<210> 980
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 980
acttctgttt gctactttcc 20

<210> 981
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 981
agaatgttta attggaagag 20

<210> 982
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 982
cagtgggaga gtgaggtggg 20

<210> 983
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 983
tcgctcttac ctcagaaaga 20

<210> 984
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 984
ttttttgtcc cacctcgctc 20

<210> 985
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 985
ctcggggctc tcaggaacca 20

<210> 986
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 986
caggatactc agcctggtgg 20

<210> 987
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 987
gctggaggct cctgatccct 20

<210> 988
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 988
tcccacctcg ctcttacctc 20

<210> 989
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 989
ctcctagaag cctggcctcg 20

<210> 990
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 990
ggctctcagg aaccaatctt 20

<210> 991
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 991
gtgggagaag aagagtgtct 20

<210> 992
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 992
aacctatatt atctttaata 20

<210> 993
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 993
cattcttggc cgccttctg 20

<210> 994
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 994
gaaattgctg gcaggctctg 20

<210> 995
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 995
gctgagaatg tttaattgga 20

<210> 996
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 996
ttgctacttt cctgattgca 20

<210> 997
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 997
tgcttttagtc ccaggccagc 20

<210> 998
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 998
ttagctgaca ttgtttgaga 20

<210> 999
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 999
gtcttcttggtg ctgagaatgt 20

<210> 1000
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1000
gagcaacaaa caaaatgatc 20

<210> 1001
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1001
ttctgtttgc tacttttctg 20

<210> 1002
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1002
ctagagacca tggacatcag 20

<210> 1003
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1003
ctctcaggaa ccaatctttg 20

<210> 1004
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1004
actagagaga gcaacaaaca 20

<210> 1005
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1005
tgctactttc ctgattgcat 20

<210> 1006
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1006
tgacttctgt ttgctacttt 20

<210> 1007
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1007
gatgactcag gtcaggatac 20

<210> 1008
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1008
ttattgactt ctgtttgcta 20

<210> 1009
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1009
ctcgtcttta cctcagaaag 20

<210> 1010
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1010
gggctctcag gaaccaatct 20

<210> 1011
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1011
ctgagaatgt ttaattggaa 20

<210> 1012
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1012
gtttgctact ttcctgattg 20

<210> 1013
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1013
aaacctatat tatctttaat 20

<210> 1014
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1014
tgactcaggt caggatactc 20

<210> 1015
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1015
ctggtttgcta ctttcctgat 20

<210> 1016
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1016
gtacagtggg agagtgaggt 20

<210> 1017
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1017
aaacaaaatg atcttgaaaa 20

<210> 1018
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1018
caatctttgc actcacattc 20

<210> 1019
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1019
tagctgacat tgtttgagaa 20

<210> 1020
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1020
tttattgact tctgtttgct 20

<210> 1021
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1021
gactcaggtc aggatactca 20

<210> 1022
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1022
ggaagagtgg gcgctcagag 20

<210> 1023
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1023
tgagaatggt taattggaag 20

<210> 1024
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1024
caaacaaaat gatcttgaaa 20

<210> 1025
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1025
ttgacttctg ttgctactt 20

<210> 1026
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1026
tcttacctca gaaagatttg 20

<210> 1027
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1027
cttggctgag aatgtttaat 20

<210> 1028
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1028
tcttcttggc tgagaatgtt 20

<210> 1029
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1029
ttctcggggc tctcaggaac 20

<210> 1030
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1030
aggctgctag agaccatgga 20

<210> 1031
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1031
tagaagcctg gcctcggtcc 20

<210> 1032
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1032
ctagagagag caacaaacaa 20

<210> 1033
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1033
tctcggggct ctcaggaacc 20

<210> 1034
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1034
tctgtttgct acttttctga 20

<210> 1035
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1035
gaatgtttta ttggaagagt 20

<210> 1036
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-i antisense

<400> 1036
tcttggctga gaatgtttta 20

<210> 1037
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1037
acaaaatgat cttgaaaaac 20

<210> 1038
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1038
aacaaaatga tcttgaaaaa 20

<210> 1039
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1039
agcaacaaac aaaatgatct 20

<210> 1040
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1040
tgtttgctac tttcctgatt 20

<210> 1041
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1041
agaagcctgg cctcggtccc 20

<210> 1042
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1042
atatttattg acttctgttt 20

<210> 1043
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1043
ggtcaggata ctcagcctgg 20

<210> 1044
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1044
ttcttggtg agaatgttta 20

<210> 1045
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1045
tcaggtcagg atactcagcc 20

<210> 1046
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1046
atttattgac ttctgtttgc 20

<210> 1047
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1047
catctcctag aagcctggcc 20

<210> 1048
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1048
acaaacaaaa tgatcttgaa 20

<210> 1049
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1049
caggtcagga tactcagcct 20

<210> 1050
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1050
tggcctcggt ccctgtggcc 20

<210> 1051
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1051
agagtgggcg ctcagagctc 20

<210> 1052
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1052
ggtgggagaa gaagagtgtc 20

<210> 1053
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1053
tattgacttc tgtttgctac 20

<210> 1054
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1054
aatgtttaat tggaagagtg 20

<210> 1055
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1055
actgtcttct tggctgagaa 20

<210> 1056
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1056
actcaggtca ggatactcag 20

<210> 1057
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1057
tagagaccat ggacatcagc 20

<210> 1058
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1058
cctcgctctt acctcagaaa 20

<210> 1059
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1059
tattttattga cttctgtttg

20

<210> 1060
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1060
ctcaggtcag gatactcagc

20

<210> 1061
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1061
ctgtcttctt ggctgagaat

20

<210> 1062
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1062
ttgaaaaaca tgctttttga

20

<210> 1063
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1063
aacaaacaaa atgatcttga

20

<210> 1064
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1064
cacctcgctc ttacctcaga 20

<210> 1065
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1065
acatgctttt tgagagcact 20

<210> 1066
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1066
acctcgctct tacctcagaa 20

<210> 1067
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1067
aggtaattaa gcctaagcct 20

<210> 1068
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1068
agagaccatg gacatcagca 20

<210> 1069
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1069
tgaaaaacat gctttttgag 20

<210> 1070
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1070
caacaaacaa aatgatcttg 20

<210> 1071
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1071
tagagagagc aacaaacaaa 20

<210> 1072
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1072
caggtaatta agcctaagcc 20

<210> 1073
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1073
ccacctcgct cttacctcag 20

<210> 1074
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1074
tgtcttcttg gctgagaatg 20

<210> 1075
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1075
agggtgggaga agaagagtgt 20

<210> 1076
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1076
gagagtgagg tgggagaaga 20

<210> 1077
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1077
tcctagaagc ctggcctcgg 20

<210> 1078
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1078
cctagaagcc tggcctcgg 20

<210> 1079
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1079
cttcttggct gagaatgttt 20

<210> 1080
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1080
agtgggagag tgaggtggga 20

<210> 1081
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1081
tacagtggga gagtgaggtg 20

<210> 1082
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1082
gaccatggac atcagcatta 20

<210> 1083
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1083
agaccatgga catcagcatt 20

<210> 1084
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1084
gaggtgggag aagaagagtg

20

<210> 1085
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1085
agagtgaggt gggagaagaa

20

<210> 1086
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1086
ctagaagcct ggcctcggtc

20

<210> 1087
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1087
tatgcttttag tcccaggcca

20

<210> 1088
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1088
gggagagtga ggtgggagaa

20

<210> 1089
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1089
tgggagagtg aggtgggaga

20

<210> 1090
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1090
gagacatgg acatcagcat

20

<210> 1091
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1091
acagtgggag agtgaggtgg

20

<210> 1092
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1092
ggagagtggag gtgggagaag

20

<210> 1093
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1093
gtgggagagt gaggtgggag

20

<210> 1094
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1094
gcaacaaaca aaatgatctt

20

<210> 1095
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1095
tgaggtggga gaagaagagt

20

<210> 1096
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1096
aggtcaggat actcagcctg

20

<210> 1097
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1097
agtgaggtgg gagaagaaga

20

<210> 1098
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1098
gtgaggtggg agaagaagag

20

<210> 1099
<211> 20
<212> DNA
<213> artificial

<220>
<223> human VCC-1 antisense

<400> 1099
gagtgaggtg ggagaagaag

20

<210> 1100
<211> 22
<212> DNA
<213> Artificial

<220>
<223> human VCC-1 PCR forward primer

<400> 1100
cgacagttgc gatgaaagtt ct

22

<210> 1101
<211> 24
<212> DNA
<213> Artificial

<220>
<223> human VCC-1 PCR reverse primer

<400> 1101
agagaccatg gacatcagca ttag

24

<210> 1102
<211> 25
<212> DNA
<213> Artificial

<220>
<223> human VCC-1 PCR probe

<400> 1102
tctcttccct cctcctgttg ctgcc

25

<210> 1103
<211> 20
<212> DNA
<213> Artificial

<220>
<223> cyclophilin PCR forward primer

<400> 1103
cccaccgtgt tcttcgacat

20

<210> 1104
<211> 22
<212> DNA
<213> Artificial

<220>
<223> cyclophilin PCR reverse primer

<400> 1104
tttctgctgt ctttgggacc tt

22

<210> 1105
<211> 24
<212> DNA
<213> Artificial

<220>
<223> cyclophilin PCR probe

<400> 1105
cgcgctctcct ttgagctggt tgca

24

<210> 1106
<211> 119
<212> PRT
<213> Homo sapiens

<400> 1106

Met Lys Val Leu Ile Ser Ser Leu Leu Leu Leu Leu Pro Leu Met Leu
1 5 10 15

Met Ser Met Val Ser Ser Ser Leu Asn Pro Gly Val Ala Arg Gly His
20 25 30

Arg Asp Arg Gly Gln Ala Ser Arg Arg Trp Leu Gln Glu Gly Gly Gln
35 40 45

Glu Cys Glu Cys Lys Asp Trp Phe Leu Arg Ala Pro Arg Arg Lys Phe
50 55 60

Met Thr Val Ser Gly Leu Pro Lys Lys Gln Cys Pro Cys Asp His Phe
65 70 75 80

Lys Gly Asn Val Lys Lys Thr Arg His Gln Arg His His Arg Lys Pro
85 90 95

Asn Lys His Ser Arg Ala Cys Gln Gln Phe Leu Lys Gln Cys Gln Leu
100 105 110

Arg Ser Phe Ala Leu Pro Leu
115

<210> 1107
<211> 1172
<212> DNA
<213> Homo sapiens

<400> 1107
gattcccata aagcacatgg tctaattctgt tacgtaacag caagacagcg tcacctcacc 60
tggttctcgcc ctcaaattggg aacgctggcc tgggactaaa gcatagacca ccaggctgag 120
tattctgacc tgagtcattcc ccagggatca ggagcctcca gcagggaacc ttccattata 180
ttcttcaagc aacttacagc tgcaccgaca gttgcgatga aagttctaatt ctcttccctc 240
ctcctgttgc tgccactaat gctgatgtcc atgggtctcta gcagcctgaa tccaggggtc 300
gccagaggcc acagggaccg aggccaggct tctaggagat ggctccagga aggcggccaa 360
gaatgtgagt gcaaagattg gttcctgaga gccccgagaa gaaaattcat gacagtgtct 420
gggtgcgcaa agaagcagtg cccctgtgat catttcaagg gcaatgtgaa gaaaacaaga 480
caccaaaggc accacagaaa gccaaacaag cattccagag cctgccagca atttctcaaa 540
caatgtcagc taagaagctt tgctctgcct ttgtaggagc tctgagcgcc cactcttcca 600
attaacatt ctcagccaag aagacagtga gcacacctac cagacactct tcttctccca 660
cctcactctc cactgtacc caccctaaa tcattccagt gctctcaaaa agcatgtttt 720
tcaagatcat tttgtttgtt gctctctcta gtgtcttctt ctctcgtcag tcttagcctg 780
tgccctcccc ttaccaggc ttaggcttaa ttacctgaaa gattccagga aactgtagct 840
tcctagctag tgtcatttaa ccttaaattgc aatcaggaaa gtagcaaaca gaagtcaata 900
aatattttta aatgtcacag atcaaaattg tttccttcaa atgggggtctg ccaattcaca 960
accagatgac ccattttacc ctattcactg cagactgaat ccagattcta cacatactta 1020
tccccaccaa gaccctcact ctgtctccat tggcctactt gttcatcttt cactcattcg 1080
acaaatcttt ctgaggtaag agcgagggtg gacaaaaaaaa aaaaagcata ccaatgaacc 1140
agacacgggc ttattaaaga taatataggt tt 1172